AU716056B2 - Identification of DEC, (dentritic and epithelial cells, 205 kDa), a receptor with C-type lectin domains, nucleic acids encoding DEC, and uses thereof - Google Patents

Description

WO 96/23882 PCTIUS96/01383 IDENTIFICATION OF DEC, (DENTRITIC AND EPITHELIAL CELLS, 205 kDa), A RECEPTOR WITH C-TYPE LECTIN DOMAINS, NUCLEIC ACIDS ENCODING DEC, AND USES THEREOF The research leading to the present invention was supported in part with National Institutes of Health Grant No. AI13013. The Government may have certain rights in the invention.

FIELD OF THE INVENTION The present invention relates to the identification and characterization of a receptor associated with antigen presentation in immune responses, endocytosis, and transepithelial transport. Identification of the receptor, its characterization as having ten lectin-binding domains, and evidence of its role in the uptake and processing of oligosaccharides and oligosaccharide-decorated molecules, glycoproteins, has important ramifications for modifying immune response, and for trans-epithelial transport of molecules.

BACKGROUND OF THE INVENTION Dendritic cells are a unique class of leukocytes whose primary function is to capture, process, and present antigens to T cells (Steinman, 1991, Annu. Rev.

Immunol. 9:271-96). Interaction between dendritic cells and specific T cells in the peripheral immune system leads to the induction of immune responses, whereas in the thymus presentation by dendritic cells leads to negative selection (Tanaka et al., 1993, Eur. J. Immunol. 23:2614-2621: Matzinger et al., 1989, Nature 338:74- 76). Like dendritic cells, thymic epithelial cells present MHC-bound peptides to T cells, but instead of inducing T cell activation or negative selection, thymic epithelial cells direct positive selection (Hugo et al., 1993. Immunol. Rev.

135:133-35; Elliott. Immunol. Rev. 135:215-25). Consistent with the known requirements for interactions with T cells, both dendritic cells and thymic epithelial cells express a number of cell surface proteins that facilitate cell-cell contact and mediate T cell activation (Steinman. 1991. Annu. Rev Immunol.

9:271-96: Hugo et al.. 1993. Immunol Rev. 135:133-35: Elliott. Immunol Rev.

135:215-25). An additional fundamental requirement for both dendritic cells and thymic epithelial cells is the uptake and processing of antigen, yet neither cell type is known to express receptors that are specialized for antigen capture or presentation.

Over the decade since its initial isolation by Kraal et al (J Exp Med 163:981), the monoclonal antibody NLDC-145 has been utilized as a histochemical and flow cytometric marker for mouse dendritic cells (DCs) in a variety of tissues (Kraal et al, supra; Crowley et al, 1989, Cell Immunol 118:108; Vremec et al, 1992, J Exp Med 176:47; Pollard and Lipscomb, 1990, J Exp Med 172:159; Soesatyo et al, 1990, Cell Tiss Res 259:587; Austyn et al, 1994, J Immunol 152:2401; Lu et al, 1994, J Exp Med 179:1823; and Breel et al, 1988, Immunol 63:657). Kraal et al, 1990, Immunobiology 181(4-5): 385-397 also disclose a second antibody, 6D2, which is also reactive with DEC (as defined below). The antigen bound by NLDC-145 is also abundant on thymic cortical epithelium. However, cloning and characterization of the NLDC-145 antigen has proved elusive. For one thing, dendritic cell cDNA libraries have not been readily prepared. Dendritic cells themselves are rare, making their RNA extremely rare.

Moreover, monoclonal antibodies are not usually effective reagents for screening expression libraries, eg a kgt-11 expression library.

Accordingly, there is a need in the art to clone and characterize the antigen recognized by monoclonal antibody NLDC-145.

S*

0r There is a further need in the art to harness the immunomodulatory abilities of S dendritic cells, eg, to induce tolerance or immunity.

The citation of any reference herein should not be construed as an admission that such reference is prior art to the instant invention.

WO 96/23882 PCT/US96/01383 3 SUMMARY OF THE INVENTION The present invention relates to an integral membrane protein, termed herein "DEC," found primarily on dendritic cells, but also found on B cells, brain capillaries, bone marrow stroma, epithelia of intestinal villi and pulmonary airways, as well as cortical epithelium of the thymus and the dendritic cells in the T cell areas of peripheral lymphoid organs. In addition, trace amounts of this protein are found in organs like the liver, heart, and kidney. The murine and human counterparts of DEC have an apparent molecular mass of 205 kDa, the murine counterpart has an isoelectric point at pH 7.5, .and carbohydrates comprise about 7 kDa of the total mass of murine DEC. The carbohydrates appear to consist of eight distinct but related biantennary N-linked glycans, with no O-linked glycans present. Because the protein has been found predominantly on Dendritic cells and thymic Epithelial Cells, and has a molecular weight of 205 kDa, it is termed DEC-205. In a specific embodiment, the invention relates to isolation and cloning of human DEC, which is further characterized by having a carboxylterminal sequence RHRLHLAGFSSVRYAQGVNEDEIMLPSFHD (SEQ ID NO: and characterized by binding to a rabbit polyclonal antibody raised against full length murine DEC-205, but not reacting with monoclonal antibody NLDC-145.

In a more specific embodiment, human DEC has the amino acid sequence depicted in SEQ ID NO:8; it may be encoded by the nucleotide sequence depicted in SEQ ID NO:7. Another characteristic of DEC, based on the deduced amino acid sequence information obtained from cloning the dec cDNA is a unique coated pit localization consensus domain or motif on the cytoplasmic tail of the protein, which, as shown in Figure 9, has regions of homology and regions of dissimilarity between the two counterpart proteins. It has been further discovered that DEC- 205 is rapidly internalized via coated vesicles, and delivers bound substances to a multivesicular endosomal compartment that resembles the MHC class-II containing vesicles implicated in antigen processing.

WO 96/23882 PCT/US96/01383 4 Accordingly, in its primary aspect, the present invention is directed to identification of additional ligands of the DEC-205 receptor, which can be advantageously targeted to dendritic cells and other cells that bear DEC-205.

Targeting antigens for presentation by dendritic cells can provide for tolerance when the dendritic cells are quiescent, or for immune stimulation vaccination) when the dendritic cells are activated, by stimulation with a cytokine or lymphokine, such as colony stimulating factor (CSF).

Furthermore, the presence of DEC on epithelial cells suggests an important role in trans-epithelial transport of molecules, from the basolateral surface of-the lung respiratory epithelium into lung airways or the basolateral surface of the intestinal epithelium into the lumen of the intestines, and from the apical (lumenal) surface of these epithelial to the pulmonary or intestinal circulation, respectively.

Thus, the invention provides for parenteral delivery of pharmacological agents, antibiotics, to infections of the lung or the intestines, by targeting the pharmacological agent with a ligand to DEC, and for systemic delivery of pharmacological agents by aerosolization and inhalation via the lungs, or ingestion and absorption via the intestines.

In a further aspect, the invention provides for targeting pharmacological agents to cross the blood brain barrier via DEC located on the brain capillaries.

Thus, in a preferred aspect, the invention provides a method for identifying a ligand for DEC. comprising contacting a protein comprising at least one DEC lectin domain with a candidate ligand; and detecting binding of the candidate ligand with the DEC lectin domain. Binding of the candidate ligand and the DEC lectin domain indicates that the ligand candidate is a ligand for DEC. In a preferred aspect, the ligand is a saccharide. which binds to one or more of the lectin domains on DEC.

WO 96/23882 PCIfIJS96/01383 According to one aspect of the invention, the protein comprising at least one DEC lectin domain is expressed by cells as an integral membrane protein, and the candidate ligand is labeled, such that binding of the candidate ligand with the DEC lectin domain is detected by detecting association of the label with the cells. In another embodiment, the protein comprising at least one DEC lectin domain is solubilized, and the candidate ligand is irreversibly associated with a solid phase support, such that binding of the candidate ligand with the DEC lectin domain is detected by detecting binding of the protein with the solid phase support. In yet another embodiment, the protein comprising at least one DEC lectin domain is irreversibly associated with a solid phase support, and the candidate ligand is labeled, such that binding of the candidate ligand with the DEC lectin domain is detected by detecting association of label with the solid phase support. In one embodiment, the protein comprising at least one DEC lectin domain is a truncated DEC protein; in another embodiment, the protein comprising at least one DEC lectin domain is a full length DEC protein.

The present invention advantageously provides a nucleic acid encoding at least a portion of a DEC protein. Thus, the invention provides for expression of DEC proteins, or truncated fragments thereof, including chimeric proteins, which can be used for identifying a DEC ligand. Moreover, the nucleic acid of the invention comprises at least fifteen base pairs, thus, the nucleic acids of the invention provide useful probes for detecting expression of mRNA for DEC, PCR primers for reverse transcriptase polymerase chain reaction (RT-PCR) amplification of RNA, or for cloning DEC, and probes for the presence of DEC cDNA or genomic DNA, in a library or cell. In a preferred embodiment, the nucleic acid encodes a human DEC protein. In a specific embodiment, infra, a nucleic acid encoding human DEC is provided.

The present invention further provides an expression vector comprising the nucleic acid encoding DEC. wherein the nucleic acid is a DNA molecule encoding at least a lectin domain of DEC, operatively associated with an expression control WO 96/23882 PCTIUS96/01383 6 sequence. In a further aspect, the invention provides a recombinant host cell comprising the expression vector. In various embodiments, the host cell is a mammalian cell selected from the group consisting of a Chinese hamster ovary cell, an African Green Monkey COS cell, a Madin-Darby canine kidney cell, and an NIH-3T3 fibroblast cell.

The invention further provides an antibody reactive with a human DEC-205 protein, in particular a monoclonal antibody and a polyclonal antibody.

As mentioned above, the present invention advantageously provides for identifying ligands of DEC, which ligands are capable of targeting a molecule to which they are attached, conjugated, to a cell bearing DEC in vitro or in vivo. The ability to target cells that express DEC in vivo has important implications from the perspective of specifically targeting dendritic cells, epithelial cells, of the thymus, small intestine, and lung. Thus, the invention is naturally directed to a pharmaceutical composition comprising a molecule targeted to a tissue selected from the group consisting of pulmonary circulation, intestinal circulation, pulmonary *airways, lumen of the small intestine, dendritic cells in the skin and T cell areas of lymphoid organs, thymus, and brain, which molecule is conjugated to a DEC-ligand. Preferably, the DEC-ligand is selected from the group consisting of a carbohydrate that binds DEC and an anti-DEC antibody, and a pharmaceutically acceptable carrier. In specific embodiments, the molecule is selected from the group consisting of an anti-cancer drug, an anti-viral drug, an antibiotic, an anti-parasitic drug, and an anti-inflammatory drug.

In another aspect of the invention related to targeting, a recombinant vector for introduction of a gene into cells selected from the group consisting of dendritic cells, thymic epithelial cells, lung epithelial cells, small intestine epithelial cells, and brain capillary cells comprising a DNA vector conjugated to a DEC-ligand is provided, wherein the DEC-ligand is selected from the group consisting of a carbohydrate that binds DEC and an anti-DEC antibody. In specific embodiments.

WO 96/23882 PCT/US96/01383 7 the DNA vector is selected from the group consisting of a viral vector, a liposome vector, and a naked DNA vector.

In yet a further embodiment, grounded on the ability to target a molecule to dendritic cells, the present invention provides a vaccine comprising an antigen from a pathogen conjugated to a DEC-ligand, wherein the DEC-ligand is selected from the group consisting of a carbohydrate that binds DEC and an anti-DEC antibody, and an immune stimulator. Examples of pathogens include, but are not limited to, a virus, a bacterium, a parasite, and a tumor. The immune stimulator may be selected from the group consisting of a cytokine, a lymphokine, and an adjuvant. In particular, the invention advantageously provides for targeting a molecule that is either a poor immunogen, or that is not immunogenic at all, to dendritic cells for efficient processing (as DEC is shown herein to be associated with antigen processing mechanisms of dendritic cells) and presentation to responsive T lymphocytes.

Alternatively, the invention provides a composition to induce immune suppression comprising an autoantigen or an allergen conjugated to a DEC-ligand, wherein the DEC ligand is selected from the group consisting of a carbohydrate that binds DEC and an anti-DEC antibody, with the proviso that the composition lack immune stimulatory agents. By targeting an autoantigen or allergen to dendritic cells without including stimulatory agents, cytokines, lymphokines, or adjuvants, the quiescent dendritic cells can process and present antigen.

Presentation of antigen by quiescent dendritic cells is believed to induce antigenspecific T cell anergy or immune tolerance. The autoantigen may be selected from the group consisting of myelin basic protein, collagen or a fragment thereof.

DNA, a nuclear protein, a nucleolar protein, a mitochondrial protein, and a pancreatic 3-cell protein.

It is a primary object of the instant invention to provide ligands for DEC.

Accordingly, an important corollary object of the invention is to identify ligands that specifically bind DEC.

It is a further object to provide nucleic acids encoding DEC.

A related object is to express nucleic acids encoding DEC, or a portion thereof comprising a carbohydrate binding portion of a DEC lectin domain.

These and other objects of the present invention can be readily appreciated by reference to the following Drawings, Detailed Description of the Invention, and Examples.

BRIEF DESCRIPTION OF THE DRAWINGS FIGURE 1. The apparent mass of the antigen bound by NLDC-145 is 205 kDa. (A) Immunoprecipitation of 3 5 S)methionine-cysteine-labeled bone marrow DC extracts with immobilized NLDC-145 (right) reveals an actively synthesized antigen with an apparent mass 200 kDa. This antigen is not precipitated by immobilized nonspecific rat IgG2a (left). NLDC-145 binds an antigen of 205 kDa in non-reducing Western blots of crude thymic detergent extract. Three-fold serial dilutions of extract, starting at ,.20 0.17 thymic equivalents per lane, were loaded onto duplicate gels, in the absence (left filter) or presence (right strip) of 5% 2-mercaptoethanol, and blotted to nitrocellulose. Filters were probed with 10 ,g/ml of NLDC-145 IgG, the peroxidaseconjugated anti-rat IgG. Staining patterns were visualized by ECL. No bands were observed on the reducing gel. STD: positions of prestained broad-range molecular mass 5 markers (Bio-Rad) traced from the original filter onto the developed film.

U

FIGURE 2. Summary: purification of DEC-205 from thymi. All steps were performed at 0-4°C. Leupeptin and PMSF were added to ice-cold buffers just before use.

WO 96/23882 PCT/US96/01383 9 FIGURE 3. Analysis of purified DEC-205 and step yields during the purification. Reducing 8% acrylamide SDS-PAGE analysis of 5 fg of purified protein, stained first with Coomassie Brilliant Blue R-250 (left), then counterstained with silver (right). Isovolumic Western blot of key fractions from the purification, stained with 10 ig/ml of NLDC-145 IgG. Fractions in lanes 1-4 and 6-8 were diluted to the volume of the post-nuclear supernatant, so that the intensities of their 205 kDa bands could be compared and yields estimated. Lane intentional five-fold increase in antigen concentration, to demonstrate a "ladder" of minor mAb-reactive bands ranging down to about 80 kDa in apparent mass. Abbreviations: nuc, nuclear; memb, membrane; extr, 0.5% NP-40 extract; nonads, individual nonadsorbed fractions from early (nonads-5) and late (nonadsin the column loading process.

FIGURE 4. DEC-205 is an integral membrane protein with a pi of 7.5. (A) Immunoblot of thymic membrane proteins solubilized with detergent, 1 M KCI or 100 mM Na 2

CO

3 pH 11.5 (lanes 1, 2, and proteins initially insoluble in the high salt and high-pH buffers, but then released from membranes with detergent (lanes 4 and The filter was stained with 10 pg/ml ofNLDC-145 IgG. (B) Isoelectric focusing of 10 /ig of purified DEC-205 under denaturing conditions. A single lane from a silver-stained slab gel is shown, with pH values assigned after elution of ampholytes from a neighboring unstained lane.

FIGURE 5. Studies of the carbohydrates bound to DEC-205. DEC-205 is a glycoprotein. Purified 205 kDa protein, transferrin (Tf, positive control), and creatinase (cre, negative control) were electroblotted to nitrocellulose, and the filter was oxidized with NaIO 4 converting vic-diols within sugars to immobilized aldehydes. Reaction with a digoxigenin (DIG)-labeled hydrazide, followed by an anti-DIG antibody conjugated to alkaline phosphatase. revealed the positions of glycoproteins on the blot. Like transferrin. but unlike creatinase. DEC-205 stains for sugar. The glycans on DEC-205 comprise about 7 kDa of its apparent molecular mass. Apotransferrin (aTf) and DEC-205 were either treated or not WO 96/23882 PCT/US96/01383 with anhydrous trifluoromethanesulfonic acid (TFMSA), to nonselectively hydrolyze protein-bound carbohydrates. Both treated proteins exhibited increased electrophoretic mobility, corresponding to a 5 kDa loss of apparent mass by apotransferrin, and a 7 kDa loss by DEC-205. FACE analysis of N-linked glycans released from DEC-205 with PNGase F. Eight bands are resolved, migrating between 5.1 and 10.1 glucose units. (Glc),o: positions of selected bands in a standard oligo-glucose ladder. Exoglycosidase digestions and FACE analysis of the mixture of N-linked glycans released from DEC-205. Lane 1: Undigested N-linked oligosaccharides (the dark band at (Glc), in lanes 1-5 is a detergent artifact). Lane 2: digested with a-galactosidase. Lane 3: digested with a-galactosidase plus NANase III. Lane 4: digested with the previous 2 enzymes plus P-galactosidase. Lane 5: digested with the previous 3 enzymes plus P-Nacetylhexoseaminidase. Lane 6: as for lane 5, but 2-fold higher concentration of P-N-acetylhexoseaminidase. Lane 7: digested with the previous 4 enzymes plus amannosidase. Lane 8: as for lane 7, but 2-fold higher concentration of amannosidase plus a-fucosidase. Lane 9: mannosylchitobiose core standards: FC, fucosylated core; C, non-fucosylated core. Summary of findings from lectin staining and FACE analysis. Two fucosylated core structures are present, with and without bisecting GlcNAc. Further heterogeneity at the termini produces the 8 glycan variants observed in FIGURE 6. N-terminal amino acid sequence of DEC-205, and blotting by polyclonal antibodies. The amino-terminal sequence (SEQ ID NO: as determined by two different core facilities. A peptide spanning the first 19 residues was synthesized and coupled to KLH for use as an immunogen. Preclearing study: NLDC-145 specifically depletes the 205 kDa bands detected by both polyclonal antibodies. Immunoblots of crude thymic membrane extract, a depleted fraction produced by passing the same extract over the NLDC-145 immunoaffinity column twice, and material eluted from the column. Filters were stained with: gig/ml of NLDC-145 IgG. 0.1 jg/ml of anti-N-terminal peptide IgG. and 0.1 /g/ml of anti-DEC-205 IgG. All three antibodies bind the same protein.

WO 96/23882 PCT/US96/01383 11 FIGURE 7. Schematic representation of DEC-205.

FIGURE 8. Sequence of murine DEC-205 and related proteins. The predicted amino acid sequence of murine DEC-205 (SEQ ID NO:3) is aligned with the sequences of the bovine PLA2 receptor (SEQ ID NO:4) and the human macrophage mannose receptor (SEQ ID NO:5). Amino acid positions where there is identity among all three proteins are shaded. Protein domains are separated, and consensus amino acids that define C-type CRDs (Weis et al., Science 254:1608-15) are indicated blow the relevant sequence as follows: invariant amino acids are shown in single letter code, 0 aliphatic, x aliphatic or aromatic, 4 aromatic, Z E or Q, B D or N, 92 D, N, E or Q. The two missing cysteines in CRD 8 are highlighted with a Peptide sequences determined by automated Edman degradation from purified DEC-205 protein are overlined and numbered (N indicates amino terminal, T indicates peptides generated with Trypsin, and L indicates peptides generated with endoproteinase lys-C).

FIGURE 9. Comparison of carboxyl-terminal cytoplasmic domain sequences of human (top) (SEQ ID NO:1) and murine (bottom) (SEQ ID NO:6) DEC-205.

Regions of identity are underlined; regions of similarity are italicized.

FIGURE 10. DEC-205 Expression. Expression of DEC-205 in mouse tissues and transfected Cos-7 cells. A. Northern blot of poly-A+ A extracted from the indicated tissues. Symbols: Br, brain mRNA: DC. dendritic cell mRna; Ht, heart mRNA; Kd, kidney mRNA; Lv, liver mRNA; LN, lymph node mRNA; Sk, skin mRNA; Thm thymus mRNA; tg. tongue mRNA.

FIGURE 11. Endocytosis of DEC-205. Ultrastructural analysis of DEC-205 on dendritic cells with polyclonal rabbit anti-DEC-205 F(ab)'2 fragments and 1Onm gold-labeled goat anti-rabbit IgG (Amersham). The bars represent 100 ptm.

Symbols: MVV. multivesicular endosome: Ly. Lysosome: CP. coated pit: 0', fixation at time zero: fixation after a one-minute incubation at 37°C: fixation WO 96/23882 PCT/US96/01383 12 after a five-minute incubation at 37 0 C; 20', fixation after a twenty-minute incubation at 37 0 C; 60', fixation after a sixty-minute incubation at 37°C.

FIGURE 12. Antigen Presentation. Antigen presentation by Dendritic cells incubated with rabbit anti-DEC-205 antibodies or non-reactive rabbit antibody controls. IL-2 production by the 2R.50 cells is plotted against the concentration of antibody in the cultures on a log scale. The error bars indicate the standard deviation from the mean. Symbols: anti-DEC-205, cultures that received the indicated amount of rabbit anti-DEC-205 polyclonal IgG; anti-IgG2a. cultures that received the indicated amount of IgG2a specific polyclonal rabbit antibodies; IgG, cultures that received the indicated amount of non-immune rabbit IgG.

FIGURE 13. Selective staining of Langerhans cells with monoclonal and polyclonal antibodies to DEC-205. Cultured epidermal cells were double-labeled with a PE-tagged mAb to class II MHC proteins (y axis) and multiple antibodies to leukocyte antigens, followed by FITC-anti-Ig (x axis). The mean FITC fluorescence intensity for the MHC-II DCs arrows in E and H) is shown in the upper right corer of each panel.

Specificity: Langerhans cells stain for DEC-205, but not for macrophage, B cell or T cell antigens. Rat IgG2a hybridoma supernatants were applied.

Titrations of the monoclonal and polyclonal reagents used in subsequent studies: Graded doses of NLDC-145 mAb 2 and 6 I/g/ml).

Polyclonal, nonimmune rat IgG2a (6 ug/ml).

Rabbit IgGs and fragments at 3. 10, 30 and 100 ftg/ml FIGURE 14. Trypsin sensitivity and resynthesis of DEC-205 epitopes.

Langerhans cells or lymph node B cells that had been cultured overnight were either exposed to 0.25% trypsin for 30 min on ice. or were not treated. The lymph node B cells had been stimulated with LPS to sustain viability.

Cells were either stained immediately (dl) or after an additional day of culture WO 96/23882 PCT/US96/01383 13 The antibodies were: 30 jg/ml anti-DEC-205 or nonimmune F(ab') 2 fragments C, E, G, I, and 2 /g/ml NLDC-145 or nonimmune rat IgG2a; or (clone MI/9, rat IgG2a) hybridoma supernatant D, F, H, J, and L).

FIGURE 15. Expression of DEC-205 by fresh and cultured dendritic cells (arrows) from spleen and skin. Spleen DCs, enriched in the low-density fraction of spleen cells, were identified with anti-CD lIc (y axis, A-H) and counterstained with: NLDC-145; F(ab')2 fragments of the anti-DEC-205 polyclonal; and corresponding nonimmune controls. Staining was performed either immediately after flotation (fresh), or after overnight culture. Fresh and cultured Langerhans cells, identified in an epidermal suspension with a mAb to class II MHC proteins (y axis, are shown for comparison.

FIGURE 16. Expression of class II MHC proteins and DEC-205 by bone marrow DCs grown from progenitors in the presence of GM-CSF. On days 6, 7 and 8 of culture, cells were examined both by flow cytometry and on cytocentrifuge slides after staining with: 10 j/g/ml of TIB-120 (clone M5/114, anti anti I-Ed.k) or nonimmune IgG C, 30 jg/ml of anti- DEC-205 or nonimmune IgG D, or 2 /g/ml of NLDC-145 H, (d6) At day 6, the cultures contained large proliferating cell aggregates that expressed heterogeneous levels of class II MHC proteins and little DEC-205. The aggregates were dislodged from plastic-adherent stromal cells. (d7. d8) Over two subsequent days of culture, the aggregates released large numbers of nonadherent cells with typical dendritic morphology, abundant class II MHC proteins, and high levels of DEC-205.

FIGURE 17. Expression of DEC-205 on peritoneal cells. Peritoneal cells, either resident or in exudates elicited with the indicated proinflammatory agents, were stained with 30 pg/ml of anti-DEC-205 or nonimmune fragments and FITC-anti-rabbit The cells were then counterstained with PE-tagged mAbs to macrophagcs. B cells and T cells. Shown here is staining by PE-anti-Mac- WO 96/23882 PCT/US96/01383 14 1/CD lb (mAb M1/70, y axis). The Mac-l brigh cells are macrophages (arrowheads), the Mac-1dim cells are B cells (arrows) and the Mac-1 negative cells, T cells. Abbreviations: Con A, concanavalin A; TGC, thioglycollate;

BCG,

Mycobacterium bovis Bacille Calmette-Gu6rin.

FIGURE 18. Expression of DEC-205 by leukocytes in fresh cell suspensions from three organs. B cells are arrowed. Cells from spleen bone marrow and peripheral blood were stained with PE-tagged antibodies to subsets of leukocytes (y axis), and counterstained with 30 yg/ml of nonimmune (A- E, K-O, and U-Y) or anti-DEC-205 P-T, and Z-6) F(ab') 2 fragments (x axis, FITC). The PE-labeled mAbs reacted with granulocytes (RB6-8C5, anti Gr-1), the integrin CD 11b, abundant on granulocytes and macrophages (M1/70, anti-Mac-1), B cells (RA3-6B2, anti-B220/CD45RB), T cells (53-2.1, anti-Thy-1.2/CD90), and class II MHC proteins (AMS-32.1, anti- I-Ad).

FIGURE 19. Immunoblot. Graded doses of whole-cell NP-40 extracts of bone marrow dendritic cells (BMDC), bulk splenic leukocytes (SPL, ca. 65% B cells) and resident peritoneal cells (PC, ca. 70% B cells. 30% macrophages) were transferred to a filter. The filter was stained with 10 tg/ml of NLDC-145 IgG.

BMDCs express roughly 10 times more DEC-205 per cell than splenic B cells, and roughly 50 times more than peritoneal B cells.

FIGURE 20. Inability of antibodies to DEC-205 to block dendritic cell stimulatory activity in vitro. A mixed leukocyte reaction, where graded doses of mitomycin C-treated spleen dendritic cells were added to 3 x 105 allogeneic lymph node cells in the continuous presence of 10 yg/ml of each of the indicated antibodies, except for anti-DEC-205. which was used at 30 /ug/ml. Only the mAb to the costimulator protein B7-2 (clone GL-1) inhibited T cell proliferation. Anti- Igf: negative control polyclonal to a surface Ig-associated signalling protein on B cells (Sanchez et al.. 1993. J. Exp. Med. 178:1049).

WO 96/23882 PCT/US96/01383 FIGURE 21. Expression of DEC-205 in the thymus and in lymph nodes. (a- Low power of thymus cortex and medulla stained with: monoclonal NLDC-145 polyclonal anti-DEC-205 F(ab')2 fragments and polyclonal anti-DEC-205 IgG all at 10 /g/ml, and counterstained with hematoxylin.

Presumptive dendritic cells (arrowheads) are scattered throughout the medulla, but the strongest thymic staining is on cortical epithelium. Low power views of a mesenteric lymph node, showing a B cell follicle the T cell area of the deep cortex and the medulla stained with: mAb NLDC-145 polyclonal anti-DEC-205 F(ab') 2 fragments and polyclonal anti-DEC-205 IgG Darkly-stained dendritic cells are distributed throughout the T cell areas. Higher power views to show the distribution of DEC-205 at the junction of the thymic cortex and medulla within the deep cortex of a lymph node a venule is arrowed), and in B cell follicles no hematoxylin counterstain).

FIGURE 22. Expression of DEC-205 in the spleen. Low power views of a splenic white pulp nodule, stained with antibodies to: B cells (rabbit anti-Igp, a); DEC-205 (polyclonal anti-DEC-205 IgG, and class II MHC proteins (mAb M5/114, The central arteries within the T cell areas are arrowed. The T cell areas contain few B cells anti-Igp), but numerous scattered DEC-205- and class II MHC-positive dendritic cells B cell follicles are denoted with a and the marginal sinus by arrowheads. Higher power views of splenic T cell areas (periarterial sheaths, central arteries are arrowed) stained with: mAb NLDC- 145 polyclonal anti-DEC-205 and anti-class II MHC Staining for DEC-205 has a punctate quality, in addition to the more prominent staining of dendritic cell bodies.

FIGURE 23. Expression of DEC-205 in several nonlymphoid organs. Brain capillaries (arrows, a-c) and small arteries (arrow, stained with: mAb NLDC-145 polyclonal anti-DEC-205 F(ab') fragments and polyclonal anti-DEC-205 IgG Lung. showing anti-DEC-205 staining of airway epithelium (arro:ws. c and isolated cells within the lung parenchyma WO 96/23882 PCTJUS96/01383 16 (arrowheads, g and and some presumptive alveolar macrophages Class II MHC proteins are not evident within airway epithelium, but there are many positive profiles surrounding the airways (arrowheads, An extruded plug of bone marrow. Lacy stromal cells (arrows) express low levels of DEC-205. The darker staining of round cells is background staining by peroxidase-expressing eosinophils. Tongue, showing DEC-205 staining of a minority of presumptive Langerhans cells (arrows) at suprabasal levels within the oral epithelium, shown as an example of a stratified squamous epithelium. Jejunum: DEC-205 is expressed by the absorptive epithelial cells of the intestinal villi, with the highest levels observed at the apices of the villi. Numerous cells within the lamina propria also stain darkly, but this staining is again a background of eosinophil peroxidase.

FIGURE 24. Tissue distribution of DEC-205 by immunoblotting. Lysates of the indicated organs were blotted to compare relative levels of expression of DEC- 205 protein filter stained with mAb NLDC-145) and the LAMP-1 lysosomal membrane antigen filter stained with mAb 1D4B). Fifty jg of total protein were loaded in each lane.

FIGURE 25. Amino acid and nucleotide sequence comparisons for human and murine DEC-205. Matrix plot (pam 250 matrix) of translated murine (yaxis) and human (x-axis) DEC-205 amino acid sequences. The window size for this plot was 60, the minimum percent score was 60, and the hash value is 2. (B) Matrix plot (DNA identity matrix) of murine (y-axis) and human (x-axis) DNA sequences. The window size was 60, the minimum percent score was 65, the hash value was 6, and the jump value was 1. Both strands were evaluated.

DETAILED DESCRIPTION OF THE INVENTION The present invention relates to an integral membrane protein, termed herein "DEC." found primarily on dendritic cells, but also found on B cells, brain capillaries, bone marrow stroma. epithelia of intestinal villi and pulmonary airways.

WO 96/23882 PCTIUS96/01383 17 as well as cortical epithelium of the thymus and the dendritic cells in the T cell areas of peripheral lymphoid organs. In addition, trace amounts of this protein are found in organs like the liver, heart, and kidney. The murine and human counterparts of DEC have an apparent molecular mass of 205 kDa, the murine counterpart has an isoelectric point at pH 7.5, and carbohydrates comprise about 7 kDa of the total mass of murine DEC. The carbohydrates appear to consist of eight distinct but related biantennary N-linked glycans, with no O-linked glycans present. Because the protein has been found predominantly on Dendritic cells and thymic Epithelial Cells, and has a molecular weight of 205 kDa, it is termed DEC- 205. Although characterization of the murine and human counterparts of DEC demonstrates the presence of ten carbohydrate binding domains, with a high degree of homology, it is possible that DEC from other species may have more or fewer such domains. Similarly, DEC may be expressed by other cell types, such as epithelial cells from other tissues or organs.

The invention further relates to cloning of the gene encoding DEC-205, and characterization of the encoded protein. The sequence information indicates that DEC-205 is a receptor with ten C-type lectin domains, which is homologous, or similar, to the macrophage mannose receptor and other related receptors that bind carbohydrates and mediate endocytosis. The human counterpart also appears to have lectin domains. Accordingly, DEC is believed to have a corresponding number of lectin domains, and to be involved in antigen processing by dendritic cells.

Still another aspect of the present invention is the identification of a human DEC protein and gene encoding it.

Another characteristic of DEC. based on the deduced amino acid sequence information obtained from cloning the dec cDNA is a unique coated pit localization consensus domain or motif on the cytoplasmic tail of the protein. which. as shown WO 96/23882 PCT/US96/01383 18 in Figure 9, has regions of homology and regions of dissimilarity between the two counterpart proteins.

It has been further discovered that DEC-205 is rapidly internalized via coated vesicles, and delivers bound substances to a multivesicular endosomal compartment that resembles the MHC class-II containing vesicles implicated in antigen processing. The invention is also based, in part, on the further discovery that rabbit antibody specific for DEC-205 was efficiently processed by dendritic cells and presented to rabbit-specific T cell clones.

Accordingly, and most importantly, the present invention is directed to identification of additional ligands of the DEC-205 receptor, which can be advantageously targeted to dendritic cells and other cells that bear DEC-205.

Targeting antigens for presentation by dendritic cells can provide for tolerance when the dendritic cells are quiescent, or for immune stimulation vaccination) when the dendritic cells are activated, by stimulation with a cytokine or lymphokine. such as colony stimulating factor (CSF).

Furthermore, the presence of DEC on epithelial cells suggests an important role in trans-epithelial transport of molecules, from the basolateral surface of the lung respiratory epithelium into lung airways or the basolateral surface of the intestinal epithelium into the lumen of the intestines, and from the apical (lumenal) surface of these epithelial to the pulmonary or intestinal circulation, respectively. Thus, the invention provides for parenteral delivery of pharmacological agents, e.g., antibiotics. to infections of the lung or the intestines, by targeting the pharmacological agent with a ligand to DEC. and for systemic delivery of pharmacological agents by aerosolization and inhalation via the lungs, or ingestion and absorption via the intestines.

In a further aspect, the invention provides for targeting pharmacological agents to cross the blood brain barrier via DEC located on the brain capillaries.

WO 96/23882 PCT/US96/01383 19 Accordingly, various terms are used throughout this specification, which have the meanings as defined below.

The term "candidate ligand" is used herein to refer to a molecule under consideration of test for its ability to specifically bind to DEC. As discussed in greater detail, infra, candidate ligands include, but are by no means limited to, saccharides sugars, carbohydrates, or glycans). The term "ligand" as used herein can also refer to an antibody reactive with DEC.

A molecule is "antigenic" when it is capable of specifically interacting with an antigen recognition molecule of the immune system, such as an immunoglobulin (antibody) or T cell antigen receptor. An antigenic polypeptide contains at least about 5, and preferably at least about 10, amino acids. An antigenic portion of a molecule can be that portion that is immunodominant for antibody or T cell receptor recognition, or it can be a portion used to generate an antibody to the molecule by conjugating the antigenic portion to a carrier molecule for immunization. A molecule that is antigenic need not be itself immunogenic, i.e., capable of eliciting an immune response without a carrier.

A composition comprising (where is a single protein, DNA molecule, vector, recombinant host cell, etc.) is substantially free of (where "B" comprises one or more contaminating proteins, DNA molecules, vectors, etc.) when at least about 75% by weight of the proteins. DNA, vectors (depending on the category of species to which A and B belong) in the composition is Preferably, comprises at least about 90% by weight of the A+B species in the composition, most preferably at least about 99% by weight. It is also preferred that a composition, which is substantially free of contamination, contain only a single molecular weight species having the activity or characteristic of the species of interest.

WO 96/23882 PCT/US96/01383 The phrase "pharmaceutically acceptable" refers to molecular entities and compositions that are physiologically tolerable and do not typically produce an allergic or similar untoward reaction, such as gastric upset, dizziness and the like, when administered to a human. In a specific embodiment, as used herein, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the compound is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water or aqueous solution saline solutions and aqueous dextrose and glycerol solutions are preferably employed as carriers, particularly for injectable solutions. Suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin.

The phrase "therapeutically effective amount" is used herein to mean an amount sufficient to reduce by at least about 15 percent, preferably by at least 50 percent, more preferably by at least 90 percent, and most preferably prevent, a clinically significant deficit in the activity, function and response of the host. Alternatively, a therapeutically effective amount is sufficient to cause an improvement in a clinically significant condition in the host.

The term "adjuvant" refers to a compound or mixture that enhances the immune response to an antigen. An adjuvant can serve as a tissue depot that slowly releases the antigen and also as a lymphoid system activator that non-specifically enhances the immune response (Hood et al.. Immunology. Second Ed., 1984.

Benjamin/Cummings: Menlo Park. California, p. 384). Often. a primary challenge with an antigen alone, in the absence of an adjuvant. will fail to elicit a humoral or cellular immune response. Adjuvants include, but are not limited to. complete Freund's adjuvant. incomplete Freund's adjuvant. saponin. mineral gels such as WO 96/23882 PCT/US96/01383 21 aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil or hydrocarbon emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and Corynebacterium parvum. Preferably, the adjuvant is pharmaceutically acceptable.

Various abbreviations used throughout this specification include: PBS, phosphatebuffered saline; mAb, monoclonal antibody; SPF, specific pathogen-free; PMSF, phenylmethylsulfonyl fluoride; DIFP, diisopropyl fluorophosphonate; FACE, fluorophore-assisted carbohydrate electrophoresis.

Genes Encoding DEC. or Fragments. Derivatives. Chimeras. or Analogs Thereof The present invention contemplates isolation of a gene encoding a functional portion of a DEC receptor of the invention, including a full length, or naturally occurring form of DEC, and any antigenic fragments thereof from any animal, particularly mammalian or avian, and more particularly human, source. As used herein, the term "gene" refers to an assembly of nucleotides that encode a polypeptide, and includes cDNA and genomic DNA nucleic acids. In specific embodiments, infra, a specific nucleotide sequence of a human DEC-encoding DNA is provided (SEQ ID NO:8); also provided are deduced coding sequences for both murine and human DEC polypeptides having the amino acid sequences depicted in SEQ ID NO:3 and SEQ ID NO:8, respectively, are provided.

Accordingly, there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, Sambrook. Fritsch Maniatis. Molecular Cloning: A Laboratory Manual Second Edition (1989) Cold Spring Harbor Laboratory Press. Cold Spring Harbor, New York (herein "Sambrook et al.. 1989"); DNA Cloning: A Practical Approach. Volumes I and II Glover ed. 1985): Oligonucleotide Synthesis Gait ed. 1984): Nucleic Acid H'bridization Hames S.J. H-iggins eds. (1985)]: Transcription And WO 96/23882 PCTIUS96/01383 22 Translation Hames S.J. Higgins, eds. (1984)]; Animal Cell Culture [R.I.

Freshney, ed. (1986)]; Immobilized Cells And Enzymes [IRL Press, (1986)]; B. Perbal, A Practical Guide To Molecular Cloning (1984); F.M. Ausubel et al.

Current Protocols in Molecular Biology, John Wiley Sons, Inc. (1994).

Therefore, if appearing herein, the following terms shall have the definitions set out below.

A "nucleic acid molecule" refers to the phosphate ester polymeric form of ribonucleosides (adenosine, guanosine, uridine or cytidine; "RNA molecules") or deoxyribonucleosides (deoxyadenosine, deoxyguanosine, deoxythymidine, or deoxycytidine; "DNA molecules") in either single stranded form, or a doublestranded helix. Double stranded DNA-DNA, DNA-RNA and RNA-RNA helices are possible. The term nucleic acid molecule, and in particular DNA or RNA molecule, refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, this term includes doublestranded DNA found, inter alia, in linear or circular DNA molecules restriction fragments), plasmids, and chromosomes. In discussing the structure of particular double-stranded DNA molecules, sequences may be described herein according to the normal convention of giving only the sequence in the 5' to 3' direction along the nontranscribed strand of DNA the strand having a sequence homologous to the mRNA). A "recombinant DNA molecule" is a DNA molecule that has undergone a molecular biological manipulation.

A nucleic acid molecule is "hybridizable" to another nucleic acid molecule, such as a cDNA. genomic DNA, or RNA. when a single stranded form of the nucleic acid molecule can anneal to the other nucleic acid molecule under the appropriate conditions of temperature and solution ionic strength (see Sambrook et al.. supra).

The conditions of temperature and ionic strength determine the "stringency" of the hybridization. For preliminary screening for homologous nucleic acids, low stringency hybridization conditions, corresponding to a Tm of 55°. can be used. ec...

WO 96/23882 PCr/S96/01383 23 SSC, 0.1% SDS, 0.25% milk, and no formamide; or 30% formamide, 5x SSC, SDS). Moderate stringency hybridization conditions correspond to a higher Tm, 40% formamide, with 5x or 6x SCC. High stringency hybridization conditions correspond to the highest Tm, 50% formamide, 5x or 6x SCC.

Hybridization requires that the two nucleic acids contain complementary sequences, although depending on the stringency of the hybridization, mismatches between bases are possible. The appropriate stringency for hybridizing nucleic acids depends on the length of the nucleic acids and the degree of complementation, variables well known in the art. The greater the degree of similarity or homology between two nucleotide sequences, the greater the value of Tm for hybrids of nucleic acids having those sequences. The relative stability (corresponding to higher of nucleic acid hybridizations decreases in the following order: RNA:RNA, DNA:RNA, DNA:DNA. For hybrids of greater than 100 nucleotides in length, equations for calculating Tm have been derived (see Sambrook et al., supra, 9.50-0.51). For hybridization with shorter nucleic acids, i.e., oligonucleotides, the position of mismatches becomes more important, and the length of the oligonucleotide determines its specificity (see Sambrook et al., supra, 11.7-11.8). Preferably a minimum length for a hybridizable nucleic acid is at least about 10 nucleotides; more preferably at least about 15 nucleotides; most preferably the length is at least about 20 nucleotides.

A DNA "coding sequence" is a double-stranded DNA sequence which is transcribed and translated into a polypeptide in a cell in vitro or in vivo when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxyl) terminus. A coding sequence can include, but is not limited to, prokaryotic sequences. cDNA from eukaryotic mRNA, genomic DNA sequences from eukaryotic mammalian) DNA, and even synthetic DNA sequences. If the coding sequence is intended for expression in a eukaryotic cell, a polyadenylation signal and transcription termination sequence will usually be located 3' to the coding sequence.

WO 96/23882 PCT/US96/01383 24 Expression control sequences, transcriptional and translational control sequences are DNA regulatory sequences, such as promoters, enhancers, terminators, and the like, that provide for the expression of a coding sequence in a host cell. In eukaryotic cells, polyadenylation signals are control sequences.

A "promoter sequence" is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream direction) coding sequence. For purposes of defining the present invention, the promoter sequence is bounded at its 3' terminus by the transcription initiation site and extends upstream direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background.

Within the promoter sequence will be found a transcription initiation site (conveniently defined for example, by mapping with nuclease S as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase.

A coding sequence is "under the control of" or "operatively associated with" a transcriptional and translational control sequence in a cell when RNA polymerase transcribes the coding sequence into mRNA. which is then trans-RNA spliced and translated into the protein encoded by the coding sequence.

A "signal sequence" is included at the beginning of the coding sequence of a protein to be expressed on the surface of a cell. This sequence encodes a signal peptide, N-terminal to the mature polypeptide, that directs the host cell to translocate the polypeptide. The term "translocation signal sequence" is used herein to refer to this sort of signal sequence. Translocation signal sequences can be found associated with a variety of proteins native to eukaryotes and prokaryotes.

and are often functional in both types of organisms.

As used herein, the term "sequence homology" in all its grammatical forms refers to the relationship between proteins that possess a "common evolutionary origin." WO 96/23882 PCT/US96/01383 including proteins from superfamilies the immunoglobulin superfamily) and homologous proteins from different species myosin light chain, etc.) (Reeck et al., 1987, Cell 50:667).

Accordingly, the term "sequence similarity" in all its grammatical forms refers to the degree of identity or correspondence between nucleic acid or amino acid sequences of proteins that do not share a common evolutionary origin (see Reeck et al., supra).

Two DNA sequences are "substantially homologous" or "substantially similar" when at least about 75% (preferably at least about 80%, and most preferably at least about 90 or 95%) of the nucleotides match over the defined length of the DNA sequences. Sequences that are substantially homologous can be identified by comparing the sequences using standard software available in sequence data banks, or in a Southern hybridization experiment under, for example, stringent conditions as defined for that particular system. Defining appropriate hybridization conditions is within the skill of the art. See, Maniatis et al., supra; DNA Cloning, Vols.

I II, supra; Nucleic Acid Hybridization, supra.

Similarly, two amino acid sequences are "substantially homologous" or "substantially similar" when greater than 70% of the amino acids are identical, or functionally identical. Preferably, the similar or homologous sequences are identified by alignment using, for example, the GCG (Genetics Computer Group.

Program Manual for the GCG Package, Version 7, Madison, Wisconsin) pileup program.

The term "corresponding to" is used herein to refer similar or homologous sequences, whether the exact position is identical or different from the molecule to which the similarity or homology is measured. Thus. the term "corresponding to" refers to the sequence similarity, and not the numbering of the amino acid residues or nucleotide bases.

WO 96/23882 PCTIUS96/01383 26 A gene encoding DEC, whether genomic DNA or cDNA, can be isolated from any source, particularly from a human cDNA or genomic library. Methods for obtaining DEC gene are well known in the art, as described above (see, e.g., Sambrook et al., 1989, supra). In specific embodiment, infra, a cDNA encoding murine DEC-205 is isolated from a dendritic cell library. In addition, probes derived from the murine gene were used to isolate the corresponding human dec cDNA and the murine genomic dec gene.

Accordingly, any animal cell potentially can serve as the nucleic acid source for the molecular cloning of a dec gene. The DNA may be obtained by standard procedures known in the art from cloned DNA a DNA "library"), and preferably is obtained from a cDNA library prepared from tissues with high level expression of the protein a dendritic cell cDNA or thymic epithelial cDNA library, since these are the cells that evidence highest levels of expression of DEC), by chemical synthesis, by cDNA cloning, or by the cloning of genomic DNA, or fragments thereof, purified from the desired cell (See, for example. Sambrook et al., 1989, supra; Glover, D.M. 1985. DNA Cloning: A Practical Approach.

MRL Press, Ltd., Oxford, U.K. Vol. I, II). Clones derived from genomic DNA may contain regulatory and intron DNA regions in addition to coding regions: clones derived from cDNA will not contain intron sequences. Whatever the source.

the gene should be molecularly cloned into a suitable vector for propagation of the gene.

In the molecular cloning of the gene from genomic DNA, DNA fragments are generated, some of which will encode the desired gene. The DNA may be cleaved at specific sites using various restriction enzymes. Alternatively. one may use DNAse in the presence of manganese to fragment the DNA, or the DNA can be physically sheared, as for example, by sonication. The linear DNA fragments can then be separated according to size by standard techniques, including but not limited to, agarose and polyacrylamide gel electrophoresis and column chromatography.

WO 96/23882 PCTIUS96/01383 27 Once the DNA fragments are generated, identification of the specific DNA fragment containing the desired dec gene may be accomplished in a number of ways. For example, if an amount of a portion of a dec gene or its specific RNA, or a fragment thereof, is available and can be purified and labeled, the generated DNA fragments may be screened by nucleic acid hybridization to the labeled probe (Benton and Davis, 1977, Science 196:180; Grunstein and Hogness, 1975, Proc.

Natl. Acad. Sci. U.S.A. 72:3961). For example, a set of oligonucleotides corresponding to the partial amino acid sequence information obtained for the DEC protein can be prepared and used as probes for DNA encoding DEC, as was done in a specific example, infra, or as primers for cDNA or mRNA in combination with a poly-T primer for RT-PCR). Preferably, a fragment is selected that is highly unique to DEC of the invention. Those DNA fragments with substantial homology to the probe will hybridize. As noted above, the greater the degree of homology, the more stringent hybridization conditions can be used. In a specific embodiment, the human dec cDNA was cloned using a 300 base-pair probe derived from the 3' coding sequence of murine dec cDNA. The human cDNA was obtained from a B lymphoma library, using high stringency hybridization conditions (0.1 SSC, 65 0 Thus, high stringency hybridization conditions are favored to identify a homologous dec gene from other species.

Further selection can be carried out on the basis of the properties of the gene, e.g., if the gene encodes a protein product having the isoelectric, electrophoretic, amino acid composition, or partial amino acid sequence of DEC protein as disclosed herein. Thus, the presence of the gene may be detected by assays based on the physical, chemical, or immunological properties of its expressed product. For example, cDNA clones, or DNA clones which hybrid-select the proper mRNAs, can be selected which produce a protein that. has similar or identical electrophoretic migration, isoelectric focusing or non-equilibrium pH gel electrophoresis behavior, proteolytic digestion maps, or antigenic properties as known for DEC. For example, the rabbit polyclonal antibody to murine DEC, described in detail infi-a. can be used to confirm expression of DEC. both murine WO 96/23882 PCTfUS96/01383 28 and human counterparts. In another aspect, a protein that has an apparent molecular weight of 205 kDa, and which is specifically digested to form a defined ladder (rather than a smear) of lower molecular weight bands, is a good candidate for DEC.

A dec gene of the invention can also be identified by mRNA selection, by nucleic acid hybridization followed by in vitro translation. In this procedure, nucleotide fragments are used to isolate complementary mRNAs by hybridization.

Such DNA fragments may represent available, purified dec DNA, or may be synthetic oligonucleotides designed from the partial amino acid sequence information. Immunoprecipitation analysis or functional assays tyrosine phosphatase activity) of the in vitro translation products of the products of the isolated mRNAs identifies the mRNA and, therefore, the complementary

DNA

fragments, that contain the desired sequences. In addition, specific mRNAs may be selected by adsorption of polysomes isolated from cells to immobilized antibodies specifically directed against DEC, such as the rabbit polyclonal anti-murine DEC antibody described herein.

A radiolabeled dec cDNA can be synthesized using the selected mRNA (from the adsorbed polysomes) as a template. The radiolabeled mRNA or cDNA may then be used as a probe to identify homologous dec DNA fragments from among other genomic DNA fragments.

The present invention also relates to cloning vectors containing genes encoding analogs and derivatives of DEC of the invention, that have the same or homologous functional activity as DEC. and homologs thereof from other species. The production and use of derivatives and analogs related to DEC are within the scope of the present invention. In a specific embodiment, the derivative or analog is functionally active, capable of exhibiting one or more functional activities associated with a full-length, wild-type DEC.

WO 96/23882 PCTIUS96/01383 29 In another aspect, a DEC protein of the invention can be prepared by substituting a lectin domain or domains from another protein, such as the mannose receptor of macrophages or the phospholipase receptor on muscle, for those found in DEC 205.

DEC derivatives can be made by altering encoding nucleic acid sequences by substitutions, additions or deletions that provide for functionally equivalent molecules. Preferably, derivatives are made that have enhanced or increased functional activity relative to native DEC. Alternatively, such derivatives may encode soluble fragments of DEC extracellular domain that have the same or greater affinity for the natural ligand of DEC of the invention. Such soluble derivatives may be potent inhibitors of ligand binding to DEC.

Due to the degeneracy of nucleotide coding sequences, other DNA sequences which encode substantially the same amino acid sequence as a dec gene may be used in the practice of the present invention. These include but are not limited to allelic genes, homologous genes from other species, and nucleotide sequences comprising all or portions of dec genes which are altered by the substitution of different codons that encode the same amino acid residue within the sequence, thus producing a silent change. Likewise, the DEC derivatives of the invention include, but are not limited to, those containing, as a primary amino acid sequence, all or part of the amino acid sequence of a DEC protein including altered sequences in which functionally equivalent amino acid residues are substituted for residues within the sequence resulting in a conservative amino acid substitution. For example, one or more amino acid residues within the sequence can be substituted by another amino acid of a similar polarity, which acts as a functional equivalent.

resulting in a silent alteration. Substitutes for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs.

For example, the nonpolar (hydrophobic) amino acids include alanine. leucine, isoleucine. valine. proline, phenylalanine. tryptophan and methionine. The polar neutral amino acids include glycine. serine. threonine. cysteine. tyrosine.

asparagine. and glutamine. The positively charged (basic) amino acids include WO 96/23882 PCTIS96/0383 arginine, lysine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Such alterations will not be expected to affect apparent molecular weight as determined by polyacrylamide gel electrophoresis, or isoelectric point.

The genes encoding DEC derivatives and analogs of the invention can be produced by various methods known in the art. The manipulations which result in their production can occur at the gene or protein level. For example, the cloned DEC gene sequence can be modified by any of numerous strategies known in the art (Sambrook et al., 1989, supra). The sequence can be cleaved at appropriate sites with restriction endonuclease(s), followed by further enzymatic modification if desired, isolated, and ligated in vitro. In the production of the gene encoding a derivative or analog of DEC, care should be taken to ensure that the modified gene remains within the same translational reading frame as the DEC gene, uninterrupted by translational stop signals, in the gene region where the desired activity is encoded.

Additionally, the DEC-encoding nucleic acid sequence can be mutated in vitro or in vivo. to create and/or destroy translation, initiation, and/or termination sequences, or to create variations in coding regions and/or form new restriction endonuclease sites or destroy preexisting ones, to facilitate further in vitro modification. Preferably.

such mutations enhance the functional activity of the mutated DEC gene product.

Alternatively, deletion mutants can be produced that encode fragments of DEC, one or a few of the lectin domains (see Taylor et al., 1992, J. Biol. Chem.

267:1719). Any technique for mutagenesis known in the art can be used, including but not limited to. in vitro site-directed mutagenesis (Hutchinson. et al.. 1978. J.

Biol. Chem. 253:6551; Zoller and Smith. 1984. DNA 3:479-488: Oliphant et al..

1986. Gene 44:177: Hutchinson et al.. 1986. Proc. Natl. Acad. Sci. U.S.A. 83:710).

use of TAB® linkers (Pharmacia). etc. PCR techniques are preferred for site directed mutagenesis (see Higuchi. 1989. "Using PCR to Engineer DNA". in PCR WO 96/23882 PCTIUS96/01383 31 Technology: Principles and Applications for DNA Amplification, H. Erlich, ed., Stockton Press, Chapter 6, pp. 61-70).

The identified and isolated gene can then be inserted into an appropriate cloning vector. A large number of vector-host systems known in the art may be used.

Possible vectors include, but are not limited to, plasmids or modified viruses, but the vector system must be compatible with the host cell used. Examples of vectors include, but are not limited to, E. coli, bacteriophages such as lambda derivatives, or plasmids such as pBR322 derivatives or pUC plasmid derivatives, pGEX vectors, pmal-c, pFLAG, etc. The insertion into a cloning vector can, for example, be accomplished by ligating the DNA fragment into a cloning vector which has complementary cohesive termini. However, if the complementary restriction sites used to fragment the DNA are not present in the cloning vector, the ends of the DNA molecules may be enzymatically modified. Alternatively, any site desired may be produced by ligating nucleotide sequences (linkers) onto the DNA termini; these ligated linkers may comprise specific chemically synthesized oligonucleotides encoding restriction endonuclease recognition sequences. Recombinant molecules can be introduced into host cells via transformation, transfection, infection.

electroporation, etc., so that many copies of the gene sequence are generated.

Preferably, the cloned gene is contained on a shuttle vector plasmid. which provides for expansion in a cloning cell, E. coli, and facile purification for subsequent insertion into an appropriate expression cell line, if such is desired. For example, a shuttle vector, which is a vector that can replicate in more than one type of organism, can be prepared for replication in both E. coli and Saccharomvces cerevisiae by linking sequences from an E. coli plasmid with sequences form the yeast 2p plasmid.

In an alternative method. the desired gene may be identified and isolated after insertion into a suitable cloning vector in a "shot gun" approach. Enrichment for the desired gene. for example. by size fractionation. can be done before insertion into the cloning vector.

WO 96/23882 PCTIUS96/01383 32 Expression of DEC Polypeptides The nucleotide sequence coding for DEC, or antigenic fragment, derivative or analog thereof, or a functionally active derivative, including a chimeric protein, thereof, can be inserted into an appropriate expression vector, a vector which contains the necessary elements for the transcription and translation of the inserted protein-coding sequence. Such elements are termed herein a "promoter." Thus, the nucleic acid encoding DEC of the invention is operationally associated with a promoter in an expression vector of the invention. Both cDNA and genomic sequences can be cloned and expressed under control of such regulatory sequences.

An expression vector also preferably includes a replication origin.

The necessary transcriptional and translational signals can be provided on a recombinant expression vector, or they may be supplied by the native gene encoding DEC and/or its flanking regions.

Potential host-vector systems include but are not limited to mammalian cell systems infected with virus vaccinia virus, adenovirus. etc.); insect cell systems infected with virus baculovirus); microorganisms such as yeast containing yeast vectors; or bacteria transformed with bacteriophage, DNA, plasmid DNA, or cosmid DNA. The expression elements of vectors vary in their strengths and specificities. Depending on the host-vector system utilized, any one of a number of suitable transcription and translation elements may be used.

A recombinant DEC protein of the invention, or functional fragment, derivative, chimeric construct, or analog thereof, may be expressed chromosomally. after integration of the coding sequence by recombination. In this regard, any of a number of amplification systems may be used to achieve high levels of stable gene expression (Se' Sambrook et al.. 1989. supra).

WO 96/23882 PCT/US96/01383 33 The cell into which the recombinant vector comprising the nucleic acid encoding DEC is cultured in an appropriate cell culture medium under conditions that provide for expression of DEC by the cell.

Any of the methods previously described for the insertion of DNA fragments into a cloning vector may be used to construct expression vectors containing a gene consisting of appropriate transcriptional/translational control signals and the protein coding sequences. These methods may include in vitro recombinant DNA and synthetic techniques and in vivo recombination (genetic recombination).

Expression of DEC protein may be controlled by any promoter/enhancer element known in the art, but these regulatory elements must be functional in the host selected for expression. Promoters which may be used to control DEC gene expression include, but are not limited to, the SV40 early promoter region (Benoist and Chambon, 1981, Nature 290:304-310), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto, et al., 1980, Cell 22:787-797), the herpes thymidine kinase promoter (Wagner et al., 1981, Proc. Natl. Acad. Sci.

U.S.A. 78:1441-1445), the regulatory sequences of the metallothionein gene (Brinster et al., 1982, Nature 296:39-42); prokaryotic expression vectors such as the p-lactamase promoter (Villa-Kamaroff, et al., 1978, Proc. Natl. Acad. Sci. U.S.A.

75:3727-3731), or the tac promoter (DeBoer, et al.. 1983, Proc. Natl. Acad. Sci.

U.S.A. 80:21-25); see also "Useful proteins from recombinant bacteria" in Scientific American, 1980, 242:74-94; promoter elements from yeast or other fungi such as the Gal 4 promoter, the ADC (alcohol dehydrogenase) promoter, PGK (phosphoglycerol kinase) promoter, alkaline phosphatase promoter; and the animal transcriptional control regions, which exhibit tissue specificity and have been utilized in transgenic animals.

Expression vectors containing a nucleic acid encoding a DEC of the invention can be identified by four general approaches: PCR amplification of the desired plasmid DNA or specific mRNA, nucleic acid hybridization. presence or absence of selection marker gene functions, and expression of inserted WO 96/23882 PCTIS96/01383 34 sequences. In the first approach, the nucleic acids can be amplified by PCR to provide for detection of the amplified product. In the second approach, the presence of a foreign gene inserted in an expression vector can be detected by nucleic acid hybridization using probes comprising sequences that are homologous to an inserted marker gene. In the third approach, the recombinant vector/host system can be identified and selected based upon the presence or absence of certain "selection marker" gene functions P-galactosidase activity, thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, etc.) caused by the insertion of foreign genes in the vector. In another example, if the nucleic acid encoding DEC is inserted within the "selection marker" gene sequence of the vector, recombinants containing the DEC insert can be identified by the absence of the DEC gene function. In the fourth approach, recombinant expression vectors can be identified by assaying for the activity, biochemical, or immunological characteristics of the gene product expressed by the recombinant, provided that the expressed protein assumes a functionally active conformation.

Once a particular recombinant DNA molecule is identified and isolated, several methods known in the art may be used to propagate it. Once a suitable host system and growth conditions are established, recombinant expression vectors can be propagated and prepared in quantity. As previously explained, the expression vectors which can be used include, but are not limited to, the following vectors or their derivatives: human or animal viruses such as vaccinia virus or adenovirus; insect viruses such as baculovirus; yeast vectors; bacteriophage vectors lambda), and plasmid and cosmid DNA vectors, to name but a few.

In addition. a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Different host cells have characteristic and specific mechanisms for the translational and post-translational processing and modification glycosylation. cleavage of signal sequence]) of proteins. Appropriate cell WO 96/23882 PCT/US96/01383 lines or host systems can be chosen to ensure the desired modification and processing of the foreign protein expressed. For example, expression in a bacterial system can be used to produce an nonglycosylated core protein product. However, the transmembrane DEC protein expressed in bacteria may not be properly folded.

Expression in yeast can produce a glycosylated product, although the pattern of glycosylation will likely differ from that obtained by expression in a mammalian cell. Expression in eukaryotic cells can increase the likelihood of "native" glycosylation and folding of a heterologous protein. Moreover, expression in mammalian cells, such as Chinese hamster ovary (CHO), African Green Monkey COS cells, and fibroblast NIH-3T3 cells 293 cells), can provide a tool for reconstituting, or constituting, DEC activity. Furthermore, different vector/host expression systems may affect processing reactions, such as proteolytic cleavages, to a different extent.

In a preferred aspect of the invention, DEC is introduced into model epithelial cells, such as Madin-Darby canine kidney (MDCK) cells, for investigation of the efficacy and rate of trans-epithelial migration of ligands or molecules targeted to DEC. Alternatively, as set forth below, the dec gene can be introduced into epithelial or dendritic cells for gene therapy, either by in vivo or ex vivo gene transfer.

Vectors are introduced into the desired host cells by methods known in the art. e.g., transfection, electroporation. microinjection, transduction, cell fusion. DEAE dextran, calcium phosphate precipitation, lipofection (lysosome fusion). use of a gene gun, or a DNA vector transporter (see, Wu et al., 1992, J. Biol. Chem.

267:963-967; Wu and Wu, 1988. J. Biol. Chem. 263:14621-14624: Hartmut et al..

Canadian Patent Application No. 2.012.311, filed March 15, 1990).

A recombinant DEC protein expressed as an integral membrane protein can be isolated and purified by standard methods. Generally. the integral membrane protein can be obtained by lysing the membrane with detergents, such as but not WO 96/23882 PCT/US96/01383 36 limited to, sodium dodecyl sulfate (SDS), Triton X-100, Nonidet P-40 digoxin, sodium deoxycholate, and the like, including mixtures thereof.

Solubilization can be enhanced by sonication of the suspension. In a specific embodiment, infra, DEC-205 is solubilized from thymic membrane pellets in a buffer containing 0.5% NP-40. Soluble forms of the protein can be obtained by collecting culture fluid, or solubilizing inclusion bodies, by treatment with detergent, and if desired sonication or other mechanical processes, as described above. The solubilized or soluble protein can be isolated using various techniques, such as polyacrylamide gel electrophoresis (PAGE), isoelectric focusing, 2dimensional gel electrophoresis, chromatography ion exchange, affinity, immunoaffinity, and sizing column chromatography), centrifugation, differential solubility, immunoprecipitation, or by any other standard technique for the purification of proteins. In a specific embodiment, infra, DEC-205 was purified using an affinity column with monoclonal antibody NLDC-145. In a another embodiment, infra, DEC-205 was purified by immunoprecipitation with either monoclonal antibody NLDC-145.

Characterization of DEC Structure Once a recombinant which expresses the DEC gene sequence is identified, and expression of an abundance of the protein is achieved, the recombinant DEC product can be analyzed. This is achieved by assays based on the physical or functional properties of the product, including radioactive labelling of the product followed by analysis by gel electrophoresis, immunoassay, etc.

For example, the ability of the expressed protein, or a fragment comprising the cytoplasmic domain thereof, to mediate endocytosis and targeting to coated pits.

and thence to endocytic vesicles associated with Class II MHC processing, can be determined. In one embodiment. infra, endocytosis was evaluated bv electron microscopy, using an anti-DEC antibody and a gold-labeled secondary antibody reactive with the anti-DEC antibody. In another embodiment, the ability to process WO 96/23882 PCT/US96/01383 37 and present antigen is evaluated by assaying antibody-specific T cell proliferation in response to processing of anti-DEC antibody and a control non-specific antibody.

The structure of DEC of the invention can be analyzed by various methods known in the art. Preferably, the structure of the various domains, particularly the lectin binding and cytoplasmic domains, is analyzed. Structural analysis can be performed by identifying sequence similarity with other known proteins. The degree of similarity (or homology) can provide a basis for predicting structure and function of DEC, or a domain thereof. In a specific embodiment, sequence comparisons can be performed with sequences found in GenBank.-using, for example, the FASTA and FASTP programs (Pearson and Lipman. 1988, Proc.

Natl. Acad. Sci. USA 85:2444-48).

The protein sequence can be further characterized by a hydrophilicity analysis Hopp and Woods, 1981, Proc. Natl. Acad. Sci. U.S.A. 78:3824). A hydrophilicity profile can be used to identify the hydrophobic and hydrophilic regions of the DEC protein.

Secondary structural analysis Chou and Fasman, 1974, Biochemistry 13:222) can also be done. to identify regions of DEC that assume specific secondary structures.

Manipulation. translation, and secondary structure prediction, as well as open reading frame prediction and plotting, can also be accomplished using computer software programs available in the art.

By providing an abundant source of recombinant DEC. the present invention enables quantitative structural determination of DEC. or domains thereof. In particular, enough material is provided for nuclear magnetic resonance (NMR).

infrared Raman. and ultraviolet especially circular dichroism (CD).

spectroscopic analysis. In particular NMR provides very powerful structural WO 96/23882 PCT/US96/01383 38 analysis of molecules in solution, which more closely approximates their native environment (Marion et al., 1983, Biochem. Biophys. Res. Comm. 113:967-974; Bar et al., 1985, J. Magn. Reson. 65:355-360; Kimura et al., 1980, Proc. Natl.

Acad. Sci. U.S.A. 77:1681-1685). Other methods of structural analysis can also be employed. These include but are not limited to X-ray crystallography (Engstom, 1974, Biochem. Exp. Biol. 11:7-13).

More preferably, co-crystals of DEC and a DEC-specific ligand can be studied.

Analysis of co-crystals provides detailed information about binding, which in turn allows for rational design of ligand agonists and antagonists. Computer modeling can also be used, especially in connection with NMR or X-ray methods (Fletterick, R. and Zoller, M. 1986, Computer Graphics and Molecular Modeling, in Current Communications in Molecular Biology, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York).

In yet a further embodiment, a putative DEC of the invention can be tested to determine whether it cross-reacts with an antibody specific for murine DEC-205.

For example, the putative DEC can be reacted with a rabbit polyclonal antibody, as described in the Example, infra, to determine whether it binds. Alternatively, a DEC protein can be used to generate antibodies, which can be tested for cross reactivity with DEC-205 from mice or human sources. The degree of cross reactivity provides information about structural homology or similarity of proteins.

The carbohydrate composition of DEC can be studied by various means known in the art, including but not limited to, lectin binding, chemical analysis, immunoassay, immunochemical analysis by converting glycoconjugates to digoxigenin-labeled hydrazones after periodate oxidation of vic-diols). chemical deglycosylation. enzymatic deglycosylation. and exoglycosidase digestions followed by FACE (fluorophore-assisted carbohydrate electrophoresis) analysis.

WO 96/23882 PCT/US96/01383 39 Ligands for DEC Most importantly, the present invention advantageously provides for identifying ligands of DEC, carbohydrate ligands that bind to one or more of the lectin domains of DEC. Such ligands are especially useful for targeting binding to DEC.

As used herein, "ligand" has its ordinary meaning, a molecule capable of specifically binding to a receptor, in this case DEC. As used herein, the term "carbohydrate ligand" refers to a carbohydrate or sugar that is capable of specifically binding DEC. Generally, such carbohydrates, alternatively termed herein "glycans," "saccharides," or "oligosaccharides," are the carbohydrate portion of a glycoprotein.

Identification and isolation of a gene encoding DEC of the invention provides for expression of the receptor, or truncated portions thereof, in quantities greater than can be isolated from natural sources, in recombinant cells for classical receptor binding experiments, or in indicator cells that are specially engineered to indicate the activity of a receptor expressed after transfection or transformation of the cells.

According, the present invention contemplates identifying specific ligands DEC using various screening assays known in the art. The recombinantly expressed protein can comprise one or more DEC lectin domains, and may be a truncated form of the native protein or portions of the native protien expressed as a chimeric construct with another protein.

Any screening technique known in the art can be used to screen for DEC ligands.

The present invention contemplates screens for small molecule ligands or ligand analogs and mimics, as well as screens for natural ligands that bind to DEC in vivo.

In particular, the present invention provides for identification of carbohydrate groups that bind DEC. and more specifically, identification of carbohydrate groups that bind DEC with high affinity and specificity.

In a preferred aspect of the invention, detection of DEC ligands is accomplished by binding solubilized DEC or DEC fragments to columns prepared from sugars or WO 96/23882 PCTAJS96/01383 glycans conjugated to a solid phase support, such as SEPHAROSE (Taylor et al., 1992, J. Biol. Chem. 267:1719). In particular, the invention contemplates dissecting the ligand specificity of various of the lectin domains by expressing truncated mutant DEC proteins comprising only one or a few of the domains.

Alternatively, candidate glycans can be conjugated to a carrier protein, such as bovine serum albumin, which is labelled, with 1251, and binding detected to DEC or DEC fragments expressed by a cell, such as a recombinant cell as described supra (Taylor et al., supra). In yet another embodiment, binding of labeled glycan-carrier protein is evaluated in microtiter assays, as described (Taylor and Drickamer, 1993, J. Biol. Chem. 268:399). Candidate carbohydrate ligands include, but are not limited to, mannose, fucose, N-acetyl-glucosamine, glucose, galactose, N-acetyl-galactosamine, to mention but a few such carbohydrates. Other ligand candidates include disaccharides, and larger order polysaccharides, such as are recognized by various lectins.

As used herein, the term "detection of binding" refers to any of the miriad techniques commonly employed to detect the association of one molecule with another, DEC-ligand with DEC. These techniques include the immunoassay techniques discussed infra, or modifications thereof, and generally depend on detecting association of a label conjugated with one of the binding entities, either the DEC-lectin containing polypeptide or the candidate ligand. with the other entity, which may be found on a solid phase support or a cell. However, detection of binding can be accomplished indirectly, by detecting the absence of a labeled binding entity, from supernatant. In a further aspect, binding can be detected by first removing unbound substances, followed by removing the labeled entity using a chaotropic agent) from the bound pair. These and other techniques for detecting binding of one entity to another are well known in the art.

For solid phase or heterogeneous phase assays, one entity of the binding pair will be irreversibly associated with a solid phase support, such as a bead SEPHAROSE). latex particle. chromatographic support, magnetic particle, silica WO 96/23882 PCT/US96/01383 41 particle, silicon wafer, or a plastic microtiter plate. The term "irreversibly associated" refers to covalent or non-covalent binding, characterized by no dissociation, or a rate of dissociation that is so low in comparison to the assay time that it is virtually undetectable.

Knowledge of the primary sequence of DEC, and the similarity of that sequence with proteins of known function, can provide an initial clue as the inhibitors or antagonists of the protein. In the present instance, correlation of the deduced sequence of DEC with the sequences of mannose receptor of macrophage and phospholipase receptor on muscle, assisted characterization of DEC as a receptor with multiple lectin domains. Identification and screening of antagonists is further facilitated by determining structural features of the protein, using X-ray crystallography, neutron diffraction, nuclear magnetic resonance spectrometry, and other techniques for structure determination, as described above.

In a specific embodiment, identification of carbohydrate ligands for DEC will be accomplished by attaching known glycans to a protein such as the classic neoglycoprotein. bovine serum albumin, or ovalbumin. or creatinase. In particular, it is advantageous to use a protein that is not naturally glycosylated, so that only the effects of an added glycan are being assayed. The binding assay may comprise a classical binding assay, as described above, or may involve an antigen processing assay, by evaluating stimulation of antigen-specific T lymphocytes. In this regard, a large number of T cell lines and clones specific for BSA and ovalbumin are available: the ability of neo-glycosylated BSA or ovalbumin to efficiently stimulate specific T cell proliferation is indicative of the ability of the glycan conjugated to the BSA or ovalbumin to bind to DEC.

In another embodiment, the heavily glycosylated protein fetuin. present in fetal calf serum, can be used to evaluate glycan ligands. A fetuin binding system. based on T cell activation or endocytosis of a marker. can be developed. Specific glycosidases can be used to specifically "knock-out" glycans. and the ability of the WO 96/23882 PCT/US96/01383 42 modified fetuin to function in the binding system evaluated. Diminishment of functional activity would indicate that the enzymatically modified sugar residue was involved in binding to DEC.

In a further aspect, the observation that the ninth and tenth lectin domains of DEC may be involved in membrane associated antibody-mediated antigen presentation, by "chaperoning" antibody into endosomes, suggests that these domains are specific for binding carbohydrates found on cell surface immunoglobulin molecules.

Another approach uses recombinant bacteriophage to produce large libraries. Using the "phage method" (Scott and Smith, 1990, Science 249:386-390; Cwirla, et al., 1990, Proc. Natl. Acad. Sci., 87:6378-6382; Devlin et al., 1990, Science, 249:404- 406), very large libraries can be constructed (106-108 chemical entities). A second approach uses primarily chemical methods, of which the Geysen method (Geysen et al., 1986, Molecular Immunology 23:709-715; Geysen et al. 1987, J. Immunologic Method 102:259-274) and the recent method of Fodor et al. (1991, Science 251, 767-773) are examples. Furka et al. (1988, 14th International Congress of Biochemistry, Volume 5, Abstract FR:013; Furka, 1991, Int. J. Peptide Protein Res.

37:487-493), Houghton Patent No. 4,631,211, issued December 1986) and Rutter et al. Patent No. 5,010,175, issued April 23, 1991) describe methods to produce a mixture of peptides that can be tested as agonists or antagonists.

In another aspect, synthetic libraries (Needels et al., 1993, "Generation and screening of an oligonucleotide encoded synthetic peptide library," Proc. Natl.

Acad. Sci. USA 90:10700-4; Lam et al., International Patent Publication No. WO 92/00252 and U.S. Patent No. 5.382,513. issued January 17, 1995, each of which is incorporated herein by reference in its entirety), and the like can be used to screen for ligands according to the present invention.

Alternatively. assays for binding of soluble ligand to cells that express recombinant forms of a ligand binding domain or domains (preferably domains) of DEC can be WO 96/23882 PCT/US96/01383 43 performed. As discussed in the Examples, infra, the presence of multiple lectin domains on DEC may contribute to the affinity and specificity of binding to glycans.

The screening can be performed with recombinant cells that express the DEC, or alternatively, using purified receptor protein, produced recombinantly, as described above. For example, the ability of labeled, soluble or solubilized DEC that includes the ligand-binding portion of the molecule, to bind ligand can be used to screen libraries, as described in the foregoing references.

Antibodies to DEC According to the invention, DEC produced recombinantly or by chemical synthesis, and fragments or other derivatives or analogs thereof, including fusion proteins, may be used as an immunogen to generate antibodies that recognize DEC. Such antibodies include but are not limited to polyclonal, monoclonal, chimeric, single chain, Fab fragments, and an Fab expression library. In a specific embodiment, infra, a rabbit polyclonal antibody is prepared against the N-terminal amino acid sequence of DEC-205. In another, a polyclonal antibody against intact, purified.

DEC-205 was generated.

Various procedures known in the art may be used for the production of polyclonal antibodies to DEC, or derivative or analog thereof. For the production of antibody, various host animals can be immunized by injection with the non-allogeneic DEC.

or a derivative fragment or fusion protein) thereof, including but not limited to rabbits, mice, rats, sheep, goats, etc. In one embodiment, the DEC or fragment thereof can be conjugated to an immunogenic carrier, bovine serum albumin (BSA) or keyhole limpet hemocyanin (KLH). Various adjuvants may be used to increase the immunological response. depending on the host species. as described above.

WO 96/23882 PCT/US96/01383 44 For preparation of monoclonal antibodies directed toward DEC, or fragment, analog, or derivative thereof, any technique that provides for the production of antibody molecules by continuous cell lines in culture may be used. These include but are not limited to the hybridoma technique originally developed by Kohler and Milstein (1975, Nature 256:495-497), as well as the trioma technique, the human B-cell hybridoma technique (Kozbor et al., 1983, Immunology Today 4:72), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole et al., 1985, in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp.

77-96). In an additional embodiment of the invention, monoclonal antibodies can be produced in germ-free animals utilizing recent technology (PCT/US90/02545).

According to the invention, human antibodies may be used and can be obtained by using human hybridomas (Cote et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:2026- 2030) or by transforming human B cells with EBV virus in vitro (Cole et al., 1985, in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, pp. 77-96). In fact, according to the invention, techniques developed for the production of "chimeric antibodies" (Morrison et al., 1984, J. Bacteriol. 159-870; Neuberger et al., 1984, Nature 312:604-608; Takeda et al., 1985. Nature 314:452-454) by splicing the genes from a mouse antibody molecule specific for an DEC together with genes from a human antibody molecule of appropriate biological activity can be used; such antibodies are within the scope of this invention.

According to the invention, techniques described for the production of single chain antibodies Patent 4,946,778) can be adapted to produce DEC-specific single chain antibodies. An additional embodiment of the invention utilizes the techniques described for the construction of Fab expression libraries (Huse et al..

1989, Science 246:1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity for DEC. or its derivatives, or analogs.

Antibody fragments which contain the idiotype of the antibody molecule can be generated by known techniques. For example, such fragments include but are not limited to: the fragment which can be produced by pepsin digestion of the WO 96/23882 PCT/US96/01383 antibody molecule; the Fab' fragments which can be generated by reducing the disulfide bridges of the F(ab')2 fragment, and the Fab fragments which can be generated by treating the antibody molecule with papain and a reducing agent.

In the production of antibodies, screening for the desired antibody can be accomplished by techniques known in the art, radioimmunoassay,

ELISA

(enzyme-linked immunosorbant assay), "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitin reactions, immunodiffusion assays, in situ immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), western blots, precipitation reactions, agglutination assays gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention. For example, to select antibodies which recognize a specific epitope of DEC. one may assay generated hybridomas for a product which binds to a DEC fragment containing such epitope. For selection of an antibody specific to DEC from a particular species of animal, one can select on the basis of positive binding with DEC expressed by or isolated from cells of that species of animal, and the absence of binding to DEC from other species. Binding to DEC may be detected as binding to dendritic cells that express DEC.

The foregoing antibodies can be used in methods known in the art relating to the localization and activity of the DEC, for Western blotting, imaging DEC in situ. measuring levels thereof in appropriate physiological samples. etc. The antibodies of the present invention advantageous provide for detecting and enumerating human dendritic cells. Alternatively. such antibodies can be used to isolate human dendritic cells, by panning. In yet another embodiment. the WO 96/23882 PCT/US96/01383 46 antibodies of the invention can be used to target molecules to human dendritic cells. It will be recognized that this is a significant advantage, since the prior art antibody of Kraal et al. failed to recognize human DEC.

Antibodies that are targeted to DEC and participate in the activity of DEC, e.g., endocytosis, can be generated. Such antibodies can be tested using the assays described supra for identifying ligands. In a specific embodiment, a rabbit polyclonal anti-DEC antibody targets binding of DEC, is endocytosed. and is efficiently presented to immunoglobulin-specific T cells.

Targeting Molecules to DEC The present invention advantageously provides for targeting molecules to DEC for immune modulation, stimulation of T cell immunity, suppression immunity or induction of T cell anergy, and clonal deletion mechanism; trans-epithelial transport, with delivery of a molecule across epithelium into the pulmonary circulation or intestinal circulation, or from the bloodstream into the pulmonary or intestinal lumen; and crossing the blood brain barrier. In particular, a ligand for DEC, as described supra, or an antibody reactive with DEC (or a DEC-binding portion thereof), as described supra, is conjugated to a molecule which is to be targeted to DEC.

Immunomodulation. With respect to immunomodulation. the present invention provides for both stimulating T cell-mediated immune responses. particularly for vaccination, and inducing tolerance, particularly with respect to autoimmunity.

Stimulation of T cell immunity can be effected by introducing an antigen. ma weak or poorly immunogenic antigen, conjugated to a DEC-binding moiety (ligand or antibody) into a subject, along with a factor that activates the dendritic cells that initially present antigen to the T cells. Dendritic cell activation can be accomplished by use of an adjuvant. such as an adjuvant as described above, which has the ability to induce a generalized immune response. Alternatively. the WO 96/23882 PCTIUS96/01383 47 "vaccine" of the invention may comprise the antigen conjugated to the DECbinding moiety and a cytokine or a lymphokine, such as granulocyte-macrophage colony stimulating factor (GM-CSF), or some other CSF. Suitable antigens for use in such a vaccine include bacterial, viral, parasite, and tumor antigens.

Alternatively, the present invention provides for inducing tolerance. Tolerance is desirable to avoid detrimental immune responses, in particular, autoimmunity and allograft rejection. Presentation of antigen by non-activated dendritic cells, in the skin and T cell areas of the lymphoid organs, induces T cell anergy, and possibly causes destruction of the responder clone. Thus, in one embodiment, tolerance is induced by administering an antigen modified by conjugation with a DEC-binding moiety under conditions that promote dendritic cell quiescence, e.g., in the absence of an infection, without adjuvant, using pyrogen-free pharmaceutical carriers, and in the absence of additional lymphokines or cytokines.

It is further believed that high level expression of DEC may act as a tolerizing influence. Accordingly, the invention further relates to introducing recombinant dendritic cells, or cell recombinantly modified to express both DEC and MHC Class II, into a subject, along with antigen conjugated to a DEC-binding moiety.

Alternatively, the dec gene can be targeted to appropriate cells in vivo. for gene therapy.

In a further embodiment, tolerance can be induced through the clonal deletion mechanism. In particular, antigen conjugated with a DEC-binding moiety can be introduce into a subject, preferably directly into the thymus, either by targeting or physical injection, for processing and presentation by the thymic epithelium and medullary dendritic cells. This processing and presentation step is believed to be involved in the selection process to eliminate autoreactive T cells, i.eL.. clonal deletion. In a further aspect, the level of expression of DEC may be manipulated.

by introducing additional dec genes into the thymic epithelium and medullary dendritic cells.

48 Attractive candidates for conjugation with a DEC-ligand to induce tolerance, T cell anergy. or clonal deletion include, but by no means are limited to. allergenic substances, autoantigens such as myelin basic protein, collagen or fragments thereof, DNA. nuclear and nucleolar proteins, mitochondrial proteins, pancreatic 3cell proteins, and the like (see Schwarz. 1993, In Fundamental Immunology. Third Edition, W.E. Paul Raven Press, Ltd.: New York, pp. 1033-1097).

Trans-Epithelial Migration. In another embodiment, a molecule can be targeted for trans-epithelfl migration by conjugating it with a DEC-binding moiety. In one aspect of theinvention. the invention provides for targeting a therapeutic molecule for absorption across lung or intestinal epithelium. Thus, the invention provides for delivering an aerosolized therapeutic agent by inhalation, by pulmonary administration of the drug. In another aspect, the invention provides for delivery of a therapeutic agent by DEC-mediated absorption across the small intestine. In particular, the invention advantageously provides for absorption, or more accurately, trans-mucosal migration, of hydrophilic molecules, which are usually not as easily absorbed as hydrophobic molecules. This aspect of the invention takes advantage of the presence of DEC on the apical (or lumenal) surface of the epithelial cells.

.9 In another aspect of the invention, the presence of DEC on the basolateral surface of the epithelial cells provides a route for transport of a molecule conjugated to a DEC-ligand from the bloodstream into the lumen of the lung or the small intestine.

This delivery route can be very important for administration of an acid labile.

hydrophilic therapeutic agent to the intestines. Such a drug cannot be ingested, as the acid conditions present in the stomach would result in its destruction: transport of such a drug from the bloodstream to the lumen of the intestines would not readily occur spontaneously, since a hydrophilic agent does not have a significant S. partition coefficient across cell membranes. In specific embodiments. the present 30 invention provides for administration of chemotherapeutic agents and antibiotics.

particularly anti-parasite drugs. by conjugating them to a ligand for DEC, and WO 96/23882 PCTIUS96/01383 49 administering the agent parenterally, preferably intravenously, such that the drug is targeted for transport from the basolateral surface of the intestinal epithelium to the lumenal surface.

In the same way, a therapeutic agent may be targeted for delivery from the bloodstream to the airways of the lung by targeting the DEC receptor on the basolateral surface of the lung epithelium. Such a delivery system would be particularly advantageous for delivery of drugs to individuals with impaired lung capacity, who cannot inhale adequately, and thus, for whom administration via the bloodstream is indicated. Such lung impairments include, but are not limited to, pneumonia, emphysema, lung cancer, adult respirator distress syndrome, dyspnea, hemoptysis, chronic obstructive pulmonary disease (COPD), fibrogenic dust diseases, pulmonary fibrosis, organic dust diseases, chemical injury, smoke injury, thermal injury (burn or freeze), asthma (allergy, bronchoconstriction, other causes of asthma, irritants), hypersensitivity pneumonitis, Goodpasture's Syndrome, pulmonary vasculitis, and immune complex-associated inflammation.

Thus, the invention provides for administration of antibiotics, anti-inflammatory agents, complement inhibitors complement receptor 1 [CD35]), and the like for trans-epithelial migration into the lumen of the lung.

Trans-Blood Brain Barrier Migration. In still another embodiment, a molecule targeted for the brain can be conjugated to a DEC-binding moiety. The molecule would then bind to DEC found in the capillaries of the brain, which are believed to promote trans-blood brain barrier transport or migration. Presently, there are few or no generally effective mechanisms for directing molecules across the blood brain barrier. Such molecules for transport across the blood brain barrier include, but are not limited to. neurotrophic factors (brain-derived neurotrophic factor. NT-3, NT-4.

ciliary neurotrophic factor), growth factors nerve growth factor), and the like: antibiotic or antiviral agents, for incipient infections of the brain: and vectors for gene therapy.

WO 96/23882 PCT/US96/01383 Targeting Vectors for Gene Therapy. In yet another embodiment, the present invention provides ligands for targeting DNA vectors to cells that express DEC, in particular, dendritic cells, epithelial cell of the thymus, small intestine, and lung, and brain capillaries. Accordingly, a DNA vector, such as a viral vector, can be modified by conjugation with a DEC ligand for targeting to cells that express DEC.

Examples of DNA virus vectors include, but are not limited to, a defective herpes virus 1 (HSVI) vector (Kaplitt et al., 1991, Molec. Cell. Neurosci. 2:320-330), an attenuated adenovirus vector, such as the vector described by Stratford-Perricaudet et al. (1992, J. Clin. Invest. 90:626-630), a defective adeno-associted virus vector (Samulski et al., 1987, J. Virol. 61:3096-3101; Samulski et aL, 1989, J. Virol.

63:3822-3828), as well as a papillomavirus vector, Epstein Barr virus (EBV) vector, and the like. The viral particles can be modified to include a ligand for DEC, by chemically cross-linking a DEC ligand to the virus.

Alternatively, the vector can be introduced in vivo by lipofection. Synthetic cationic lipids designed to limit the difficulties and dangers encountered with liposome mediated transfection can be used to prepare liposomes for in vivo transfection of a gene encoding DEC (Felgner, et. al., 1987, Proc. Natl. Acad. Sci.

U.S.A. 84:7413-7417; see Mackey, et al., 1988, Proc. Natl. Acad. Sci. U.S.A.

85:8027-8031)). The use of cationic lipids may promote encapsulation of negatively charged nucleic acids, and also promote fusion with negatively charged cell membranes (Felgner and Ringold, 1989. Science 337:387-388). The use of lipofection to introduce exogenous genes into the specific organs in vivo has certain practical advantages. Molecular targeting of liposomes to specific cells represents one area of benefit. Accordingly. the present invention advantageously provides for targeting a gene for dendritic cells and thymic epithelium by conjugating a DEC-ligand to a liposome vector. Lipids may be chemically coupled to other molecules for the purpose of targeting (see Mackey. et. al.. 1988. supra). Targeted antibodies or glycans could be coupled to liposomes chemically.

WO 96/23882 PCT/US96/01383 51 It is also possible to introduce the vector in vivo as a naked DNA plasmid, preferably by using a DEC ligand as a vector transporter (see, Wu et al., 1992, J. Biol. Chem. 267:963-967; Wu and Wu, 1988, J. Biol. Chem. 263:14621-14624; Hartmut et al., Canadian Patent Application No. 2,012,311, filed March 15, 1990).

The present invention will be better understood by reference to the following Examples, which are provided by way of exemplification and not limitation.

EXAMPLE 1: DEC-205, A 205 kDa PROTEIN ABUNDANT ON MOUSE DENDRITIC CELLS AND THYMIC EPITHELIUM THAT IS DETECTED BY THE MONOCLONAL ANTIBODY NLDC-145: PURIFICATION, CHARACTERIZATION, AND N-TERMINAL AMINO ACID SEQUENCE This Example describes the purification and biochemical characterization of the antigen recognized by monoclonal antibody NLDC-145 (Krall et al., 1986, J. Exp.

Med. 163:981). We refer to the protein as DEC-205, in view of its abundant expression by Dendritic and thymic Epithelial Cells, and the observed molecular mass. The protein has been purified at a scale that permits direct biochemical study. The antigen proves to be an integral membrane glycoprotein with a mildly alkaline (pI 7.5) and an electrophoretic molecular mass of 205 kDa. not 145 kDa.

as originally reported (Kraal et al., supra). About 7 kDa of the mass is contributed by covalently-bound carbohydrates. A panel of plant lectins was used to gain preliminary information on the structures of these glycans. The glycans were then subjected to a variety of exogylcosidase digestions and fluorophore-assisted carbohydrate electrophoresis (FACE) (Jackson. 1990, Biochem. J. 270:705; Jackson and Williams, 1991, Electrophoresis 12:94: Jackson. 1993. Biochem. Soc. Trans.

21:121: Jackson. 1994. Anal. Biochem 216:243). Eight distinct but related biantennary N-linked glycan structures were resolved. These variants differed at their termini, but were based on two fucosylated trimannosyl chitobiose core structures (with and without a bisecting GlcNAc). O-linked glycans were not detected. The amino terminus of the protein is not blocked, and the sequence of its WO 96/23882 PCT/US96/01383 52 first 25 amino acids is not significantly homologous or similar to any known protein. Two new polyclonal antibodies are described, one raised to the N-terminal peptide sequence, the second to the intact purified protein. On immunoblots, both of these polyclonals recognize a 205 kDa band, which can be specifically depleted by preclearing extracts with NLDC-145.

Materials and Methods Purification of NLDC-145 and preparation of immunoaffinity resins-- NLDC-145 (rat IgG2a) ascitic fluids were prepared in normal, 6-8 week old, non-SPF, CD2 (BALB/c x DBA/2 Fl) female mice (Trudeau Institute) as described (North and Izzo, 1993, J. Exp. Med. 177:1723). The monoclonal was purified by sequential chromatography on immobilized Protein A and Protein G (Pierce). Both the monoclonal and nonspecific rat IgG2a (Zymed) were coupled to resins by reductive amination (AminoLink, Pierce).

Immunoprecipitation Bone marrow dendritic cells (BMDC) were prepared from proliferating marrow precursors, as described by Inaba et al. (1992, J. Exp. Med 176:1693). Eight days after the cultures were initiated, 4.8 x 10 7 BMDC were cultured for 1 h in 10 ml of methionine- and cysteine-free medium. Labeling was initiated by adding 1 mCi of 3 "S)methionine-cysteine (ICN), and cells were collected after 4 h of culture. BMDC were lysed by resuspending them in 700 ml of ice-cold lysis buffer (50 mM Tris-HC1, pH 6.8, 1% Nonidet P-40 (Calbiochem), mg/ml BSA (Intergen), with a mixture of protease inhibitors: 5 mM EDTA, mg/ml Pefabloc SC (Boehringer Mannheim), 100 mg/ml PMSF, 5 mg/ml aprotinin.

5 mg/ml pepstatin A and 10 mg/ml leupeptin (the latter 4 inhibitors from Sigma)).

Lysates were precleared with 20 mg of rat IgG (Jackson ImmunoResearch). 10 ml of FCS. and 100 ml of packed immobilized Protein G (Pierce). The supernatant was precleared a second time with 100 ml of Protein G, for I h. The precleared lysate was divided into 100 ml aliquots. Proteins in two aliquots (6.9 x 10" BMDC equivalents) were adsorbed to 50 ml of packed, washed immunoaffinity resin (either NLDC-145 or rat IgG2a). rotating 1 h. Washes were performed as WO 96/23882 PCT/US96/01383 53 described (Fireston and Winguth, 1990, Methods Enzymol. 182:688). Proteins were analyzed by SDS-PAGE in 10% acrylamide minigels.

Immunoblotting-- SDS-PAGE was performed in 8% acrylamide minigels, 1.5 mm thick. Transfer to nitrocellulose (BA-85, Schleicher and Schuell) was performed at constant volts overnight at 4 0 C. Filters were blocked in PBS containing 3% nonfat dry milk and 0.1% Tween 20 for 1 h at room temperature with shaking. Incubation with primary antibodies (0.1-10 pg/ml of purified IgG, ascites or serum diluted 1:1000, or hybridoma supernatant diluted 1:1) was performed in heat-sealed bags for 1 h at room temperature. Filters were washed, then immunostaining was visualized with peroxidase-conjugated donkey anti-rat or anti-rabbit IgG (Jackson), followed by enhanced chemiluminescence (Amersham).

Purification of DEC-205 from thymi-- The strategy is summarized in Figure 2.

Thymi were removed from 50 outbred CD-1 Swiss mice (Taconic) per preparation.

Thymi were placed into 50 ml of ice-cold PBS containing 200 mg/ml PMSF and mM EDTA to remove blood, and washed once with the same buffer. Washed organs could be frozen at -20 0 C. All subsequent purification steps were performed at 0-4 0 C. Thymi were transferred to a 40 ml Dounce homogenizer (Kimble/Kontes), and resuspended in 30 ml of hypotonic lysis buffer (10 mM Tris- HC1, pH 6.8, with a mixture of protease inhibitors: 5 mM EDTA. 100 mg/ml PMSF, 4 mg/ml aprotinin, 0.5 mg/ml Pefabloc SC, 4 mg/ml pepstatin A, 10 /g/ml leupeptin). Organs were homogenized with 20 strokes of the loose (0.2 mm clearance) pestle, then 20 strokes of the tight (0.1 mm clearance) pestle. The suspension was left on ice for 20 min, then re-homogenized with an additional strokes of the tight pestle. Nuclei and debris were pelleted by low speed centrifugation (1200 x g. 5 min. 4 0 The turbid "postnuclear" supernatant was collected, and the nuclear pellet was washed with 5-8 changes of 15 ml hypotonic lysis buffer, until the supernatant was nearly clear. Supernatants from each wash were pooled. To collect membranes. pooled postnuclear supernatant was WO 96/23882 PCT/US96/01383 54 centrifuged at 100,000 x g for 1 h at 4°C (RC-28S centrifuge, F28/36 rotor, Du Pont-Sorvall). Proteins in the membrane pellet were extracted into 5 ml of hypotonic lysis buffer containing 0.5% (8.3 mM) NP-40. The membrane extract was clarified by a second one-hour, 100,000 x g centrifugation.

Clarified membrane extract was precleared by passage over a nonspecific rat IgG column. Nonadsorbed fractions from the preclearing column were pooled, then applied to the NLDC-145 affinity column. Washes were performed in 2 steps: 6 ml (3 bed volumes) of wash-1 (hypotonic lysis buffer with 0.5 M NaC1, without NP-40, substituting 0.5% (17 mM) n-octyl glucoside (Boehringer Mannheim)), then ml of wash-2 (wash-1 without added NaCI). The column was eluted with at least 5 bed volumes of 50 mM glycine-NaOH, pH 11, 0.5% n-octyl glucoside, reducing the maximum flow rate to 10 ml cm- 2 The pH of eluted fractions (1 ml) was adjusted to 7 with 20-30 ml of 2 M glycine-HCI, pH 2. Peak eluates were pooled and concentrated to <1 ml by ultrafiltration in Centricon-100 units (Amicon) that had been pre-coated with 0.1% SDS, to reduce nonspecific losses to the plastic. Typically, 70-150 jg of DEC-205 could be obtained from 50 thymi.

Isoelectric focusing-- Isoelectric focusing was performed in thin (0.75 mm) slab gels, under denaturing conditions acrylamide gels containing 8 M urea. 4% total Ampholine (2:1 ratio of pH 3.5-10 and 5-7, Pharmacia), 0.67% NP-40. glycerol). Samples were focused at 400 constant volts overnight, for a minimum of 6000 volt-hours, at which time the current was less than 1 mA. Lanes were either silver-stained or cut into 0.5 cm sections and eluted into degassed dHO for pH gradient measurement.

Detection of glycans-- DEC-205, transferrin (positive control) and creatinase (negative control) were blotted onto nitrocellulose as before. Glycoconjugates were converted to digoxigenin (DIG)-labeled hydrazones after mild nonselective periodate oxidation of vic-diols to aldehydes. Staining patterns were visualized WO 96/23882 PCTUS96/01383 with an anti-DIG antibody conjugated to alkaline phosphatase (First CHOice, Boehringer Mannheim).

Chemical deglycosylation-- Two 100 pl samples each of DEC-205 (40 pg) and apotransferrin (100 pg, positive control) were transferred into 0.1% trifluoroacetic acid, 0.05% SDS by G-25 SF spin chromatography, then were lyophilized to dryness. Cleavage was performed with anhydrous trifluoromethanesulfonic acid (Sojar et al., 1987, Methods Enzymol. 138:341) (Oxford GlycoSystems).

Polypeptides were separated from cleavage products and excess reagents by TCA precipitation, followed by electrophoresis in 8% acrylamide minigels, adjacent to untreated controls.

Enzymatic deglycosylation-- Peptide-N-glycosidase F from Flavobacterium meningosepticum (PNGase F, Boehringer Mannheim) was used to cleave asparagine-linked glycans (Tarentino et al., 1985, Biochem. 24:4665). Aliquots p/g per eventual gel lane) of DEC-205 were denatured by boiling for 5 min in the presence of 0.1% SDS. After cooling on ice and brief spinning in a microfuge to collect liquid, 1/5 volume of 5X PNGase buffer (250 mM sodium phosphate, pH 50 mM EDTA, 2.5% NP-40, 5% 2-mercaptoethanol) was added, then 1 unit of PNGase F (5 xl). Reactions were incubated overnight at 37 0 C, then were terminated by adding 1/4 volume of 4X nonreducing SDS-PAGE sample buffer.

and boiling for 5 min.

Lectin blotting-- Several digoxigenin-labeled plant lectins (Boehringer Mannheim) were used to stain electroblotted DEC-205 and appropriate positive and negative control glycoproteins. The lectins, their specificities and the concentrations used for staining are summarized in Table 1.

Exoglycosidase digestions and FACE analysis-- N-linked oligosaccharides were released from DEC-205 with PNGase F and labeled with the fluorophore ANTS (8aminonaphthalene-l.3.6-trisulfonic acid) (Jackson. 1990, supra: Jackson and WO 96/23882 PCTIUS96/01383 56 Williams, supra; Jackson, 1993, supra; Jackson, 1994, supra). Recombinant exoglycosidases were from Glyko. Electrofluorograms were visualized on an SE1000 FACE workstation (Glyko).

Amino acid sequencing-- DEC-205 was electrophoresed in multiple lanes of mm thick 4% minigels prepared using Duracryl (Millipore). Gels were blotted onto polyvinylidene difluoride (PVDF, Bio-Rad). After transfer, filters were soaked for 1 min in 1% acetic acid, stained for 2 min in 0.1% Ponceau S, then were destained briefly in dH20. Bands at 205 kDa were excised and submitted for analysis. The N-terminal sequence was aligned to all current databases on the BLAST Internet servers (NCBI, National Library of Medicine, NIH), running the program BLASTP (Altschul et al., 1990, J. Med. Biol. 215:403).

Polyclonal antibodies to intact DEC-205-- Two New Zealand White rabbits (Hazelton) were injected 6 times with the 205 kDa bands cut from Coomassiestained, 1.5 mm thick, 4% Duracryl SDS-PAGE gels. Doses ranged from 40-70 /tg of stained protein per animal, per injection (4-6 slices), and were given every 3 weeks, with test bleeds (about 15 ml of serum) taken 2 weeks post-injection. For the first injection, slices were emulsified in Complete Freund's adjuvant (CFA) and injected intradermally into multiple sites on the back. Incomplete Freund's (IFA) was the adjuvant for boosts. Responses were monitored by Western blotting crude thymic membrane extracts with graded doses of serum. Animals were boosted further with the unfractionated eluate from the immunoaffinity column, soluble protein rather than gel slices. Four boosts, averaging 50 14g per injection, were given to both rabbits. IgG fractions were prepared by Protein A chromatography.

Polyclonal antibodies to the N-terminal peptide-- The hapten-coupling strategy focused on the lone cysteine at residue 19 (Figure 6A). Peptide N (SESSGNDPFTIVHENTGKC) (SEQ ID NO: 2) was coupled to keyhole limpet hemocyanin (IKLH) and ovalbumin (OVA) using maleimide chemistry (Imject.

Pierce). An average of about 250 peptides were conjugated to each molecule of WO 96/23882 PCTIUS96/01383 57 KLH, and about 6 peptides per molecule of OVA. The KLH-peptide conjugate was divided into aliquots of 400-500 tg each, and was injected eight times into two New Zealand White rabbits (200-250 /tg per injection), again emulsifying into CFA for the initial immunization and IFA for boosts. To remove any anti-KLH reactivity from the sera, they were precleared on a KLH-cysteine column. Antipeptide antibodies were isolated on a peptide-OVA column, where the peptide was coupled to an irrelevant carrier.

Results NLDC-145 immunoprecipitates and Western blots an antigen of 205 kDa, not 145 kDa-- To determine the molecular mass of the NLDC-145 antigen, DCs generated from proliferating bone marrow progenitors in vitro (Inaba et al.. supra). This method provided abundant NLDC-145 DCs in high purity. On day 8 of culture, the DCs were metabolically labeled with 3 S]methionine-cysteine. Extracts were immunoprecipitated using either immobilized NLDC-145 or control nonspecific rat IgG2a. Autoradiography of the precipitates after reducing SDS- PAGE (Figure 1A) revealed that NLDC-145 bound a single specific band with an apparent mass slightly greater than 200 kDa (myosin marker), not 145 kDa, as originally reported (Kraal et al., supra). Numerous nonspecific bands were also visible in both lanes, including a prominent band at 45 kDa, presumably G-actin (Fosman, 1976, Handbook of Biochemistry and Molecular Biology. Volume 1:Proteins, CRC Press:Cleveland, Ohio).

To verify this measurement, NLDC-145 was used as the probe in a Western blot.

Five thymi from 8 week-old BALB/c mice were homogenized in 2 ml of the same lysis buffer used for immunoprecipitation. Graded doses of clarified thymic extract were electrophoresed under nonreducing and reducing conditions, and blotted to nitrocellulose. NLDC-145 bound a single major band (Figure 1B) that co-migrated with the prestained myosin marker at 205 kDa. confirming the estimate made by immunoprecipitation (above). Under nonreducing conditions (Figure 1B. left filter), as few as 7 x 10" thymic equivalents could be clearly visualized with this WO 96/23882 PCTIUS96/01383 58 dose of monoclonal NLDC-145 IgG. However, after reduction of disulfides in the crude extract with mercaptoethanol (right strip), the mAb failed to stain, even at the highest dose of lysate. We concluded that the antigen recognized by NLDC-145 has a mass of 205 kDa, and that the epitope detected by the mAb requires an intramolecular disulfide bond.

Purification of DEC-205-- The epithelial cells of the thymic cortex express the antigen abundantly (Kraal et al., supra), even more abundantly than the lessnumerous DCs in the thymic medulla. Therefore, a scheme to isolate the protein from thymi was developed (Figure Briefly, thymi were homogenized under hypotonic lysis conditions, in the presence of a "cocktail" of high doses of 6 protease inhibitors. Membranes were isolated and extracted with NP-40. After clarification, the extract was precleared on a rat IgG column, then chromatographed on the NLDC-145 column.

SDS-PAGE analysis of purified, concentrated DEC-205 (Figure 3A) revealed a predominant 205 kDa band and only trace contaminant bands on Coomassie staining. Silver staining exposed a large number of lower molecular mass contaminants, dictating the need for further purification by preparative electrophoresis before amino acid sequencing.

In an effort to follow step yields during the purification process, key fractions were diluted to the same volume (the volume of the post-nuclear supernatant). and immunoblotted (Figure 3B). Because the fractions were isovolumic. staining intensities on the filter should reflect the relative concentrations of DEC-205 at each phase of the separation. Roughly 30% of the protein appeared to be lost to the nuclear pellet (lane 1) in the first step, hypotonic lysis. Another 10% or so (lane 3) failed to sediment with the membrane pellet (lane 4) during the first highspeed centrifugation. A constant small fraction perhaps 5-10% cumulatively passed through the NLDC-145 column, in both early and late nonadsorbed fractions WO 96/23882 PCT/US96/01383 59 (lanes 6 and The cumulative yield in the final eluate (lane 8) was therefore about When the eluate was intentionally overloaded at five times the isovolumic concentration (lane 10), a "ladder" of at least 6 smaller, minor bands was clearly and consistently seen. All of these bands must contain the NLDC-145 epitope.

They ranged down in rather orderly fashion not a continuous "smear") to a fairly intense 80 kDa component. Careful inspection of earlier fractions (in particular, lanes 2, 3, 4, and 8) revealed that these minor bands were present from the earliest stages in the isolation. Presumably, these bands were produced by proteolytic degradation of the intact 205 kDa protein.

DEC-205 is an integral membrane protein with an isoelectric point of To determine whether the 205 kDa protein was an integral membrane protein, thymic membrane pellets (prepared as in Figure 2) were resuspended in: hypotonic lysis buffer containing 0.5% NP-40 (as usual); the same buffer containing 1 M KCI instead of detergent; or 100 mM Na,CO pH 11.5, containing all 6 protease inhibitors used in routine purifications. After one hour of gentle mixing, suspensions were clarified (100.000 x g, 60 min, and supernatants were collected. Precipitates from the high-salt and high-pH extractions were then resuspended in hypotonic lysis buffer with 0.5% NP-40, and the extraction and clarification steps were repeated. A Western blot of the five extracts generated this way (Figure 4A) revealed that DEC-205 could not be released from the membrane pellet under conditions of either high ionic strength (lane 2) or extreme pH (lane Detergent was required for its solubilization (lanes 1, 4 and DEC-205 is therefore an integral membrane protein (Fujiki et al.. 1982, J. Cell Biol. 93:97).

Isoelectric focusing was performed in slab gels under denaturing conditions with silver staining. A relatively homogeneous isoelectric point was observed at pH (Figure 4B). A sharply focused central band at that pH was consistently bordered by a narrow "fringe" of fainter staining. extending from pH 7.4 to pH 7.6.

WO 96/23882 PCT/US96/01383 DEC-205 is a glycoprotein, bearing heterogeneous N-linked glycans To determine whether DEC-205 was glycosylated, purified 205 kDa protein was electrophoresed on a gel which also contained samples of transferrin (a known glycoprotein) and creatinase (a known nonglycoprotein), and was electroblotted to nitrocellulose. Filters were oxidized with sodium meta-periodate at room temperature, nonselectively converting vicinal diols in carbohydrates to aldehydes.

A digoxigenin (DIG)-tagged hydrazide was applied to the filter, converting the aldehydes to DIG-hydrazones. The filter was blocked, and then covalently-bound DIG was detected by staining with an anti-digoxigenin antibody conjugated to alkaline phosphatase. The staining pattern (Figure 5A) revealed that DEC-205 (lane 2) is a glycoprotein, like transferrin (lane 1).

To determine how much of the apparent molecular mass was contributed by glycans, the purified protein was chemically deglycosylated. Anhydrous trifluoromethanesulfonic acid (TFMSA) does not attack the primary structure of proteins, yet hydrolyzes both asparagine-linked and serine/threonine-linked glycans at their points of attachment to amino acid sidechains (Sojar et al., supra; Dabich et al., 1993, Biochem. Biophys. Acta 1164:47). Upon TFMSA treatment (Figure both apotransferrin (lane 2) and DEC-205 (lane 4) exhibited increased electrophoretic mobility compared to untreated samples (lanes 1 and Linear regression analysis of the migratory distances of the treated samples revealed that, as expected. deglycosylated apotransferrin lost 5 kDa in apparent molecular mass (MacGillivray et al.. 1983, J. Biol. Chem. 258:3543), while DEC-205 lost roughly 7 kDa. This 7 kDa shift was consistent with the removal of two to three complextype N-linked glycans from the 205 kDa protein. An uncertain number of smaller O-linked glycans might also have been removed.

To begin to define the types of carbohydrate residues present on the protein, blotted purified material was probed with a panel of digoxigenin-labeled plant lectins.

Asparagine-linked glycans were removed from an aliquot of DEC-205 by treating it with peptide N-glycosidase F (PNGase Treated and untreated protein was WO 96/23882 PCT/US96/01383 61 blotted to nitrocellulose along with positive and negative control glycoproteins.

After confirming transfer by staining the filters with Ponceau S (not shown), membranes were blocked and stained with DIG-lectins, used at the concentrations listed in Table 1.

TABLE 1 Table 1: Staining of electroblots with digoxigenin-labeled plant lectins Staining on Staining on Concentration PNGaseF-treated undigested Lectin Source Specificity (ag/ml) DEC-205 DEC-205 SNA Sambucus nigra

MAA

PNA

DSA

Maackia amurensis Arachis hypogaea Datura stramoniun NANAa2- 6Gal/GalNAc NANAa2-3Gal Galpl-3GalNAc Galpl-4GlcNAc, GlcNAc-Ser/Thr L-Fucl I-6GlcNAc Manal-3Man (al-3 al-6 al -2) strong strong very weak at 200 kDa AAA Aleuria aurantia GNA Galanthus nivalis Lectin staining patterns (Table 1) showed that the N-linked glycans lacked N-acetyl neuraminic acid in either of its two most common linkages to galactose, a2-6 and a2-3, since the protein failed to bind lectins SNA and MAA, respectively. The core disaccharide of O-linked glycans was not present in unsubstituted form, since PNA did not bind. Pretreatment of the protein with neuraminidase did not render it stainable with PNA (not shown), so any O-glycans present were not capped with sialic acid. If present, they are few in number, since selective removal of N-linked glycans with PNGase F reduced the protein's apparent mass by 7 kDa (not shown).

just as nonselective chemical deglycosylation did. Undigested DEC-205 stained intensely with DSA. and staining was ablated by PNGase F digestion. Thus. one or more of the N-glycans terminates with Galpl-4GlcNAc. Terminal fucose linked a 1-6 to GlcNAc is also present on at least one of the N-glycans. since the undigested protein stained strongly with AAA. Lectin GNA weakly stained a band with a mobility slightly greater than the DSA and AAA bands. Presumably WO 96/23882 PCT/US96/01383 62 this 200 Kda band, containing high-mannose N-linked glycans, represented a subpopulation of newly-synthesized molecules which had not yet undergone oligosaccharide processing reactions in the Golgi complex.

The structures of the N-linked glycans on DEC-205 were further defined by fluorophore-assisted carbohydrate electrophoresis (FACE). PNGase F released 8 different N-linked glycan structures from DEC-205, with electrophoretic migrations ranging from 5.1 to 10.1 glucose units (Figure 5C). The glycan yield was too low to permit excision and sequencing of each of the 8 individual bands, so the mixture was subjected to analysis with exoglycosidases (Figure 5D). Digestion with agalactosidase (lane 2) simplified the pattern, indicating that some of the glycans terminate with Galal-(l or 2)Gal. Addition of NANase III (lane 3, specific for a2-3, a2-6 and a2-8 linked N-acetylneuraminic acid) simplified the pattern still further (loss of sialic acid reduces band mobility), demonstrating that some of the glycans terminate with sialic acid. Neither NANase I (selective for a2-3 linkages) nor NANase II (selective for both a2-3 and a2-6 linkages) altered the pattern of bands (not shown). This was consistent with the lack of staining by lectins SNA and MAA (above), and demonstrated that the terminal sialic acid present on certain DEC-205 glycans is linked a2-8. Further treatment with p-galactosidase (lane 4) produced a loss of two galactoses (consistent with DSA staining and a biantennary structure), and reduced the complexity of the pattern to a doublet. On addition of P-N-acetylhexosaminidase to the enzyme mixture (lane the lower band of the doublet released 2 GlcNAc to yield a band characteristic of a fucosylated trimannosyl chitobiose core. However, the upper band resisted digestion, suggesting the presence of either a "bisecting" GlcNAc linked to a trimannosvl core between the antennas, or possibly a branching fucose. The bisecting GlcNac was revealed by the fact that the upper band could be at least partially digested (2-fold decrease in fluorescence intensity) when the enzyme concentration was doubled (lane Further digestion with a-mannosidase (lane 7) was incomplete, mostly releasing a single mannose (major band), but showed the beginning of release of a band that co-migrated with the fucosylated mannosylchitobiose core structure (lane 9, Doubling the amount of a-niannosidase and adding an a-fucosidase WO 96/23882 PCT/US96/01383 63 specific for fucose linked al-2,-3,-4 and -6 to GlcNAc (lane 8) led to essentially complete digestion, releasing a band that co-migrated with the non-fucosylated mannosylchitobiose core (lane 9, In combination, lectin staining and FACE analysis demonstrated that DEC-205 contains biantennary N-linked glycans with two kinds of fucosylated core structures, one with a bisecting GlcNAc, one without (Figure 5E). Further heterogeneity is introduced at the outer ends of these structures, which terminate with either a-linked galactose, 131-4 linked galactose or a2-8-linked sialic acid, in a total of 8 different permutations.

N-terminal amino acid sequence, and polyclonal antibodies to the N-terminal peptide and intact DEC-205-- Purified DEC-205 was submitted for amino-terminal sequencing, and the first 25 residues were identified unambiguously (Figure 6A).

When the sequence was aligned against all available protein sequence databases, no significant homologies were found. In order to verify that the 205 kDa protein we had purified was the antigen recognized by NLDC-145, a 19-residue synthetic Nterminal peptide (Figure 6A, first 19 amino acids) was synthesized, purified, coupled to keyhole limpet hemocyanin, and injected into a pair of rabbits. Peptidereactive antibodies from hyperimmune sera were purified on an affinity resin prepared by coupling the peptide to the irrelevant carrier ovalbumin. In parallel, purified DEC-205 was injected into a second pair of rabbits, and hyperimmune IgG was purified by Protein A chromatography. On immunoblots, both polyclonals stained a 205 kDa band in crude extracts, like NLDC-145 (Figure 6B. 'extract' lanes). The affinities of both polyclonals for the blotted 205 kDa protein were roughly 100 times higher than the monoclonal. Here. 0.1 pg/ml of either polyclonal gave a staining intensity comparable to that obtained with 10 izg/ml of NLDC-145 IgG. Both polyclonals bound "ladders" of minor bands, similar to those seen with the mAb. Staining of the 205 kDa band was specifically ablated when the extracts were precleared with immobilized NLDC-145 (Figure 6B.

'depleted' lanes), but was restored on proteins eluted from the preclearing resin WO 96/23882 PCITUS96/01383 64 (Figure 6B, 'eluate' lanes), confirming that the correct protein had been purified and sequenced.

Discussion A purification method based on immunoaffinity chromatography was used to isolate the antigen bound by the mAb NLDC-145, an antigen which was reported to be expressed at high levels by murine dendritic cells and thymic epithelium (Kraal et al., supra). As a protein source, whole murine thymi were lysed rather than attempting the daunting task of purifying large numbers of DCs. The isolated protein was about 95% pure, and was obtained with a yield in the hundredmicrogram range, sufficient for N-terminal amino acid sequencing and basic biochemical studies. It would have required approximately 109-1010 DCs to provide a comparable amount of protein.

The electrophoretic molecular mass of the protein was consistently 205 kDa. In the original report by Kraal et al (supra), NLDC-145 was used to immunoprecipitate detergent extracts from surface-iodinated low-density lymph node cells. Only a single serine protease inhibitor, 1 mM PMSF, was present in the lysis buffer. A single predominant labeled protein was bound, with an apparent molecular mass of 145 kDa under both reducing and nonreducing electrophoresis conditions, leading the authors to append the number "145" to the clone's name. When Pure et al.

(1990, J. Exp. Med. 172:1459) attempted to reproduce the immunoprecipitation, they prepared detergent extracts of 5 S)methionine-labeled cultured epidermal DCs (Langerhans cells), using a lysis buffer that contained multiple serine protease inhibitors (1 mM PMSF. 1 zg/ml aprotinin and 0.1% DIFP). They resolved a protein with an apparent molecular mass of 200 kDa under reducing conditions.

In this Example. immunoprecipitation of the antigen from bone marrow dendritic cells in the presence of high doses of inhibitors directed not only to serine proteases, but also to sulhydryl. aspartic and metalloproteases. yielded a protein of an apparent mass of 200 kDa. in agreement with Pure et al. The mAb could be WO 96/23882 PCT/US96/01383 used to stain Western blots under nonreducing conditions, and measured a mass of 205 kDa independently by this method. The protein that eluted from the NLDC- 145 immunoaffinity column had a mass of 205 kDa, and the amino terminus of this protein revealed a sequence with no significant homology or similarity to any other protein currently in the databases. In order to prove that the 205 kDa purified protein was the antigen detected by NLDC-145, polyclonal antibodies to the Nterminal peptide and to the intact purified protein were prepared. Both polyclonals stained a 205 kDa band on immunoblots. This staining could be eliminated by pretreating extracts with NLDC-145, demonstrating that the correct protein had been purified and sequenced. Thus, the 205 kDa protein purified here is the authentic antigen recognized by the NLDC-145 monoclonal antibody. We believe that the lysis conditions employed by Kraal et al. (supra). with minimal antiproteolytic coverage, may have permitted limited degradation of the protein.

We propose the name "DEC-205" for the protein, to indicate its high-level expression by Dendritic and thymic Epithelial Cells, and to revise the prior estimate of its electrophoretic molecular mass. DEC-205 is an integral membrane glycoprotein, bearing 2-3 biantennary complex-type N-linked glycans that comprise about 7 kDa of the overall electrophoretic molecular mass. These glycans are built on two different core structures, and vary further at their termini. to produce 8 variants, some of which contain sialic acid. Nevertheless, on electrofocusing, the isoelectric point of DEC-205 is slightly alkaline (pH suggesting that the protein may be relatively rich in basic residues. The pi is fairly homogeneous: a faint-staining, narrow "fringe" of protein surrounds the main pi, but extends only from pH 7.4 to 7.6, reflecting limited heterogeneity of charge. Considering the large overall mass of the protein and the relative paucity of bound carbohydrates.

the sialylated glycan variants detected should not perturb the pl of DEC-205 excessively.

DEC-205 is very sensitive to proteolytic degradation. Precautions had to be taken to inhibit a broad range of proteases during the purification, and to remove the WO 96/23882 PCTIUS96/01383 66 cytosolic fraction after hypotonic lysis, or else the yield was very low. Proteolysis appears to proceed by a distinctly nonrandom pathway. Despite the continuous presence of high concentrations of six protease inhibitors in our buffers, we invariably observed a "ladder" of 6-8 discrete, minor, lower molecular mass bands, ranging down to about 80 kDa and containing the NLDC-145 epitope, whenever the antigen was blotted at high levels. This orderly array of proteolytic fragments could be observed in every preparation blotted, from crude thymic membrane extract (best seen in Figure 4, but also present in Figures 1B and 3B) to the purified, ultrafiltered immunoaffmity eluate (Figure 3B). The "fringe" of staining around the main isoelectric point is likely to be at least partly produced by these relatively large proteolytic fragments.

The large size, nonrandom distribution and relative protease resistance of the "ladder" of minor bands suggests to us that the complete primary structure of DEC- 205 will reveal a modular architecture, with multiple protease-resistant domains joined by more protease-sensitive connecting segments.

EXAMPLE 2: DEC-205, A RECEPTOR EXPRESSED BY DENDRITIC CELLS AND THYMIC EPITHELIAL CELLS, HAS TEN C- TYPE LECTIN DOMAINS AND IS INVOLVED IN ANTIGEN PROCESSING This example reports that DEC-205 is a receptor with ten C-type lectin domains which is homologous to the macrophage mannose receptor (MMR), and other related receptors that bind carbohydrates and mediate endocytosis. The function of DEC-205 was investigated with monoclonal and polyclonal anti-DEC-205 antibodies. It was determined that DEC-205 on dendritic cells is rapidly internalized via coated vesicles. and delivered to a multivesicular endosomal compartment that resembles the MHC class-II containing vesicles implicated in antigen processing. Furthermore. rabbit anti-DEC-205 antibodies were efficiently processed by dendritic cells and presented to rabbit IgG specific T cell clones.

These experiments suggest that DEC-205 is a novel endocytic receptor that can be WO 96/23882 PCT/US96/01383 67 used by dendritic cells and thymic epithelial cells to direct captured antigens from the extracellular space to a processing compartment.

Materials and Methods Purification of dendritic cells-- Dendritic cells from 7 day bone marrow cultures were treated with polyclonal rabbit anti-DEC-205 F(ab)'2 fragments and 10 nm gold-labeled goat anti-rabbit IgG as described in Figure 11 and processed for electron microscopy. For each time point 10 grids were examined, and all cells that were labeled with gold were photographed. gold particles were counted and scored by a blinded observer based, on standard morphological criteria. The numbers in parentheses represent the percentage of total gold particles scored in each compartment.

Northern blotting-- For Northern blots, 2 pg of mRNA were electrophoresed in 0.8% agarose formaldehyde gels. Samples were transferred to nylon membranes and probed with an anti-sense RNA probe that spanned nucleotide positions 3688- 5200 in the DEC-205 cDNA. The blot was subsequently stripped and rehybridized with glyceralaldehyde-3-phosphate dehydrogenase probe as a loading control.

Electron microscopy-- Dendritic cells harvested from 7 day mouse bone marrow cultures were incubated with 10 Vlg/ml of either: polyclonal anti-DEC-205, Fab'2 fragments of polyclonal anti-DEC-205; or biotinylated monoclonal NLDC-145, on ice for 30'. Excess primary antibody was removed by washing cells 3 times with RPMI-1640, 10% FCS, 0.02% NaN3. The cells were then incubated for 30' on ice with either: a 1:5 dilution of 10 nm gold labeled goat anti-rabbit IgG, or a dilution of 10 nm gold labeled streptavidin respectively. Excess secondary reagent was removed by washing cells as above. Dendritic cells were then either fixed with 2.5% glutaraldehyde for a time-zero point, or incubated for the stated times at 37°C before fixation and processing for electron microscopy.

WO 96/23882 PCT/IJS96/01383 68 Antigen presentaion-- 105 BALB/c mouse Dendritic cells obtained from day 7 bone marrow cultures were co-cultured with 105 2R.50 rabbit IgG specific T hybridoma cells for 48 hours in triplicate (Boom et al., J Exp Med 1988 167:1350- 64). The supernatants were assayed for IL-2 concentration using the HT-2 indicator cell line. IL-2 production by the 2R.50 cells is plotted against the concentration of antibody in the cultures on a log scale. The error bars indicate the standard deviation from the mean.

Results and Discussion This Example reports the molecular characterization of the 205 kDa cell surface protein described in Example 1. Using oligonucleotide probes based on the protein sequence, fourteen cDNA clones were obtained from three separate thymic and dendritic cell cDNA libraries. All of the cDNA clones were derived from the same mRNA. Clones containing the putative 5' end of the DEC-205 cDNA encoded the N-terminal peptide of the DEC-205 antigen, and this was preceded by a hydrophobic leader consistent with a signal sequence. The protein contains ten Ctype lectin domains, a transmembrane domain, and a cytoplasmic domain (Figure 7).

The composite cDNA had a single 5.2 Kb open reading frame encoding a protein of 1,722 a.a. with a predicted molecular weight of 195 Kda that included all 29 unambiguous DEC-205 peptide sequences (Figure Of particular note is the high degree of sequence identity and similarity of the cytoplasmic domains of both murine and human DEC (Figure A 7.5 Kb mRNA that corresponds to this cDNA was expressed at high levels in dendritic cells, thymus, and lymph nodes, a pattern that corresponds to that which was obtained by staining tissues with the NLDC-145 monoclonal antibody (Kraal et al.. supra) (Figure The sequence of DEC-205 was aligned with known proteins in the database, and it was determined that it is homologous to the macrophage mannose receptor (MMR) (Taylor et al.. 1990. J. Biol. Chem. 265:12156-62: Ezekowitz et al.. 1990. J. Exp.

WO 96/23882 PCT/US96/01383 69 Med. 172:1785-94) and the phospholipase A2 (PLA2) receptors of rabbit skeletal muscle (Lambeau et al., 1994, J. Biol. Chem. 269:1575-8), and to bovine pancreas (Ishizaki et al., 1994, J Biol Chem. 269:5897-904) (Figure All known members of this family, which has been designated as the group VI C-type animal lectins (Drickamer and Taylor, 1993, Annu. Rev. Cell Biol. 9:237-64), are type 1 transmembrane proteins with short cyctoplasmic domains that mediate receptor endocytosis (Ezekowitz et al., 1990, J. Exp. Med. 172:1785-94; Ishizaki et al., 1994, J. Biol. Chem. 269:5897-904; Taylor et al., 1992, J. Biol. Chem. 267:1719- 26). The extracellular portions of MMR family proteins have a distinctive cysteine-rich N terminal domain, followed by a fibronectin type II repeat, and eight Ca" dependent carbohydrate recognition domains (C-type CRDs) (Taylor et al., 1990, J. Biol. Chem. 265:12156-62; Lambeau et al., 1994 J. Biol. Chem. 269:1575- 8; Ishizaki et al., 1994, J. Biol. Chem. 269:5897-904). DEC-205 diverges from this pattern only in that it has ten instead of the usual eight C-type CRDs (Figure The functions of the cysteine-rich domain and the fibronectin repeat in group VI lectins have not been defined. By contrast, there is extensive experimental evidence that the C-type CRDs are carbohydrate-binding domains (reviewed by (Drickamer and Taylor, 1993, Annu. Rev. Cell Biol. 9:237-64)) and both the MMR and rabbit PLA2 receptor bind carbohydrates (Lambeau et al., 1994, J. Biol. Chem.

269:1575-8: Drickamer and Taylor, 1993, Annu. Rev. Cell Biol. 9:237-64). The carbohydrate contact residues defined for the C-type CRDs in rat serum mannoseprotein and E-selection (Drickamer, 1992, Nature 360:183-86; Weis et al., 1991, Science 254:1608-15: Weis et al., 1992, Nature 360:127-34; Graves et al., 1994, Nature 367:532-8) are not conserved in DEC-205. However, additional mechanisms must exist for carbohydrate binding by C-type CRDs since sequence features initially defined as "essential" for carbohydrate binding are also absent from the CRDs of NKRI. and rabbit PLA2 receptors which bind avidly to carbohydrate ligands (Lambeau et al.. 1994. J. Biol. Chem. 269:1575-8: Bezouska et al.. 1994. Nature 372:150-57). CRDs are found in over one hundred other proteins (Drickamer and Taylor. 1993. Annu. Rev. Cell Biol. 9:237-64). but the CRDs in DEC-205 are most closely related to those found in the bovine and rabbit PLA2 receptors, and the MMR (34.6% identity with bPLA2 receptor and 26.7% identity with hMMR). Indeed there is an ordered correspondence between CRDs 1-5 and 7-8 in DEC-205 and CRDs 1-5 and 7-8 in other group VI animal lectins, whereas CRD 6 of DEC-205 most closely resembles the first CRDs in other family members. The unusual CRDs in DEC-205, numbers 9 and 10, are most closely related to CRDs 7 and 8 in other group VI lectins, and may have arisen during a gene duplication event. At least two of the CRDs in the MMR are known to bind mannose (Taylor et al., 1992, J. Biol. Chem.

267:1719-26), and grouping of several CRDs increases the affinity of the MMR for carbohydrate ligands (Taylor and Drickamer, 1993, J. Biol. Chem. 268:399-404. The same mechanism may be utilized by DEC-205 to increase both the afinity and diversity of carbohydrates bound by this receptor.

The receptor's function was investigated using a combination of monoclonal and polyclonal anti-DEC-205 antibodies. The observation that the cytosolic domain of DEC- 205 contains conserved aromatic amino acids (Figure 9; SEQ ID NOS:1 and which have been implicated as part of an endocytic motif (Ezekowitz et al., 1990, J. Exp. Med.

172:1785-94; Ishizaki et al., 1994, J. Biol. Chem. 269:5897-904: Chen et al., 1990, J. Biol.

Chem. 265:3116-3123; Collawn et al., 1990, Cell 63:1061-72), suggested that this receptor might be used by dendritic cells and thymic epithelial cells to deliver a variety of S: ?20 extracellular glycoprotein antigens to an intracellular antigen processing compartment.

To test this idea, the fate of immunogold-labeled monoclonal and polyclonal anti-DEC- 205 antibodies bound to DEC-205 on dendritic cells was examined by electron S microscopy in a time course experiment (Figure 11). Similar results were obtained using the monoclonal antibody and intact or F(ab')2 fragments of polyclonal antibodies in two separate experiments. At time zero, 95% of the cell-associated gold particles were found on the plasma membrane. After warming the sample to 37 0 C for only one .minute (Figure 11A), 38% of the particles were found in coated vesicles or coated pits.

By 20 minutes after crosslinking (Figure 11B), 79% of the gold particles were in a multivesicular compartment that is characteristic of dendritic cells (Steinman et al., 1979 J. Exp. Med. 149:1- 16; Kleijmeer et al., 1994, J. Invest. Dermatol. 103:516-523) and resembles the MHC class- II containing vesicles that are thought to be involved in antigen processing (Amigorena et al., 1994, Nature 369:113-120; Qiu et al., 1994, J. Cell Biol. 125:595-609; West et al., 1994, Nature 369:147-151; Tulp et al., 1994, Nature 369:120-26; Schmid and Jackson, 1994, Nature 369:103-4) (Figure 11 and Table Figure 11C illustrates the situation at minutes. Thus, DEC-205 is rapidly internalized via coated vesicles, and antibodies bound to the internalized receptor are delivered to multivesicular endosomal compartment.

TABLE 2 Compartmental localization of gold particles by electron microscopy PLASMA COATED Multi-vesicular Membrane Pit/Vesicle Endosome Lysosome 0' 156(95%) 0 0 1' 68 31 0 0 129(41%) 83(28%) 99(32%) 0 20' 12(5%) 175(79%) 32 (14%) 60' 17(7%) 46 172 To determine whether DEC-205 could deliver antigen to an active antigen processing compartment, dendritic cells were treated with rabbit anti-DEC-205 antibodies, and 0*0**0 "15 assayed for presentation of rabbit IgG-peptide/MHC complexes to T cell clones (Boom et al., 1988, J. Exp. Med. 167:1350-64). Negative controls included non-specific rabbit antibodies, and rabbit antibodies to IgG2a that are efficiently present by B cell lines (Boom et al., 1988, J. Exp, Med. 167:1350-64). It was determined that dendritic cells presented rabbit anti-DEC-205 to the T cells clones two orders of magnitude more efficiently than the non-specific rabbit antibodies or rabbit anti-IgG2a (Figure 12). Thus, DEC-205 resembles membrane immunoglobulin on B cells in that the cross-linked /eceptor is efficiently WO 96/23882 PCTMUS96/01383 72 internalized and bound ligands are delivered to an intracellular compartments that are active in antigen processing (Chestnut and Gray, 1981, J. Immunol. 126:1075- 79; Rock et al., 1984, J. Exp. Med. 160:1102-25; Lanzavecchia, 1985, Nature 314:538-39).

In conclusion, dendritic cells and thymic epithelial cells express a novel receptor, DEC-205, which contributes to antigen presentation. The multi-lectin domain structure suggests that this receptor can be used by dendritic cells and thymic epithelial cells to capture and endocytose diverse carbohydrate bearing antigens and direct them to an antigen processing compartment.

EXAMPLE 3: EXPRESSION OF THE DEC-205 ON DENDRITIC CELLS AND OTHER SUBSETS OF MOUSE LEUKOCYTES Prior studies by a variety of groups demonstrated that the mAb NLDC-145 reacted primarily with dendritic cells (DCs) and the epithelial cells of the thymic cortex.

As shown in Example 1, this mAb recognizes DEC-205, a 205 kDa integral membrane glycoprotein with a unique amino-terminal sequence, and a rabbit polyclonal antibody to purified DEC-205 with higher affinity for the blotted antigen than the original mAb was generated. Both the polyclonal and NLDC-145 antibodies have been used in this Example to reassess the expression and function of DEC-205 on leukocytes. Cytofluorography revealed that DCs derived from the epidermis (Langerhans cells) and from proliferating bone marrow progenitors (BMDCs) expressed high levels (2-3 logs) of DEC-205, while freshly-isolated spleen DCs comprised two subsets, most staining at low levels 1 log). the remainder moderately (1.5 logs). DEC-205 epitopes were sensitive to trypsin, but were regenerated in culture. Resident and inflammatory peritoneal macrophages did not express the antigen. except for small amounts on thioglycollate-elicited cells. B cells from spleen, lymph node. bone marrow, blood and peritoneal fluid expressed levels of DEC-205 that were 10 to 50-fold lower than those on BMDCs.

Marrow pro- and pre-B cells did not express DEC-205. Polyclonal anti-DEC-205 failed to inhibit either stimulation of a primary mixed leukocyte reaction by DCs in WO 96/23882 PCT/US96/01383 73 vitro, or a local graft vs. host response in vivo, where parental T cells were injected into Fl mice. DEC-205 is therefore more broadly expressed on leukocytes than previously appreciated.

The monoclonal antibody described in Kraal et al. (1986, J. Exp. Med. 163:981) was not able to block any DC functions tested, either in vitro or in mice given long-term injections of NLDC-145 IgG from birth (Breel et al., 1988, Immunol.

63:331). Because of the unique tissue distribution of the antigen recognized by NLDC-145, and because of its abundant expression on a cell type (dendritic cells) for which few restricted mAbs have been identified, the cell specificity and potential function of DEC-205 was reexamined. The new polyclonal antibody (described in Example 1) was used to improve detection of DEC-205, and to attempt to perturb DC function.

Materials and Methods Mice-- Adult (6 to 10 wk old) mice of both sexes were studied, including (C57BL/6 x DBA/2) and (BALB/C x DBA/2) F1 mice from the Trudeau Institute (Saranac Lake, NY), and (C57BL/6 x BALB/C) Fl and BALB/C mice from Japan SLC (Hamamatsu, Shizuoka, Japan).

Cell Suspensions-- Cells were studied either immediately after isolation from the animal or following a period of culture in RPMI-1640 medium supplemented with FCS, 50 tM 2- mercaptoethanol, and 20 jxg/ml gentamicin. Spleens, thymi.

and lymph nodes were either teased with forceps, or additionally digested with collagenase (Swiggard et al., 1992, In Current Protocals in Immunology. Coligan et al., (Eds). Green Publishing Associates and Wile Interscience: New York Supplement 3, pp. 3.7 1-11; Crowley et al.. 1989. Cell Immunol. 118:108). with similar results. Bone marrow cells were flushed with a syringe from femurs and tibias. while blood was obtained by cardiac puncture in heparin. All cell suspensions were depleted of red cells by lysis in 0.83% ammonium chloride solution. Dendritic cells were obtained from three sources, each as described: the WO 96/23882 PCTIUS96/01383 74 epidermal sheets of mouse ears (Schuler and Steinman, 1985, J. Exp. Med.

161:526), the low density plastic adherent population of spleen (Saveggard et al., supra; Crowley et al., supra), and proliferating bone marrow progenitors that were expanded in rGM-CSF (Inaba et al., 1992, J. Exp. Med. 176:1693). Peritoneal cells were either resident populations or were elicited by various inflammatory stimuli: proteose peptone 3 days earlier, thioglycollate broth 4 days earlier, 50 /g concanavalin A 2 days earlier, or 107 live Mycobacterium bovis BCG organisms 7 days earlier. Several populations were also studied after a period of 1-3 days in culture. The B cells in lymph node suspensions were stimulated with the B cell mitogens lipopolysaccharide (10 fig/ml LPS, from E. Coli 0111:B4, Difco, Detroit, MI), anti-IgM plus IL-4 (10 pg/ml goat anti-mouse IgM, Jackson ImmunoResearch (West Grove, PA), plus 50 U/ml of recombinant murine IL-4, kind gift of Dr. T. Sudo, Basic Research Laboratories, Toray Industries. Kamakura, Japan), and CD40 ligand (CD40L: L cells transfected with CD40L (kind gift of Dr. H. Yagita, Juntendo University School of Medicine, Japan), fixed with 1% paraformaldehyde and washed 3 times in PBS before 1:1 coculture with B cells).

Dendritic cells in skin were cultured as whole epidermal suspensions and then enriched by flotation on dense bovine albumin (Schuler and Steinman. supra), while dendritic cells in spleen were cultured from low density spleen adherent cells, with or without supplementation in rGM-CSF (200 U/ml) or keratinocyteconditioned medium, as described (Witner-Pack et al.. 1987. J. Exp. Med.

166:1484).

Two-color labeling methods were used to simultaneously identify a particular subset of leukocytes (PE-labeled antibody) and DEC-205 (NLDC-145 rat mAb or rabbit polyclonal anti-DEC-205 followed by FITC labeled anti-Ig). Nonreactive control antibodies were nonimmune rat IgG2a (Zymed. South San Francisco. CA) and rabbit IgG (Jackson ImmunoResearch: intact IgG or prepared by us).

The staining sequence was: primary anti-DEC-205 or nonimmune: (b) secondary anti-Ig (FITC conjugates of mouse anti-rat IgG or goat anti-rabbit both from Jackson ImmunoResearch): rat or rabbit IgG at 10 ig/ml to WO 96/23882 PCT/US96/01383 quench; and the PE- or biotin-labeled antibody. The latter reagents were purchased from PharMingen (La Jolla, CA), and were: biotin conjugates directed to class II MHC (clone AMS-32.1), B220/CD45RB (clone RA3-6B2) and Thy- 1.2/CD90 (clone 53-2.1) antigens; or PE conjugates directed to Mac-1/CD1 Ib (clone M1/70) and Gr-1 granulocyte (clone RB6-8C5) antigens. At least 10,000 cells per sample were examined in a FACScan cytofluorograph (Becton Dickinson Immunocytometry Systems, Mountainview CA).

Immunoblotting-- This was performed with monoclonal and polyclonal reagents, as described (in Example 1, supra).

Immunocytochemistry-- Cytospins were fixed in neat acetone for 10 min at room temperature, air-dried, and stained with antibodies exactly as described for cytofluorography. The same secondary reagents were used, except that peroxidase conjugates instead of FITC conjugates were employed. Staining was visualized with diaminobenzidine (Stable DAB, Research Genetics, Huntsville, AL).

Functional Studies-- Monoclonal (10 and 1 pg/ml) and polyclonal (30 and pg/ml) antibodies were applied at doses that were close to or above saturation, continuously, to a one-way allogeneic mixed leukocyte reaction (MLR). wherein 3 x 105 nylon wool-passed lymph node T cells were stimulated by graded doses of allogeneic irradiated or mitomycin-treated DCs (Inaba and Steinman, 1984, J. Exp.

Med. 160:1717; Inaba et al., 1987, J. Exp. Med. 166:182). Syngeneic MLRs were run in tandem. The positive control for MLR inhibition utilized a reagent that interferes with the B7 costimulation system (GL-1 rat mAb to B7-2) (Hathcock et al., 1993, Science 262:905). For in vivo experiments, we used the local graftversus-host (GVH) reaction (Atkins and Ford. 1975. J. Exp. Med. 141:664).

wherein parental lymph node cells injected into the hind foot pad induce a GVH in the draining popliteal node of Fl mice. presumably upon encountering Fl dendritic cells in the lymph node cortex. Lymph node weights of control (PBS-injected) and GVH nodes were measured at day 7. using 5 mice per group. The protocol was to inject 200 pg of anti-DEC-205 or control IgG into the foot pad at time 0. and to WO 96/23882 PCTIS96/01383 76 repeat the Ig injection 8 hours later8 hours later, adding either 107 parental lymph node cells or a corresponding volume of PBS to the injected solution.

Results Expression of DEC-205 by epidermal dendritic cells. Three forms of antibody to DEC-205 (monoclonal NLDC-145, polyclonal anti-DEC-205 IgG, and polyclonal anti-DEC-205 F(ab') 2 fragments) were applied to cultured epidermal cells. Prior data had shown strong staining of Langerhans cells by NLDC-145. Since the NLDC-145 epitope is trypsin-sensitive (below), and since trypsin is used initially to prepare the sheets of epidermis from which Langerhans cells are released, we concentrated on epidermal cells that had been cultured overnight, to allow time for the protein to be repleted on cell surfaces. The culture period also provides time for most keratinocytes to adhere to the plastic surface, and for the nonadherent Langerhans cells to acquire a low buoyant density (Crowley et al. supra; Schuler and Steinman, supra). As a result, preparations with 20-50% dendritic cells can be obtained by studying nonadherent, overnight cultures of epidermal cells, especially following flotation on columns of dense BSA.

Epidermal cells were stained with a phycoerythrin (PE)-tagged mAb to class II MHC proteins, to distinguish Langerhans cells from keratinocytes, and were counterstained with hybridoma supernatants of NLDC-145 and mAbs to other leukocyte lineages (Figure 13. The specificity of NLDC-145 for dendritic cells (Figure 13A) was demonstrated by the fact that isotype-matched IgG2a mAbs to macrophages (SER-4 anti-sialoadhesin (Coocker and Gordon, 1989, J. Exp. Med.

169:1333)), B cells (RA3-6B2 anti-B220 (Hoffman and Weissman, 1981, Nature 289:681)), and T cells (53-6.72 anti-CD8; (Ledbetter and Herzenberg. 1979, Immunol. Rev. 47:63)) were non-reactive with NLDC-145 cells (Figure 13.

panels When the same suspensions were counterstained with graded doses of either purified NLDC-145 IgG (rat lgG2ai) or polyclonal. nonimmune rat IgG2a as a nonreactive control, staining of Langerhans cells by NLDC-145 reached a plateau WO 96/23882 PCTIUS96/01383 77 at 2 /g/ml (Figure 13, compare the staining of the arrowed MHC-II dendritic cells in panels E-G with H).

The anti-DEC-205 rabbit polyclonal was also applied, both as F(ab') 2 fragments and as intact IgG, and was compared with nonimmune F(ab') 2 and IgG over a broad range of doses (0.3-100 The rabbit reagents did react with the class II MHC-negative keratinocytes, but this binding was entirely nonspecific, since the staining was comparable with immune and nonimmune reagents (Figure 13, compare panels I-L with M-P, and Q-T with The staining of MHC-II Langerhans cells, however, was strong, specific, and comparable using-anti-DEC- 205 as either intact IgG or fragments, with apparent saturation at 30 /jg/ml (Figure 13, panels I-L for fragments, panels Q-T for intact IgG).

The second rabbit polyclonal antibody, raised to a synthetic peptide spanning the first 19 residues of DEC-205, failed to stain Langerhans cells, instead giving a pattern like that of nonimmune IgG (not shown).

The trypsin sensitivity of DEC-205 epitopes was examined. Partially-enriched cultured Langerhans cells were either not treated or were exposed to trypsin (0.25% in PBS for 30 min on ice). Staining by both monoclonal and polyclonal reagents was decreased by ten-fold (1 log of fluorescence intensity in Figure 14 compare A and B to C and The epitopes were reexpressed, to levels equal to those on untreated cells, during a subsequent overnight culture period (Figure 14. compare E and F with A and B).

Expression of DEC-205 by other dendritic cell populations. Spleen DCs were identified in low buoyant density splenocyte suspensions (See Example 1: and Surggard et al.. supra) by their expression of the integrin CD I c (Figure 15A, C. E and as detected with the mAb N418 (Metlay et al.. 1990. J. Exp. Med.

171:1753). Counterstaining with either NLDC-145 or with the anti-DEC-205 polyclonal revealed that. whether freshly isolated or cultured overnight, these cells WO 96/23882 PCT/US96/01383 78 expressed less DEC-205 on their surfaces than Langerhans cells (Figure 15C, D, G and Freshly-isolated spleen DCs comprised two phenotypic subsets, as previously described (Crowley et al., supra). Most (roughly 80%) expressed relatively low but detectable levels log) of the antigen, while a smaller population stained moderately (ca. 1.5 logs: arrows, Figure 15C, D, G, and H).

After overnight culture, DEC-205 expression by all of the CD lIc DCs had risen to the moderate (1.5 log) level, but never to the levels observed on epidermal dendritic cells (ca. 2 logs: arrows, Figure 15K, L, O and P) attempts to further upregulate expression of DEC-205 by culturing the cells in rGM-CSF, or in keratinocyte-conditioned medium containing GM-CSF, did not yield an increase beyond that induced by culture alone (not shown).

In contrast, when dendritic cells were generated from bone marrow progenitors with GM-CSF (Inaba et al., 1972, supra), their expression of DEC-205 was uniformly high, comparable to the levels on Langerhans cells (not shown).

Interestingly, the actively proliferating populations at day 6 of the marrow cultures contained relatively few cells that expressed DEC-205 (Figure 16), but expression had increased to uniformly high levels by day 8.

Expression by resident and elicited peritoneal cells. Resident peritoneal cells (consisting of about 30% macrophages and 70% B cells) were compared to inflammatory peritoneal cells in exudates elicited with concanavalin A (Con A), thioglycollate (TGC), or live M bovis Bacille Calmette-Gu6rin (BCG) organisms (Figure 17). The data are shown for polyclonal nonimmune and immune F(ab'), fragments. Similar staining was obtained with the NLDC-145 monoclonal (not shown). However, nonimmune and immune intact rabbit IgG gave strong background staining on peritoneal macrophages. presumably because of binding to Fc receptors (not shown). Resident. Mac-I peritoneal macrophages did not express surface DEC-205. but peritoneal B cells expressed measurable levels (roughly 1 log above background: Figure 17 E-H arrows). Macrophages in Con A- and BCG-elicted exudates again showed little or no staining with anti-DEC-205 WO 96/23882 PCT/US96/01383 79 (Figure 17 E-H, arrowheads), even though these macrophages were all strongly class II MHC-positive (not shown). The Con A and BCG exudates contained significant numbers of T cells, but these did not stain with anti-DEC-205 (anti-Thy- 1 double label not shown). In contrast to the other peritoneal populations tested, TGC-elicited macrophages did express DEC-205, albeit at low levels (0.5-1 log above background). In each of the resident and elicited populations, B cells stained comparably.

Expression of DEC-205 by resident leukocytes in multiple tissues, particularly B cells. Given the surprising finding that resident peritoneal B cells expressed DEC- 205, we explored the distribution of the antigen further by examining cell suspensions from spleen, bone marrow, peripheral blood, lymph node, and thymus for co-expression of DEC-205 with several leukocyte markers. Results with the first 3 organs are illustrated here (Figure 18). The results with spleen and lymph node were identical (not shown). Thymocytes stained only marginally log) above background (not shown).

In spleen suspensions, B cells (B220 and MHC-II Gr-1, Mac-1 and Thy-1 Figure 18 F-J, arrows) again expressed DEC-205, staining approximately one log above background. T cells (Thy-1 and granulocytes (Gr-1 Mac-1 also stained, but less strongly than B cells.

In bone marrow (Figure 18, granulocytes stained almost a log above background, whereas marrow B cells displayed heterogeneous levels of DEC-205.

Most B220 cells in the marrow stained weakly or not at all. while a subset of cells with higher levels of B220 (arrowi. Figure 18. P-T, B220 double label) coexpressed DEC-205 at levels comparable to those on peripheral B cells. These B220brigh.DEC-205 cells also expressed surface IgM. identifying them as mature B cells (not shown). A small subset of Mac-I B220 cells presumably monocytes did not express DEC-205.

WO 96/23882 PCT/US96/01383 In peripheral blood (Figure 18 B cells (arrows) stained comparably to B cells in lymphoid tissues, while granulocytes and T cells showed weaker but measurable staining.

To gain knowledge of the relative amounts of DEC-205 expressed by different cell types (Figure 19), graded doses of whole-cell NP-40 lysates from bone marrow dendritic cells, splenocytes (about 65% B cells) and peritoneal cells (about 70% B cells and 30% macrophages) were immunoblotted. The signal from 10,000 BMDCs was approximately twice as strong as the signal from 100,000 splenocytes, corresponding to at least ten times- more DEC-205 per cell in BMDCs than splenic B cells. The signal from 100,000 peritoneal cells was weaker still, 5-10 times fainter than the signal from 10,000 DCs, corresponding to about 50 times less DEC-205 in peritoneal B cells than BMDCs.

To examine the effects of B cell activators on surface levels of DEC-205, B cells were cultured for up to 2 days in the presence of LPS, CD40 ligand, and the combination of anti-IgM and IL-4. None induced a significant increase, but the latter combination induced a modest (2-fold) decrease in surface levels of DEC- 205, as detected with both monoclonal and polyclonal reagents (not shown).

Mouse B cell viability is greatly improved during stimulation in culture, allowing us to ask whether the DEC-205 epitopes on B cells were actively synthesized by the cells, rather than adsorbed on their surfaces from an extracellular source. On B cells, as on Langerhans cells, trypsin treatment eliminated most of the staining by NLDC-145 and anti-DEC-205, but the epitopes were resynthesized during overnight culture (Figure 14 G-L).

Attempts to block dendritic cell function with antibodies to DEC-205. When oneway mixed leukocyte reactions were performed in the continuous presence of either 10.Lg/ml of NLDC-145. or 30 ttg/ml polyclonal anti-DEC-205. no inhibition of allogeneic T cell proliferation was observed (Figure 20). The rat lgG2a WO 96/23882 PCT/US96/01383 81 monoclonal GL-1, directed against the costimulator protein B7-2 (Hathcock et al., supra; Freeman et al., 1993, J. Exp. Med. 178:2185; Inaba et al., 1994, J. Exp.

Med. 180:1849), was utilized as a positive blocking control. GL-1 inhibited proliferation in this system, but did not abolish it, as expected: blockade of multiple costimulators is required to completely ablate proliferation in an allogeneic MLR (Young et al., 1992, J. Clin. Invest. 90:229).

To ascertain whether DEC-205 might play a role in the homing of T cells to the Tdependent areas of lymphoid tissue, where dendritic cells express high levels of DEC-205 (Kraal et al., supra; Example 4, supra), the local graft-versus-host (GVH) reaction was studied (Atkins and Ford, supra). This response is produced in the draining popliteal lymph node of Fl mice when parental-strain lymph node cells are injected into the hind foot pad. The T cells migrate to the draining node, where they encounter allogeneic MHC proteins, presumably initially on dendritic cells and within the cortical T cell areas. A substantial dose of nonimmune or anti- DEC-205 F(ab')2 fragments (200 Ag) was injected into the footpad at 0 hours.

Eight hours later, a second dose of antibody along with 10 million lymph node cells (ca. 70% T cells) was injected. The T cells induced a strong GVH reaction: the draining lymph nodes swelled to 5-6 times their normal size within 7 days.

Polyclonal anti-DEC-205 was unable to inhibit this primary T cell response in vivo (Table 3).

WO 96/23882 PCT/US96/01383 82 Table 3: Failure of polyclonal anti-DEC-205 to inhibit local GVH in vivo Mouse number Weight of popliteal lymph node (g) 107 parental No cells injected lymph node cells injected Fl footpad Nonimmune F(ab')2 Anti-DEC-205 F(ab' 1 2.63 2 2.36 3 2.89 4 2.06 5 2.14 Mean difference (GVH) 10.75 1.03 g )2 1 2.88 2 2.08 3 2.22 4 1.95 2.38 Mean difference (GVH) 10.65 1.03 13.27 13.83 12.01 12.80 13.93 14.91 12.01 13.19 11.31 13.33 Discussion Prior studies failed to detect the DEC-205 antigen on most types of leukocytes except for dendritic cells (Kraal et al., supra; Crowley et al., supra). This Example demonstrates that other leukocytes, especially B cells, can express DEC-205, although at much lower levels. Example 4 reports low-level expression of DEC- 205 by B cells in tissue sections. Polyclonal rabbit antibodies raised against the Nterminal peptide of DEC-205 and the intact protein described in Example 1 were used. The anti-peptide reagent failed to stain live cells, suggesting that under native conditions, the amino terminus of DEC-205 may be involved in a higherorder protein structure that alters its conformation relative to the 19-residue synthetic immunogen, or sterically hinders access by an antibody. The failure of the anti-peptide polyclonal to bind cells cannot be explained by covalent modification of the N-terminal serine of DEC-205 in tissues, since this residue was susceptible to Edman degradation in protein isolated from thymi. In contrast. the WO 96/23882 PCT/US96/01383 83 polyclonal raised to intact DEC-205 stained cells with patterns of reactivity that mimicked NLDC-145 closely.

Differences in DEC-205 expression among different classes of leukocytes were observed. Other than dendritic cells, B cells expressed the most DEC-205, although their levels were 10 to 50 times lower than those on BMDCs (Figure 19).

The DEC-205 detected on B cell surfaces was actively synthesized by the cells themselves, and unlikely to be adsorbed to their surfaces from an extracellular source, since after trypsinization, DEC-205 epitopes were regenerated in culture.

Expression of DEC-205 appears to be coordinated with the developmental transition from pre-B cell to surface IgM B cell in the marrow. However, peripheral B cell stimulation with a variety of mitogens (LPS, CD40 ligand, anti-IgM plus IL-4) was not accompanied by a significant increase in surface expression of DEC-205.

Granulocytes expressed DEC-205, with higher levels on granulocytes in bone marrow than in blood. Thymocytes and mature T cells from spleen and lymph node expressed very low but detectable levels of DEC-205, whereas T cells in blood and peritoneal fluid did not express detecable levels. It is possible that the DEC-205 detected on granulocytes and T cells was adsorbed from surrounding stromal cells that are rich in DEC-205, such as bone marrow stroma, thymic epithelium, and the dendritic cells in the T cell areas of peripheral lymphoid tissues. Most macrophage populations lack DEC-205, although thioglycollateelicited cells are weakly positive, as previously described (Wiffels et al.. 1991, Immunobiol. 184:83).

Although other leukocyte lineages express DEC-205, it is evident that dendritic cells express some 10-50 times more of the antigen, as assessed by immunoblotting. DEC-205 expression is regulated on dendritic cells in some way.

Freshly isolated splenic DCs have relatively little DEC-205. and the levels increase only modestly in culture. The dendritic cells that express high levels of DEC-205 are those in skih. in the T cell regions of peripheral lymphoid organs, and dendritic WO 96/23882 PCIUS96/01383 84 cells that are grown from proliferating bone marrow precursors in the presence of high-dose GM-CSF.

To look for a contribution of DEC-205 to immune responses in tissue culture systems, we attempted to inhibit the primary allogeneic MLR. It was hypothesized that DEC-205 might be important in the capacity of dendritic cells to interact with helper T cells. However, either monoclonal nor polyclonal antibodies were able to block this T cell response with either monoclonal or polyclonal antibodies. We also attempted to inhibit an in vivo response, the local GVH reaction, in which parental T cells injected into nonlymphoid tissue migrate to the lymph node that drains the injection site and initiate an alloreactive response against Fl dendritic cells and B cells. Again, antibodies to DEC-205 had no effect. These negative results could have trivial explanations, such as clearance of the antibody, or compensatory resynthesis of new DEC-205 protein. Given the large molecular mass of DEC-205, it is possible that both monoclonal and polyclonal antibodies bind epitopes on the native protein that do not interfere with its functions in the responses studied. Alternatively, the assay systems may be those in which DEC- 205 plays no critical role. DEC-205's putative function in immune responses appears to involve earlier events than those studied here, such as the acquisition of antigens by accessory cells, or selection events in lymphocyte development.

Further inquiries into the function of DEC-205 are enabled by the molecular cloning of the antigen described in Example 2, supra.

EXAMPLE 4: EXPRESSION OF THE DEC-205 PROTEIN IN SITU IN LYMPHOID AND NONLYMPHOID TISSUES In this Example. the monoclonal and polyclonal antibodies to DEC-205 were used to reassess the tissue distribution of DEC-205 by immunohistochemical staining of frozen sections from a variety of organs, and by multiple-organ immunoblotting.

In an effort to better define the tissue distribution of DEC-205. we have examined a variety of tissues histologically and on immunoblots. using both monoclonal and WO 96/23882 PCT/US96/01383 polyclonal antibodies, along with secondary anti-Ig reagents with greater sensitivity than those used in prior studies (Kraal et al., 1986, J. Exp. Med. 163:981; Crowley et al., 1989, Cell. Immunol. 118:108; Vremec et al., 1992, J. Exp. Med. 176:47; Austyn et al., 1994, J. Immunol. 152:2401; Lu et al., 1994, J. Exp. Med. 179:1823; Breel et al., 1988, Immunology 63:657). Abundant expression of DEC-205 was confirmed histologically on thymic and intestinal epithelia and on dendritic cells in the T cell areas of peripheral lymphoid organs. In addition, DEC-205 was visualized in several other locations: B lymphocytes within B cell follicles, the stroma of the bone marrow, the epithelia of pulmonary airways, and the capillaries of the brain. Immunoblotting confirmed the presence of substantial levels of DEC- 205 protein in lysates prepared from lymphoid tissues and from lung, marrow and intestine. Thus, while DEC-205 is expressed at high levels by dendritic cells, it is also expressed by a number of other cell types in situ.

Material and Methods Mice Adult (6-12 week old) female mice of three strains were studied: inbred C57BL/6 x DBA/2 (Trudeau Institute, Saranac Lake, NY) and BALB/C, and outbred CD-1 Swiss-Webster (the latter 2 strains from Taconic Farms, Germantown, NY).

Immunohistology Immediately after organs were removed, they were frozen at 0 C in O.C.T. tissue embedding medium (Miles, Elkhart, IN), and stored at 0 C. Tissue sections, usually 10 /m thick, were cut on a Minotome cryostat (IEC division of Damon, Needham Heights, MA) and applied to 10-well slides (Carlson Scientific. Peotone, IL). The sections were fixed in neat acetone for 10 min at room temperature, and air-dried. Subsequent steps were performed in a humid chamber. Sections were rehydrated in a drop (30-50 pL) of PBS. then primary antibody was applied. Hybridoma supernatants were used either undiluted or diluted 1:5 in PBS 1% BSA, depending on their titer. Purified IgGs. ascites fluids and antisera were diluted in the same medium to optimized doses determined by titration. usually 1-10 ug/ml for purified protein and 1:3000-1:1000 for ascites WO 96/23882 PCT/US96/01383 86 and hyperimmune sera. The primary antibodies were the NLDC-145 mAb, applied either as a hybridoma culture supernatant or as purified IgG (protein G eluate), or rabbit polyclonal anti-DEC-205, (Example 1 supra), applied either as intact IgG (protein A eluate) or as F(ab')2 fragments. Positive controls included rat mAbs to other subsets of leukocytes (RA3-6B2 anti-B220/CD45RB (TIB 146, ATCC, Rockville MD), SER-4 anti-macrophage, and 53-6.72 anti-CD8 (TIB 105, ATCC)) and MHC class II proteins (M5/114 (TIB 120, ATCC)), as well as a rabbit polyclonal to Igp, one of the signaling chains that associates with B cell surface Ig (Sanchez et al., 1993, J. Exp. Med. 178:1049). Negative controls were polyclonal rat IgG2a (Zymed, South San Francisco, CA) and rabbit IgG (Jackson ImmunoResearch, West Grove, PA), either intact or as fragments. Primary antibodies were left in contact with the sections for 45 min at room temperature, then the sections were washed 5 times with PBS, never allowing the sections to stand dry for more than a few seconds. Anti-Ig secondary antibodies were added next, usually donkey F(ab') 2 horseradish peroxidase conjugates (Jackson ImmunoResearch), diluted 1:300 in PBS 1% BSA. After a 45 minute incubation, sections were washed 5 times with PBS. The chromogenic substrate was a readyto-use formulation of diaminobenzidine containing H 2 02 (Stable DAB. Research Genetics, Huntsville, AL). Sections were washed 5 times in PBS, and usually were counterstained with Gill's Hematoxylin #1 (Fisher, Fair Lawn, NJ). Coverslips were attached using Permount histological mounting medium (Fisher).

Extraction and immunoblotting of protein from multiple organs Organs were placed in 10 volumes of a monophasic solution of phenol and guanidinium isothiocyanate (TRIzol, Gibco-BRL, Gaithersburg. MD) (Chomczynski. 1993, BioTechniques 15:532). Organs were homogenized for 15-30 s (Polytron, Brinkmann, Westbury, NY). RNA and DNA were removed by CHCI, extraction and ethanol precipitation. Proteins were precipitated from the phenol-ethanol supernatants with isopropanol (150% of the original TRIzol volume), and were redissolved in 1% SDS (30% of the original TRIzol volume, 50 0 C. 1 Extracts were clarified (3000 x g. 10 min. room temperature). and total protein levels were WO 96/23882 PCT/US96/01383 87 measured (BCA assay, Pierce, Rockford, IL). Immunoblotting was performed as described (Chomczynski, supra), normalizing protein loads to 50 /g per lane.

Filters were stained with either 10 /g/ml of NLDC-145 IgG or mAb 1D4B (anti- LAMP-1) hybridoma supernatant, diluted 1:1.

Results In every organ studied, similar results were obtained with the NLDC-145 monoclonal antibody and with the rabbit polyclonal antibody raised to purified DEC-205 protein. This will be illustrated in several lymphoid and nonlymphoid tissues. In many instances, DEC-205 was found to be expressed in sites that had not been described in prior work.

Thymus. Staining patterns in this organ were identical to those in the original description of the NLDC-145 mAb (Kraal et al., supra). Very strong peroxidase immunolabeling was observed on thymic cortical epithelium, while weaker staining was noted on scattered dendritic profiles in the medulla Figure 21, panels a-c and g).

Lymph node. Strong DEC-205 expression was apparent on dendritic profiles throughout the T cell regions of the cortex Figure 21 At higher power, there was a punctate character to the staining in the T cell areas of the deep cortex (Figure 21 The punctate pattern could represent the presence of DEC-205 in intracellular granules of dendritic cells and/or DEC-205 on the surfaces of many fine processes. No staining was evident in the medulla Figure 21 Weak staining for DEC-205 was evident on B cells in the follicles Figure 21 d-j).

This staining was obscured when hematoxylin was used to counterstain nuclei (Figure 21 but was clearly visible when hematoxylin was omitted (Figure 21 i).

Spleen. Strong staining for DEC-205 was evident in the T cell areas, the periarterial sheaths (Figure 22: the central artery of the T area is arrowed in each WO 96/23882 PCT/US96/01383 88 micrograph). The extent of staining for DEC-205 in the T areas paralleled that seen with anti-MHC class II (Fig. 21, compare b with c, and d and e withf), but the DEC-205 stain was again punctate in nature (Figure 22 as it was in the T cell areas of lymph nodes (above). As in lymph nodes (above), the B cell follicles Figure 22 a-c) stained for DEC-205, although this staining was too weak to be evident in a black and white micrograph of a specimen counterstained with hematoxylin (Figure 22, compare the strong B cell staining with anti-Igp in panel a and anti-MHC-II in panel c with the anti-DEC-205 staining in panel Anti- DEC-205 did not stain the marginal zone (see arrowheads to the marginal sinus, which stands out in panels a and c because of the strong B cell staining).

Brain. Both NLDC-145 and polyclonal anti-DEC-205 reagents produced linear staining along capillaries (arrows, Figure 23 a-c) and small arteries (arrow, Figure 23 d) in the cerebrum and cerebellum. Staining of capillaries was not observed in any other organ studied.

Lung. Many strongly stained DEC-205 profiles were scattered about the lung parenchyma (Figure 23 e, g, We have not yet determined if these profiles represent dendritic cells, macrophages or both. Some strongly stained cells within the airways, presumably alveolar macrophages, were evident Figure 23 h).

DEC-205 was present in the epithelium of all the small airways (arrows, Figure 23 e, In contrast. anti-MHC class II did not stain the airway epithelium, but did stain cells surrounding the airways (Figure 23 fJ arrowheads).

Bone marrow. When bone marrow was extruded from the femur as an intact plug and sectioned, a lacy pattern of DEC-205 stain was evident throughout the plug, presumably on marrow stromal cells (arrows, Figure 23 Most of the dark staining of round cells represented background staining of eosinophils. which express endogenous peroxidases. It was evident in the absence of any antibody (not shown).

WO 96/23882 PCrUS96Io1383 89 Upper gastrointestinal tract. The oral epithelium of the tongue served as an example of a stratified squamous epithelium. Some DEC-205 positive profiles, presumably Langerhans cells, were found suprabasally (arrows, Figure 23 Anti- MHC class II antibodies stained these intraepithelial dendritic cells more frequently and/or more intensely, and in addition stained many subepithelial profiles in the upper dermis (not shown).

Lower gastrointestinal tract. Strong staining was observed on the columnar epithelia of the small and large bowel. The staining was much greater on apical villi than on crypt epithelium (Figure 23, In the best sections, staining was also stronger along the basal surfaces than the apices of individual epithelial cells.

Many cells within the lamina propria of the villi stained darkly, but this staining was again due to endogenous peroxidase within eosinophils.

Liver. No staining for DEC-205 was apparent, except for rare profiles in the portal triads (not shown).

Heart. No staining for DEC-205 was apparent (not shown).

Kidney. No strong expression of DEC-205 was noted, although some very weak DEC-205 staining was observed on scattered cortical tubules (not shown).

Distribution of DEC-205 by multiple-organ immunoblotting. To examine the tissue distribution of the DEC-205 protein itself, TRIzol protein extracts of several different organs (Methods) were immunoblotted with both monoclonal NLDC-145 IgG (Figure 24A) and polyclonal anti-DEC-205 IgG (not shown). The quantities of organ lysate protein applied to each lane were normalized to one another in terms of protein load (50 tig per lane). Staining for the lysosomal membrane marker LAMP-1 (Chen et al., 1985. Arch. Biochem. Biophys. 239:574) revealed that comparable numbers of lysosomes were represented in each lane (Figure 24B).

Among lymphoid tissues, the signal for DEC-205 was greatest in the thymus. and WO 96/23882 PCTUS96/01383 was stronger in bone marrow and lymph nodes than in the spleen. These findings corresponded closely to the histologic staining levels described above. In nonlymphoid tissues, strong signals comparable to thymus were evident in lung and intestine (Figure 24A). Liver, kidney and brain extracts contained only trace levels of DEC-205.

Discussion Using an improved donkey F(ab') 2 secondary anti-rat Ig reagent to increase the sensitivity of antigen detection, we have shown that the NLDC-145 monoclonal antibody reacts with many more tissues than previously apparent. In particular, clear staining was observed on brain capillaries, bone marrow stroma, the epithelia of intestinal villi and pulmonary airways, and B cells in the follicles of all peripheral lymphoid tissues. These newly-recognized depots of DEC-205 antigen did not stain as strongly as tissues that were originally noted to express the DEC- 205 protein, the cortical epithelium of the thymus, and the dendritic cells in the T cell areas of peripheral lymphoid organs.

The tissue distribution of the DEC-205 protein was confirmed with a polyclonal antibody raised to purified DEC-205. Both and intact IgG forms of the rabbit antibody gave patterns of staining that were similar to those obtained with monoclonal NLDC-145. The tissue distribution was also monitored by immunoblotting with both monoclonal and polyclonal reagents, and the relative levels of expression in multiple organs corresponded to the relative intensities of immunohistochemical staining seen on tissue sections. An exception is that trace amounts of DEC-205 protein were evident in extracts from organs like liver, heart, and kidney where it was difficult to appreciate discrete DEC-205 positive cells.

This suggests that very small amounts of the protein may be present in many cell types, but at levels too low to permit histologic visualization.

91 EXAMPLE 5: SEQUENCE OF HUMAN DEC-205 Human dec cDNA was cloned using a 300 base-pair probe derived from the 3' coding sequence of murine dec cDNA. The human cDNA was obtained from a B lymphoma library, using high stringency hybridisation conditions (0.1 SSC, 65*C). The sequence of the human DEC-205 gene was determined, and is shown in SEQ ID NO:7. The deduced amino acid sequence is shown in SEQ ID NO:8. The deduced sequence in SEQ ID NO:8 includes putative segments after the stop site at after amino acid number 1743; these are irrelevant and may be ignored.

The human deduced amino acid sequence and nucleotide sequence were compared with their murine homologs, as shown in Figure 25A and 25B respectively. This comparison shows a high degree of sequence similarity or identity for the entire length of both proteins and protein coding regions of the genes (cDNAs).

The present invention is not to be limited in scope by the specific embodiments described herein since such embodiments are intended as but single illustrations of one aspect of the invention and any embodiments which are functionally equivalent are within the scope of this invention. It should be further understood that all molecular weight and nucleotide base pair sizes given for nucleotides are approximate and are :20 used for the purpose of description. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.

9 25 Various references are cited herein, the disclosures of which are incorporated by reference herein in their entireties.

9 WO 96/23882 PCTIUS96/01383 92 SEQUENCE LISTING GENERAL INFORMATION: APPLICANT: STEINMAN, RALPH A NUSSENZWEIG, MICHEL C SWIGGARD, WILLIAM J JIANG, WANPING (ii) TITLE OF INVENTION: IDENTIFICATION OF DEC, A RECEPTOR WITH C-TYPE LECTIN DOMAINS, NUCLEIC ACIDS ENCODING DEC, AND USES THEREOF (iii) NUMBER OF SEQUENCES: 8 (iv) CORRESPONDENCE

ADDRESS:

ADDRESSEE: Klauber Jackson STREET:-411 Hackensack Avenue CITY: Hackensack STATE: New Jersey COUNTRY: USA ZIP: 07601 COMPUTER READABLE FORM: MEDIUM TYPE: Floppy disk COMPUTER: IBM PC compatible OPERATING SYSTEM: PC-DOS/MS-DOS SOFTWARE: PatentIn Release Version #1.25 (vi) PRIOR APPLICATION DATA: APPLICATION NUMBER: US 08/381,528 FILING DATE: 31-JAN-1995

CLASSIFICATION:

(vii) CURRENT APPLICATION

DATA:

APPLICATION NUMBER: WO FILING DATE: 31-JAN-1996

CLASSIFICATION:

(viii) ATTORNEY/AGENT

INFORMATION:

NAME: Jackson Esq., David A.

REGISTRATION NUMBER: 26,742 REFERENCE/DOCKET NUMBER: 600-1-081 (ix) TELECOMMUNICATION

INFORMATION:

TELEPHONE: 201 487-5800 TELEFAX: 201 343-1684 TELEX: 133521 Note: In all the amino acid sequences below, "Xaa" stands for one of the three stop codons.

INFORMATION FOR SEQ ID NO:1: SEQUENCE CHARACTERISTICS: LENGTH: 30 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: peptide DESCRIPTION: cytoplasmic domain of human DEC-205 WO 96/23882 PCTIUS96/01383 (iii) HYPOTHETICAL: NO FRAGMENT TYPE: C-terminal (vi) ORIGINAL SOURCE: ORGANISM: human (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1: Arg His Arg Leu His Leu Ala Gly Phe Ser Ser Val Arg Tyr Ala Gin 1 5 10 Gly Val Asn Glu Asp Glu Ile Met Leu Pro Ser Phe His Asp 25 INFORMATION FOR SEQ ID NO:2: SEQUENCE CHARACTERISTICS: LENGTH: 25 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: peptide DESCRIPTION: human DEC-205, peptide N1 (iii) HYPOTHETICAL: NO FRAGMENT TYPE: N-terminal (vi) ORIGINAL SOURCE: ORGANISM: human (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: Ser Glu Ser Ser Gly Asn Asp Pro Phe Thr Ile Val His Glu Asn Thr 1 5 10 Gly Lys Cys Ile Gin Pro Leu Phe Asp INFORMATION FOR SEQ ID NO:3: SEQUENCE CHARACTERISTICS: LENGTH: 1723 amino acids TYPE: amino acid TOPOLOGY: linear (ii) MOLECULE TYPE: protein DESCRIPTION: predicted ai (xi) SEQUENCE DESCRIPTION: SEQ ID N( Met Arg Thr Gly Arg Val Thr Pro Gly Leu A: 1 5 10 Leu Leu Leu Arg Ser Phe Gly Leu Val Glu P: 25 Asn Asp Pro Phe Thr Ile Val His Glu Asn T .40 Pro Leu Ser Asp Trp Val Val Ala Gin Asp C mino acid sequence 0:3: la Ala Gly Leu Leu of DEC-205 Leu

J

ro Ser Glu hr Gly Lys ys Ser Gly Ser Ser Gly Cys Ile Gin Thr Asn Asn WO 96/23882 PCTIUS96/01383 Met Gin Met His Tyr Ser 145 Asp Glu Trp Cys Gin 225 Lys Ile Ala Trp, Gly 305 Asp Pro Val Asn Ala 1 385 Let Lys Phe Ser Ala 130 Glu Gly Thr Cys Leu 210 Ile Glu His Arg 3iu 290 rhr rhr ryr rrp ;ly 370 {is Trp Cys Ser Leu 115 Val Glu Asn Trp Ala 195 Leu Gly Ala Ser Leu 275 Trp Pro Glu Val Thr 355 Phe Leu I LyE Let Cys 100 Tyr Ala Asn Ser Tyr 180 Thr Pro Ser Tyr Ala 260 Val Ser Val Ser Cys 340 Tyr :ys ,yo Trj 1Gil 81 Asj Thi Asr Leu Tyr 165 His Thr Glu Cys Val 245 Ala Trp Asp Ala Gly 325 Lys Thr Tyr Cys D Val 70 r Leu Ser Ala Thr Cys 150 Gly Asp Leu Ser Tyr 230 Ser Glu Leu I Phe Pro 310 Leu Lys I Asp Leu I Lys 1 390 Ser Asp Thr Ala Asn 135 Ala Arg Cys Ser Gly 215 Gln Cys Leu 31 y Arg 295 Val rrp ?ro rhr ,eu 375 la Gin Ile Val Gin 120 Thr Gin Pro Ile Tyr 200 Cys Phe Gin Ala Leu 280 Pro Ile Gln Leu His 360 Ala Phe C His Thr Met 105 Tyr Ser Pro Cys His 185 Glu Glu Asn Asn Tyr 265 Asn Leu ly Ser ksn 345 :ys sn ;ly Arc Lyf 9( Lei Arc Asp Tyr Glu 170 Asp Tyr Gly Asn Gin 250 Ile Gin Lys Gly Val 330 Asn His Glu Ala T Leu 75 Ala 1 Trp Leu Val His 155 Phe Glu Asp Asn Gln 235 Gly Thr Leu Phe Ser 315 Ser Thr Val Ser Asp 395 Phe Thr Trp Ala Trp 140 Glu Pro Asp Gin Trp 220 Glu Ala Gly Tyr Leu 300 Ser Cys Leu ly Ser 380 L;eu HiE Asy Lys Leu 125 Lys Ile Phe His Lys 205 Glu Ile Asp Lys Ser 285 Asn Cys Glu Glu Trp 365 Ser Ile Leu Asn Cys 110 Lys Lys Tyr Leu Ser 190 Trp Lys Leu Leu Glu 270 Ala Trp 2 Ala 2 Ser C Leu 1 350 Leu P Trp A Ser M Gli Le 9! Gli AsF G13 Thi Ile 175 Gly Gly Asn Ser Leu 255 bsp %rg ksp krg In 335 ~ro ~ro sp let u Ser i Arg I His Gly P Gly Arg 160 Gly Pro Ile Glu Trp 240 Ser Ile Gly Pro Met 320 Gin Asp Asn Ala His 400 Ser Leu Ala Asp Val Glu Val Val Val Thr Lys Leu His Asn 405 410 Gly Asp 415 WO 96/23882 WO 9623882PCT1UJS96/01383 Val Lys Lys Glu Ile Trp, Thr Gly 420 Leu Giu Tyr 465 Leu Ser Thr Asn Met 545 Arg Val Ser Trp, Lys 625 Asp Tyr Giu Ser Phe 705 Asp Val Phe Asn 450 Leu Arg Asp Cys Leu 530 Lys Asp Lys Pro Giu 610 Val Pro Lys Ala Arg 690 Ser Leu Met Gin 435 Giu Gly Tyr Lys Tyr Thr Asn Pro Gin Gly 595 Vai Ser Cys Vai Giu 675 Arg Gly Gin Met Trp, Pro

LYS

Val Leu 500 Lys Ile Tyr Asp Ala 580 Gly Lys Giu Pro Phe 660 Arg Giu Gin Gly Giu 740 Ser Ser Leu Cys 485 Cys Ile Thr Asp Ser 565 Val Cys Asn Pro Giu 645 His Phe Giu Arg Ser 725 Pro Asp Val Gly 470 Lys Pro Ser Lys 550 Arg Thr Val Cys Gin 630 Giy Ile Cys Ile Trp, 710 Trp Glu Giy Pro 455 Gin Lys Pro Giu Arg 535 Ser Gly Phe Al a Arg 615 Giu Trp Glu Gin Lys 695 Leu Gin Phe Thr 440 Phe Trp, Lys Asp Lys 520 Phe Leu Giu Ser Met 600 Ser Pro His Arg Ala 680 Asp Trp Trp, Gin Leu Lys 425 Giu Val Asn Lys Lys Val Gly Glu 490 Glu Gly 505 Giu Ala Glu Gin Arg Lys Tyr Ser 570 Asn Trp 585 Ser Thr Phe Arg Giu Giu Thr Phe 650 Ile Vai 665 Leu Gly Phe Val Ile Gly Ser Asp 730 Gin Asp 745 Asn Thr Thr Gin 475 Ile Trp Pro Glu Tyr 555 Trp Asn Gly Al a Ala 635 Pro Arg Ala His Leu 715 Arg Phe Thr Leu Pro 460 Ser Thr Lys Phe Phe 540 Phe Al a Phe Lys Leu 620 Ala Ser Lys His Leu 700 Asn Thr Asp Asn Thr 445 Asn Cys Lys Arg Gly 525 Leu Trp Val Leu Thr 605 Ser Pro Ser Arg Leu 685 Leu Lys Pro Ile Ser 430 Tyr Cys Giu Asp His 510 Thr Asn Thr Ala Glu 590 Leu Ile Lys Leu Asn 670 Pro Lys Arg Val Arg 750 Pro Trp Val Lys Al1a 495 Gly Asn Tyr Gly Gin 575 Pro Gly Cys Pro Ser 655 Trp Ser Asp Ser Ser 735 Asp Ala Asn Ser Lys 480 Glu Giu Cys Met Leu 560 Gly Ala Lys Lys Asp 640 Cys Giu Phe Gin Pro 720 Al a Cys Ala Ala Ile Lys Val Leu Asp Val Pro Trp Arg Arg Val Trp His Leu WO 96/23882 WO 9623882PCr[US96/01383 .96 Tyr Giu Asp Lys Asp Tyr Ala Tyr Trp Lys Pro Phe Ala Cys Asp Ala 770 775 780 Lys Leu Glu Trp Vai Cys Gin Ile Pro Lys Gly Ser Thr Pro Gin Met 785 790 795 800 Pro Asp Trp Tyr Asn Pro Giu Arg Thr Gly Ile His Gly Pro Pro Val 805 810 815 Ile Ile Giu Gly Ser Giu Tyr Trp Phe Vai Ala Asp Pro His Leu Asn 820 825 830 Tyr Giu Giu Ala Vai Leu Tyr Cys Ala Ser Asn His Ser Phe Leu Ala 835 840 845 Thr Ile Thr Ser Phe Thr Gly Leu Lys Ala Ile Lys Asn Lys Leu Ala 850 855 860 Asn Ile Ser Gly Giu Giu Gin Lys Trp Trp Vai Lys Thr Ser Giu Asn 865 .870 875 880 Pro Ile Asp Arg Tyr -Phe Leu Giy Ser Arg Arg Arg Leu Trp His His 885 890 895 Phe Pro Met Thr Phe Gly Asp Giu Cys Leu His Met Ser Ala Lys Thr 900 905 910 Trp Leu Val Asp Leu Ser Lys Arg Ala Asp Cys Asn Ala Lys Leu Pro 915 920 925 Phe Ile Cys Giu Arg Tyr Asn Vai Ser Ser Leu Giu Lys Tyr Ser Pro 930 935 940 Asp Pro Ala Ala Lys Val Gin Cys Thr Giu Lys Trp Ile Pro Phe Gin 945 950 955 960 Asn Lys Cys Phe Leu Lys Val Asn Ser Giy Pro Val Thr Phe Ser Gin 965 970 975 Ala Ser Gly Ile Cys His Ser Tyr Giy Gly Thr Leu Pro Ser Val Leu 980 985 990 Ser Arg Gly Giu Gin Asp Phe Ile Ile Ser Leu Leu Pro Giu Met Giu 995 1000 1005 Aia Ser Leu Trp Ile Gly Leu Arg Trp Thr Ala Tyr Giu Arg Ile Asn 1010 1015 1020 Arg Trp Thr Asp Asn Arg Giu Leu Thr Tyr Ser Asn Phe His Pro Leu 1025 1030 1035 1040 Leu Val Gly Arg Arg Leu Ser Ile Pro Thr Asn Phe Phe Asp Asp Giu 1045 1050 1055 Ser His Phe His Cys Ala Leu Ile Leu Asn Leu Lys Lys Ser Pro Leu 1060 1065 1070 Thr Gly Thr Trp Asn Phe Thr Ser Cys Ser Giu Arg His Ser Leu Ser 1075 1080 1085 Leu Cys Gin Lys Tyr Ser Glu Thr Giu Asp Gly Gin Pro Trp Giu Asn .1090 1095 1100 Thr Ser Lys Thr Val Lys Tyr Leu Asn Asn Leu Tyr Lys Ile Ile Ser 1105 1110 1115 1120 WO 96/23882 PCT/US96/01383 97 Lys Pro Leu Thr Trp His Gly Ala Leu Lys Glu Cys Met Lys Glu Lys 1125 1130 1135 Met Arg Leu Val Ser Ile Thr Asp Pro Tyr Gin Gin Ala Phe Leu Ala 1140 1145 1150 Val Gin Ala Thr Leu Arg Asn Ser Ser Phe Trp Ile Gly Leu Ser Ser 1155 1160 1165 Gin Asp Asp Glu Leu Asn Phe Gly Trp Ser Asp Gly Lys Arg Leu Gin 1170 1175 1180 Phe Ser Asn Trp Ala Gly Ser Asn Glu Gin Leu Asp Asp Cys Val Ile 1185 1190 1195 1200 Leu Asp Thr Asp Gly Phe Trp Lys Thr Ala Asp Cys Asp Asp Asn Gin 1205 1210 1215 Pro Gly Ala Ile Cys Tyr Tyr Pro Gly Asn Glu Thr Glu Glu Glu Val 1220 1225 1230 Arg Ala Leu Asp Thr Ala Lys Cys Pro Ser Pro Val Gin Ser Thr Pro 1235 1240 1245 Trp Ile Pro Phe Gin Asn Ser Cys Tyr Asn Phe Met Ile Thr Asn Asn 1250 1255 1260 Arg His Lys Thr Val Thr Pro Glu Glu Val Gin Ser Thr Cys Glu Lys 1265 1270 1275 1280 Leu His Pro Lys Ala His Ser Leu Ser Ile Arg Asn Glu Glu Glu Asn 1285 1290 1295 Thr Phe Val Val Glu Gin Leu Leu Tyr Phe Asn Tyr Ile Ala Ser Trp 1300 1305 1310 Val Met Leu Gly Ile Thr Tyr Glu Asn Asn Ser Leu Met Trp Phe Asp 1315 1320 1325 Lys Thr Ala Leu Ser Tyr Thr His Trp Arg Thr Gly Arg Pro Thr Val 1330 1335 1340 Lys Asn Gly Lys Phe Leu Ala Gly Leu Ser Thr Asp Gly Phe Trp Asp 1345 1350 1355 1360 Ile Gin Ser Phe Asn Val Ile Glu Glu Thr Leu His Phe Tyr Gin His 1365 1370 1375 Ser Ile Ser Ala Cys Lys Ile Glu Met Val Asp Tyr Glu Asp Lys His 1380 1385 1390 Asn Gly Thr Leu Pro Gin Phe Ile Pro Tyr Lys Asp Gly Val Tyr Ser 1395 1400 1405 Val Ile Gin Lys Lys Val Thr Trp Tyr Glu Ala Leu Asn Ala Cys Ser 1410 1415 1420 Gin Ser Gly Gly Glu Leu Ala Ser Val His Asn Pro Asn Gly Lys Leu 1425 1430 1435 1440 Phe Leu Glu Asp Ile Val Asn Arg Asp Gly Phe Pro Leu Trp Val Gly 1445 1450 1455 Leu Ser Ser His Asp Gly Ser Glu Ser Ser Phe Glu Trp Ser Asp Gly 146C 1465 1470 WO 96/23882 PCr[US96/01383 98 Arg Ala Phe Asp Tyr Val Pro Trp Gin Ser Leu Gin Ser Pro Gly Asp 1475 1480 1485 Cys Val Val Leu Tyr Pro Lys Gly Ile Trp Arg Arg Glu Lys Cys Leu 1490 1495 1500 Ser Val Lys Asp Gly Ala Ile Cys Tyr Lys Pro Thr Lys Asp Lys Lys 1505 1510 1515 1520 Leu Ile Phe His Val Lys Ser Ser Lys Cys Pro Val Ala Lys Arg Asp 1525 1530 1535 Gly Pro Gin Trp Val Gin Tyr Gly Gly His Cys Tyr Ala Ser Asp Gin 1540 1545 1550 Val Leu His Ser Phe Ser Glu Ala Lys Gin Val Cys Gin Glu Leu Asp 1555 1560 1565 His Ser Ala Thr Val Val Thr Ile Ala Asp Glu Asn Glu Asn Lys Phe 1570 1575 1580 Val Ser Arg Leu Met Arg Glu Asn Tyr Asn Ile Thr Met Arg Val Trp 1585 1590 1595 1600 Leu Gly Leu Ser Gin His Ser Leu Asp Gin Ser Trp Ser Trp Leu Asp 1605 1610 1615 Gly Leu Asp Val Thr Phe Val Lys Trp Glu Asn Lys Thr Lys Asp Gly 1620 1625 1630 Asp Gly Lys Cys Ser Ile Leu Ile Ala Ser Asn Glu Thr Trp Arg Lys 1635 1640 1645 Val His Cys Ser Arg Gly Tyr Ala Arg Ala Val Cys Lys Ile Pro Leu 1650 1655 1660 Ser Pro Asp Tyr Thr Gly Ile Ala Ile Leu Phe Ala Val Leu Cys Leu 1665 1670 1675 1680 Leu Gly Leu Ile Ser Leu Ala Ile Trp Phe Leu Leu Gin Arg Ser His 1685 1690 1695 Ile Arg Trp Thr Gly Phe Ser Ser Val Arg Tyr Glu His Gly Thr Asn 1700 1705 1710 Glu Asp Glu Val Met Leu Pro Ser Phe His Asp 1715 1720 INFORMATION FOR SEQ ID NO:4: SEQUENCE CHARACTERISTICS: LENGTH: 1462 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: protein DESCRIPTION: bovine PLA2 receptor (iii) HYPOTHETICAL: NO FRAGMENT TYPE: N-terminal (vi) CEIGI:AL SOURCE: (A ORGANISM: bovine WO 96/23882 WO 9623882PCT/US96O 1383 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: Met Pro Leu Leu Ser Leu Ser Leu Leu Leu Leu Leu Leu Gin Val Pro 1 5 10 1 Al a Arg Giu Lys Leu Pro Leu Leu Leu 145 Tyr Pro Thr Arg Thr 225 Ile His Giu Giu Trp 305 Giy Giu Lys Pro Phe Giu Lys Val 130 His Leu Cys Arg Tyr 210 Giu Cys Ser Thr Val1 290 Ser Ser Trp, Cys Pro Asn Gin Trp 115 Gin Lys His Met Giu 195 Giu Val Tyr Ser Giu 275 Trp Asp Ala Gin Ile Asn Ile Pro 100 His Val Trp Lys Phe 180 Gly Arg Gly Gin Cys 260 Giu Met Arg Glu Asp Gin Lys Gly Leu Cys Lys Val Asp 165 Pro Arg Asp Cys Phe 245 Gin Asn Gly Thr Thr Lys Ala Tyr 70 Gly Ser Asn Gin Ser 150 Leu Phe Glu Glu Asp 230 Asn Me t Phe Leu Pro 310 Ala Gly Ser 55 Met Ser Ile Lys Asp 135 Tyr Tyr Gin Asp Lys 215 Ala Leu Gin Val Asn 295 Leu Ala Ile 40 Lys Leu Gly Tyr Lys 120 Asn Met Thr Tyr Asn 200 Trp Val1 Leu Gly Arg 280 Gln Asn Trp 25 Phe Ser Trp Cys Giu 105 Thr Thr Ser Ile Asn 185 Leu Gly Trp Ser Ala.

265 Lys Leu Tyr Al a Ile Thr Lys Leu 90 Cys Ile Leu Gly Lys 170 Gin Leu Phe Giu Ser 250 Al a His5 Asp Leu Val Ile Leu Trp 75 Gly Asp Thr Vai Gly 155 Gly Gin Trp Cys Lys 235 Leu Leu Leu Glu Asn 315 Thr Gin Thr Val Leu Ser Gly Al a 140 Gly Asn Trp, Cys Pro 220 Asp Ser Leu Gly Asp 300 Trp Pro Ser Leu Ser Asn Thr Pro 125 Ser Gly Al a His Al a 205 Asp Leu Trp, Ser Ser 285 Ala Lys Glu Giu Giu Asn Val His 110 Leu Arg Ile His His 190 Thr Pro His Ser Ile 270 G1u

G

1 y Pro Arc Asr Asn His Ser Val Gin Lys Cys Gly 175 Giu Thr Thr Ser Giu 255 Ala Al a Trp Glu Leu Leu Cys Arg Ser Ser Tyr Tyr Asp 160 Thr Cys Ser Ser Arg 240 Al a Asp Val1 Gin Ile 320 Asn Phe Giu Pro Phe Val Giu Tyr His Cys Gly Thr Phe Asn Ala Phe 325 330 335 WO 96/23882 PCTIUS96/01j383 Met Val Asp His 385 Glu Thr Asn Ser Thr 465 Ala Leu Prc Cys Ala 370 Asrj Ala Ser Al a Phe 450 Leu G1u ?he Lys Lys 355 Trp, Arg Leu Leu Ser 435 Glu Glu Gin Tyr Al a 340 Lys Lys Asn Gin Ala 420 Glu Trp Pro Ser Zeu *Trp Tyr Tyr Cys Ser 405 Glu Thr Ser His Giu 485 Cys Lys Ser Leu Asn Tyr Ala 375 Tyr Lys 390 Cys Gln Val Giu Trp Ile Asn Gly 455 Ile Phe 470 Gly His Lys Lys 100 Arg Asp 345 Pro Thr 360 Thr His Leu Gin Ser Asn Phe Leu 425 Gly Leu 440 Ser Ser Pro Asn I'rp Lys rhr His I 505 Cy As! CyE Lys Asn 410 Val Ser Vai krg Jal ~90 ~eu sGli His Glu Glu 395 Ser Thr Ser Thr Ser 475 Lys Val I Ser Thr Gly Val 365 Pro Gly 380 Lys Lys Val Leu Leu Leu His Lys 445 Phe Thr 460 Gin Leu Asn Cys C Leu Ser ;z Let Val Tr~r Thr Gly 430 Ile ksn 7ys flu L5p .1 Pro -Glu Asn *Trp Asp 415 Asp Pro Trp Val Giu 495 ThrC Tyr Lys Pro Asn 400 Ile Giu Val His Ser 480 rhr flu 500 Ser Ile Cys 545 Ile Trp Thr Arg His 625 Ser Gly Asp 530 Pro Thr Ile Al a Gin 610 Pro Leu Cys Gin Lys Giy Trp Giu 515 Thr Pro Ser Aila Giy 595 Pro Giy Cys Val Al a Leu Leu 580 Gin Arg Arg Lys Leu Leu Ile 565 Gin Gin Tyr Trp Gin 645 Arg Ile 550 Ser Asp Leu Ser Giu 630 Pro Ser 535 Thr Ser Gin Giu Gly 615 Val Val1 520 Phe Ile Val Asn Pro 600 Gly Arg Glu Arg Asp Thr Vai Asn 585 Vai Cys Asp Asn His His Ser Lys 570 T hr Lys Val Cys Arg 650 Gly.

Ala Arg 555 Thr Gly Tyr Val Arg 635 Glu Lys Ser 540 Phe Lys Giu Thr Met 620 His Lys Phe 525 Ser Glu Asp Tyr His 605 Arg Phe rhr Cys Giy Gin Thr Thr 590 Trp Glv Lvs Lvs Tyr Tyr Al a Tyr 575 Trp Asn Arg Ala Gin 655 Lys Tyr Phe 560 Phe Lys Thr Ser Met 640 Glu Giu Gly Trp Pro Phe His Pro Cys 660 Tyr Leu Asp Trp Glu Ser Giu Pro 665 670 Gly Leu Ala 675 Ser Cys Phe Lys Val1 680 Phe His Ser Glu Lys 685 Val. Leu Met WO 96/23882PCUS6O38 PCTIUS96/01383 Lys Arg 690 Thr Trp Arg Gin Ala Giu GlU 695 His Leu Ala 705 Leu Leu His Gly Phe Asn Asp Gly Thr 755 Giu Asp Ala 770 Pro Ser Tyr 785 Asp Val Arg Leu Phe Tyr Trp Ser Ser 835 Thr Ile His 850 Ala Leu Ser 865 Arg Ala Ser Gin Asn Trp Gin Arg Cys 915 Giu Cys Ser 930 Val Ile Giu 945 Lys Gly Trp Giu Gly Pro Val Giu Giu 995 Ala Phe Ile 1010 Ser Phe Ser Lys 725 Lys Arg 740 Pro Val Arg Asn Cys Giy Pro Lys 805 Gin Asp 820 Phe Giu Ser Ala Lys Tyr Asp Giu 885 Asp Lys 900 Gly Phe Ile Ser Lys Lys Leu Tyr 965 Ser Asp 980 Gly Gly Thr Met Ala 710 Phe Asn Val Cys Ser 790 Val Ala Phe His Gly 870 Phe Gly Ile Met Lys 950 Phe Trp Thr Asn His Asn Pro Ser Ala 775 Lys Pro Giu Vai Glu 855 Vai Arg Lys Ser Pro 935 Asp Asp Lys Leu Leu Ile Giu Arg Thr Leu Asn 745 Ser Phe 760 Val Tyr Arg Giu Pro Trp Tyr Leu 825 Cys Gly 840 Gin Giu Asn Trp Trp Arg Giu Arg 905 Ser Ile 920 Ser Ile Ile Pro Tyr Lys Asn Trp 985 Val Ala 1000 Phe Gly Phe Giu Giu 730 Ala Leu Lys Trp Tyr 810 Phe Trp Phe Trp Asp 890 Ser Thr Cys Lys Cys 970 Thr Ile His Cys Giu 715 Giu Gly Asp Ala Ile 795 Gin His Leu Ile Ile 875 Gly Met Gly Lys Gin 955 Leu Ser Glu Thr Giu 700 Asn Arg Ser Asn Asn 780 Cys Tyr Ile Arg His 860 Gly Ser Gly Leu Arg 940 His Leu Ala Asn Thr Giu Phe Phe Val Gin Phe Trp Giu 750 Ser Tyr 765 Lys Thr Lys Ile Asp Ala Ser Ala 830 Ser Asp 845 Ser Lys Leu Arg Pro Vai Leu Asn 910 Trp Ala 925 Lys Lys Gly Thr Leu Lys Gin Asp 990 Giu Val 1005 Asn Val Giy Asn Trp 735 Trp Phe Leu Pro Pro 815 Ser Ile Ile Glu Ile 895 Giu Ser Vai Cys Ile 975 Phe Giu Trp Ala *Giu 720 Ile Ser Giy Leu Arg 800 Trp Giu Leu Arg Glu 880 Tyr Ser Giu Trp Pro 960 Pro Cys Gin Ile Val 1040 1015 1020 Gly Leu Gin Asp Asp 1025 Asp 1030 Tyr Giu Lys Trp Leu Asn Gly Arg Pro 1035 WO 96/23882 WO 9623882PCTIUS96/0 1383 102 Ser Tyr Ser Asn Trp Ser Pro Phe Asp Thr Lys Asn Ile Pro Asn His 1045 1050 1055 Asn Thr Thr Giu Val Gin Lys Arg Ile Pro Leu Cys Gly Leu Leu Ser 1060 1065 1070 Asn Asn Pro Asn Phe His Phe Thr Gly Lys Trp Tyr Phe Asp Cys Arg 1075 1080 1085 Glu Gly Tyr Gly Phe Val Cys Glu Lys Met Gin Asp Ala Ser Gly His 1090 1095 1100 Ser Ile Asn Thr Ser Asp Met Tyr Pro Ile Pro Asn Thr Leu Glu Tyr 1105 1110 illS 1120 Gly Asn Arg Thr Tyr Lys Ile Ile Asn Ala Asn Met Thr Trp Tyr Thr 1125 1130 1135 Ala Leu Lys Thr Cys Leu Met His Gly Ala Glu Leu Ala Ser Ile Thr 1140 1145 1150 Asp Gin Tyr His Gin Ser Phe Leu Thr Val Ile Leu Asn Arg Val Gly 1155 1160 1165 Tyr Ala His Trp Ile Gly Leu Phe Thr Glu Asp Asn Gly Leu Ser Phe 1170 1175 1180 Asp Trp Ser Asp Gly Thr Lys Ser Ser Phe Thr Phe Trp, Lys Asp Asp 1185 1190 1195 1200 Giu Ser Ser Phe Leu Gly Asp Cys Val Phe Ala Asp Thr Ser Gly Arg 1205 1210 1215 Trp Ser Ser Thr Ala Cys Giu Ser Tyr Leu Gin Gly Ala Ile Cys Gin 1220 1225 1230 Vai Pro Thr Glu Thr Arg Leu Ser Gly Arg Leu Glu Leu Cys Ser Giu 1235 1240 1245 Thr Ser Ile Pro Trp Ile Lys Phe Lys Ser Asn Cys Tyr Ser Phe Ser 1250 1255 1260 Thr Val Leu Glu Ser Thr Ser Phe Giu Ala Ala His Giu Phe Cys Lys 1265 1270 1275 1280 Lys Lys Gly Ser Asn Leu Leu Thr Ile Lys Asp Glu Ala Glu Asn Ser 1285 1290 1295 Phe Leu Leu Giu Glu Leu Leu Ala Phe Arg Ser Ser Val Gin Met Ile 1300 1305 1310 Trp Leu Asn Ala Gin Phe Asp Gly Asp Asn Giu Thr Ile Lys Trp Phe 1315 1320 1325 Asp Gly Thr Pro Thr Asp Gin Ser Asn Trp Gly Ile Arg Lys Pro Giu 1330 1335 1340 Val Tyr His Phe Lys Pro His Leu Cys Val Ala Leu Arg Ile Pro Giu 1345 1350 1355 1360 Gly Val Trp Gin Leu Ser Ser Cys Gin Asp Lys Lys Gly Phe Ile Cys 1365 1370 1375 Lys Met Glu Ala Asp Ile His Thr Val Lys Lys His Pro Gly Lys Gly 1380 1385 1390 WO 96/23882 PCT/US96/01383 103 Pro Ser His Ser Val Ile Pro Leu Thr Val Ala Leu Thr Leu Leu Val 1395 1400 1405 Ile Leu Ala Ile Ser Thr Leu Ser Phe Cys Met Tyr Lys His Ser His 1410 1415 1420 Ile Ile Phe Gly Arg Leu Ala Gin Phe Arg Asn Pro Tyr Tyr Pro Ser 1425 1430 1435 1440 Ala Asn Phe Ser Thr Val His Leu Glu Glu Asn Ile Leu Ile Ser Asp 1445 1450 1455 Leu Glu Lys Asn Asp Gin 1460 INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 1457 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: peptide DESCRIPTION: human macrophage mannose receptor (iii) HYPOTHETICAL: NO FRAGMENT TYPE: N-terminal (vi) ORIGINAL SOURCE: ORGANISM: human (xi) SEQUENCE DESCRIPTION: SEQ ID Met Arg Leu Pro Leu Leu Leu Val Phe Ala Ser Val Ile Pro Gly Ala 1 5 10 Val Leu Leu Leu Asp Thr Arg Gin Phe Leu Ile Tyr Asn Glu Asp His 25 Lys Arg Cys Val Asp Ala Val Ser Pro Ser Ala Val Gin Thr Ala Ala 40 Cys Asn Gin Asp Ala Glu Ser Gin Lys Phe Arg Trp Val Ser Glu Ser 55 Gin Ile Met Ser Val Ala Phe Lys Leu Cys Leu Gly Val Pro Ser Lys 70 75 Thr Asp Trp Val Ala Ile Thr Leu Tyr Ala Cys Asp Ser Lys Ser Glu 90 Phe Gin Lys Trp Glu Cys Lys Asn Asp Thr Leu Leu Gly Ile Lys Gly 100 105 110 Glu Asp Leu Phe Phe Asn Tyr Gly Asn Arg Gin Glu Lys Asn Ile Met 115 120 125 Leu Tyr Lys Gly Ser Gly Leu Trp Ser Arg Trp Lys Ile Tyr Gly Thr 130 135 140 Thr Asp Asn Leu Cys Ser Arg Gly Tyr Glu Ala Met Tyr Thr Leu Leu 145 150 155 160 WO 96123882 WO 9623882PCTIUS96/0 1383 104 Gly Asn Ala Asn Gly Ala Thr Cys Ala Phe Pro Phe Lys Phe Giu Asn 165 170 175 Lys Trp Cys Leu 225 His Ile Leu Gly Pro 305 Pro Gly Pro Tyr Arg 385 Ile Giu Met Leu Val 465 Pro Trp Cys Pro 210 Thr Gin Thr Thr Trp 290 Gly Gly Tyr Ser Ala 370 Asp His Pro Tyr Arg 450 Met Leu Tyr Giy 195 Leu Ser Ala Glu Ser 275 Gin Ser Lys Ile Giu 355 Gly Al a Thr Asn Phe 435 Gly Lys Gly Al a 180 Thr Lys Val Arg Ile 2,60 Gly Trp Pro Asn Cys 340 Ser His Leu Ile Asp 420 Giu Giu Gly Tyr Asp Thr Phe Ser Lys 245 His Leu Ser Ser Ala 325 Lys Asp Cys Thr Giu 405 Giu Trp Pro Lys Ile 485 cys Thr Glu Tyr 230 Ser Giu Trp Asp Ala 310 Lys Lys Val Tyr Thr 390 Glu Leu Ser Ser Asp 470 Cys Thr Asp Gly 215 Gin Cys Gin Ile Arg 295 Giu Trp Gly Pro Lys 375 Cys Leu Trp Asp His 455 Gly Lys Ser Tyr 200 Ser Ile Gin Thr Gly 280 Ser Pro Glu Asn Thr 360 Ile Arg Asp Ile Gly 440 Glu Tyr Met Ala 185 Asp Giu Asn Gin Tyr 265 Leu Pro Gly Asn Thr 345 His His Lys Phe Gly 425 Thr As n Trp Lys Gly Thr Ser Ser Gin 250 Leu Asn Phe Lys Leu 330 Thr Cys Arg.

Giu Ile 410 Leu Pro Asn Ala Ser 490 Arg Asp Leu Lys 235 Asn Thr Ser Arg Ser 315 Giu Leu Pro Asp Gly 395 Ile Asn Val krg ksp 475 %rg Ser Lys Trp 220 Ser Ala Giy Leu Tyr 300 Cys Cys Asn Ser Giu 380 Gly Ser Asp Thr Gin 460 Arg Ser Asp Leu 205 Asn Ala Giu Leu Ser 285 Leu Val Val1 Ser Gin 365 Lys Asp Gin Ile Phe 445 Giu Gly Gin Gil, 190 Phe Lys Leu Leu Thr 270 Phe Asn Ser Gin Phe 350 Trp Lys Leu Leu Lys 430 rhr ksp :ys 31Y Trp, *Gly Asp *Thr *Leu 255 Ser Asn Trp Leu Lys 335 Val Trp Ile Thr Gly 415 Ile Lys Cys Glu Pro 495 Leu Tyr Pro Trp 240 Ser Ser Ser Leu Asn 320 Leu Ile Pro Gin Ser 400 Tyr Gin Trp Val1 rrp 480 G1u Ile Val Giu Val Giu Ly's Gly Cys Arg 505 Lys Gly Trp Lys Lys His His 510 WO 96/23882 PCT1US9601383 Phe Tyr Cys Tyr 515 Met Ile Gly His Thr Leu Ser Thr Phe Ala Giu Ala 520 525 Asn Arg 545 Lys Gin Met Gly Cys 625 Thr Ser Trp Ser Ala 705 Ser Glu Cys Cys Pro 785 Glu Glu Gly Lys Gin 530 Tyr Tyr Trp Pro Gly 610 Lys Pro Leu Phe Ile 690 Ser Pro Asn Gly Glu 770 Lys Asp Lys Asp Tyr 850 Thr Glu Phe Thr Gly 595 Leu His Glu Cys Glu 675 Asn Gly Ser Trp Glu 755 His Pro ly Glu Leu 835 Jal Cys Gin Trp Ile 580 Arg Trp Trp Pro Phe 660 Ser Asn Ser Glu Ala 740 Leu Leu Glu Trp Thr 820 Val Asn Asn Ala Thr 565 Glu Lys Asp Ala Lys 645 Lys Arg Ls Tyr Gly 725 Tyr Lys Asn Pro Val 805 Met Ser Arg Asn Phe 550 Gly Glu Pro Val Glu 630 Cys Leu Asp Glu His 710 Phe Gly Gly Asn Thr 790 Ile Asp Ile Asn Glu 535 Leu Leu Glu Gly Leu 615 Gly Pro Tyr Phe Glu 695 Lys Thr Glu Asp Trp 775 Pro Tyr Asn Gin Asp 855 Asn Thr Ser Val Cys 600 Lys Val Glu Ala Cys 680 Gin Leu Trp Pro Pro 760 Ile Ala Lys Ala Ser 840 Ala Ala Ser Asp Arg 585 Val Cys Thr Asp Lys 665 Arg Gin Phe Ser Asn 745 Thr Cys Pro Asp Arg 825 Glu Gin Tyr Phe Ile 570 Phe Ala Asp His Trp 650 Gly Ala Thr Trp Asp 730 Asn Met Gin Gin Tyr 810 Ala Ser Ser Let Val 555 Gin Thr Met Glu Pro 635 Gly Lys Leu Ile Leu 715 Gly Tyr Ser Ile Asp 795 3Gl Phe 3lu la Thr 540 Gly Thr His Arg Lys 620 Pro Ala His Gly Trp 700 Gly Ser Gin Trp Gin 780 Asn Tyr Cys Lys I Tyr I 860 Thr Leu Lys Trp Thr 605 Ala Lys Ser Glu Gly 685 Arg Leu Pro Asn Asn 765 Lys Pro ryr Lys Zys 345 ?he Ile Arg Gly Asn 590 Gly Lys Pro Ser Lys 670 Asp Leu Thr Va1 Val 750 Asp Gly Pro Phe Arg 830 Phe Ile Glu Pro Thr 575 Ser Ile Phe Thr Arg 655 Lys Leu Ile Tyr Ser 735 Glu Ile Gin Val Ser 815 Asn Leu Gly Asp Glu 560 Phe Asp Ala Val Thr 640 Thr Thr Ala Thr Gly 720 Tyr Tyr Asn Thr Ihr 800 Lys Phe rrp Leu WO 96/23882 PCT/US96/01383 106 Leu Ile Ser Leu Asp Lys Lys Phe Ala Trp Met Asp Gly Ser Lys Val 865 870 875 880 Asp Tyr Val Ser Trp Ala Thr Gly Glu Pro Asn Phe Ala Asn Glu Asp 885 890 895 Glu Asn Cys Val Thr Met Tyr Ser Asn Ser Gly Phe Trp Asn Asp Ile 900 905 910 Asn Cys Gly Tyr Pro Asn Ala Phe Ile Cys Gin Arg His Asn Ser Ser 915 920 925 Ile Asn Ala Thr Thr Val Met Pro Thr Met Pro Ser Val Pro Ser Gly 930 935 940 Cys Lys Glu Gly Trp Asn Phe Tyr Ser Asn Lys Cys Phe Lys Ile Phe 945 950 955 960 Gly Phe Met Glu Glu Glu Arg Lys Asn Trp Gin Glu Ala Arg Lys Ala 965 970 975 Cys Ile Gly Phe Gly Gly Asn Leu Val.Ser Ile Gin Asn Glu Lys Glu 980 985 990 Gin Ala Phe Leu Thr Tyr His Met Lys Asp Ser Thr Phe Ser Ala Trp 995 1000 1005 Thr Gly Leu Asn Asp Val Asn Ser Glu His Thr Phe Leu Trp Thr Asp 1010 1015 1020 Gly Arg Gly Val His Tyr Thr Asn Trp Gly Lys Gly Tyr Pro Gly Gly 1025 1030 1035 1040 Arg Arg Ser Ser Leu Ser Tyr Glu Asp Ala Asp Cys Val Val Ile Ile 1045 1050 1055 Gly Gly Ala Ser Asn Glu Ala Gly Lys Trp Met Asp Asp Thr Cys Asp 1060 1065 1070 Ser Lys Arg Gly Tyr Ile Cys Gin Thr Arg Ser Asp Pro Ser Leu Thr 1075 1080 1085 Asn Pro Pro Ala Thr Ile Gin Thr Asp Gly Phe Val Lys Tyr Gly Lys 1090 1095 1100 Ser Ser Tyr Ser Leu Met Arg Gin Lys Phe Gin Trp His Glu Ala Glu 1105 1110 1115 1120 Thr Tyr Cys Lys Leu His Asn Ser Leu Ile Ala Ser Ile Leu Asp Pro 1125 1130 1135 Tyr Ser Asn Ala Phe Ala Trp Leu Gin Met Glu Thr Ser Asn Glu Arg 1140 1145 1150 Val Trp Ile Ala Leu Asn Ser Asn Leu Thr Asp Asn Gin Tyr Thr Trp 1155 1160 1165 Thr Asp Lys Trp Arg Val Arg Tyr Thr Asn Trp Ala Ala Asp Glu Pro 1170 1175 1180 Lys Leu Lys Ser Ala Cys Val Tyr Leu Asp Leu Asp Gly Tyr Trp Lys 1185 1190 1195 1200 Thr Ala His Cys Asn Glu Ser Phe Tyr Phe Leu Cys Lys Arg Ser Asp 1205 1210 1215 WO 96/23882 PCT/US96/01383 107 Glu Ile Pro Ala Thr Glu Pro Pro Gin Leu Pro Gly Arg Cys Pro Glu 1220 1225 1230 Ser Asp His Thr Ala Trp Glu Ile Pro Phe His Gly His Cys Tyr Tyr 1235 1240 1245 Ile Glu Ser Ser Tyr Thr Arg Asn Trp Gly Gin Ala Ser Leu Glu Cys 1250 1255 1260 Leu Arg Met Gly Ser Ser Leu Val Ser Ile Glu Ser Ala Ala Glu Ser 1265 1270 1275 1280 Ser Phe Leu Ser Tyr Arg Val Glu Pro Leu Lys Ser Lys Thr Asn Phe 1285 1290 1295 Trp Ile Gly Leu Phe Arg Asn Val Glu Gly Thr Trp Leu Trp Ile Asn 1300 1305 1310 Asn Ser Pro Val Ser Phe Val Asn Trp Asn Thr Gly Asp Pro Ser Gly 1315 1320 1325 Glu Arg Asn Asp Cys Val Ala Leu His Ala Ser Ser Gly Phe Trp Ser 1330 1335 1340 Asn Ile His Cys Ser Ser Tyr Lys Gly Tyr Ile Cys Lys Arg Pro Lys 1345 1350 1355 1360 Ile Ile Asp Ala Lys Pro Thr His Glu Leu Leu Thr Thr Lys Ala Asp 1365 1370 1375 Thr Arg Lys Met Asp Pro Ser Lys Pro Ser Ser Asn Val Ala Gly Val 1380 1385 1390 Val Ile Ile Val Ile Leu Leu Ile Leu Thr Gly Ala Gly Leu Ala Ala 1395 1400 1405 Tyr Phe Phe Tyr Lys Lys Arg Arg Val His Leu Pro Gin Glu Gly Ala 1410 1415 1420 Phe Glu Asn Thr Leu Tyr Phe Asn Ser Gin Ser Ser Pro Gly Thr Ser 1425 1430 1435 1440 Asp Met Lys Asp Leu Val Gly Asn Ile Glu Gin Asn Glu His Ser Val 1445 1450 1455 Ile 1457 INFORMATION FOR SEQ ID NO:6: SEQUENCE CHARACTERISTICS: LENGTH: 30 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: peptide DESCRIPTION: murine DEC-205 (iii) HYPOTHETICAL: NO FRAGMENT TYPE: C-terminal (vi) ORIGINAL SOURCE: ORGANISM: murine 108 SEQUENCE DESCRIPTION: SEQ 1D No.-6: Arg Ser H.s .71c Arg Trp Thr GIly Phe Ser Ser Val Arg Tyr Glu gis 1 5 10 1 GI17 Thr As-n Gilu Asp Glu Val Mec Leu Pro Ser Phxe His Asp 25 OR SEQ 410:7: Ci)sE~JE~=4 APACTE~tS 2G7H: 4777 base pairs '7Y?7: nucl.eic acid 571kMEDKN-SS: double TOPOLOGY: linear (ii) MOLEZW.E TYPE: CONA (iii) -r!0T.ZTCAL

NO

(iv) xNt-SZNSE: NO (Vii) IiQE:A7E SOURCE: CLONE: DEC-205 (xi) SEQUExCZ CESCRIPT:ON: SEQ 1D NO: 8 GAT-TCCGGG GGCGGGAGCC GCGTGCGCCC GAGGACCCCG 0s t..

0*a* 0* *9 9S*e..

CAGGATA

CTGGTTC.Z-

CCATGGAAAT

TGO'TGAAAZ'!

CAGAGAT GG GCAT CATGAT

TTATGAAA-

.TGGAAAGA

TGCTGCTGAA

TTTAAATCAG

TCTCAACTG

AATCGGATGZT

CTOCAGGAAA

ACAGGCT-GG

GAGGAZAAG7 GA. 6 TOCA7-CT7G GACC3AAAGT 7-1 AAA'cc

CGACCC-CTCG

AGCCCTZ-TGG

GCA'CA6AGCC .3GGA7GGA!"A1 GGAGAC:.7 G

ATGAAGATCA

GGGGCATCTG

T.6GGAAGTTG CAL7GT CAGAA

CTAGAGGCTG

GGCCCAGTGC

TGTGGCAGAG

ATACAGTGGA

CCGCCCGGCCO

CC~GC3AGCT AGTGTAkTGGC

GGTGTCCC-AG-

CATCGOAGA:

TGACACA

-TGAA=T. CCA

TAGTGGJGCCA

CTTA.:AGCCZ

CTACCAA7-

TCAAGGAGCT

AO-AAGGCA77;

GGAATGGTCA

ACCTACTATA

CiTTCCTG7,

GTTAACAGAT

CCGGAAGGCT

GGGCTCCTCA

AATGACCCCTj CA7. GGrCT-C7

A:AA:G-"

GCCATCATG

GGTGTCCA

GAAAACGTAA

G-.CTGCAT-

TGCGCCAGCT

TGCTGCTTT

TCACCATCGT.

CAGACIGACTG7

GTGACTATAC

ATGGTCTGC

TCGGAC7TGG CAT TAAA =11

ACTGCAGC

so 120

ISO

2 43: 660 900 960 1020 1380 11.40 WO 96/23882 WO 9623882PCT1US96101383 109

CCGCTGTGAT

TAATTCCTGG

TCATTCTCTA

AGAAGTGTGG

TACTGAAGTT

GCCCAACTGT

GAAACTAAAA

GATGTGTCCT

GGATGAGGTC

ATACCTAAAT

CCTGAGAGAT

GGCTGTAACC

TATGTCTACT

ACTTTCAATT

TGATGACCCC

ATTCCATGCA

AGCCCTTGGA

CTTTTTAACG

CCCAGATTTA

GCCAAATGAG

TAGGCCATGG

TTTTGCTTGT

AACACCAGAC

AGGAAGTGAA

CTGTGCCAGC

CAAAAACAAA

GTGGCCAATA

ATTTGGAGAG

AACAGACTGT

GAAATACAGC

GAATAAGTGT

CTGTCACTCC

GCAGGCTGGC

GATAAGGCAC

GCAGATGTGG

ATAGGCCTTA

ACTCTAACAT

GTTTCCTACT

TATGTATGCA

CCAGATGAGG

CCTTTTGGAA

GATTTGATGA

GTAGATTCTT

TTTTCCAACT

GGAAAGTCTG

TGCAA GAAAA

TGTCCTGAAG

GAAAGAATTG

GCACACCTTT

GACCAGTTCA

CAAGGATCCT

TTTCAGCAGG

CGAAGAGGCT

GATACAAAAC

TGGTACAATC

TATTGGTTTG

AATCACAGCT

ATAGCAAATA

GATGATCATT

GAATGCTTGT

AGTACCAAGT

CCAGATTCTG

TTTCTAAAGA

TATGGTGGCA

TGCCAAATAA

ATGCGAAATG

AGGTGGTTGT

AGAACATAAA

ATTGGGATGA

TAGGAGAGCT

AGAGAAAGGG

GCTGGAAGAG

CAAACTGCAA

AAAAGTATGA

GTGGAGAGTA

GGAA~TTTTCT

TTGGAAAGTG

TGAGTGGACC

GCTGGCAGAG

TAAGAAAGAG

CTAGCTTCAG

GTGGCCAGCA

GGCAATGGAG

ATTATGACAT

GGCATTTCTA

TTGAATGGGT

CAGAGCGTGC

TTGCTGATCT

TTCTTGCAAC

TATCTGGTGA

TTACATACTC

ACATGTCTGC

TGCCCTTCAT

CAGCTAAAGT

TCAAACCCGT

CCCTTCCTTC

TGGATTTTGC

CAAAGCCTTC

CACAAAACTC

CATACCAACT

GAATGAGCCA

AGGTCAGTGG

AGAAAAACTG

ACATGGAGAA

TCTGACTATC

TAAATCTCTA

TAACTGGGCA

TGAGCCAGCT

GGAGGTGAAG

CCTTGGGCCT

TTTCCCCGCA

GAACTGGGAA

CCATGTGGAT

TTGGCTGTGG

TGATCGTACA

CAGAGACTGT

TGATGATAGA

GTGCCAAATT

TGGAATTCAT

TCACCTAAAC

TATAACATCT

TGGACAGAAG

ACGATATCCA

CAAGACTTGG

CTGTGAAAA

GCAATGTTCT

GTCTCTCACA

AGTGTTGAGC

TATCTGCTGG

AGTAGTGACC

CATAATGAGG

TTATTTCAGT

AATGTTCCCT

AAAGTCCAAT

AATGACGCAA

ACCTGTTACA

ACTAGCAGAT

AGAAAATACT

ACTGTTGGTG

TCCCCGGGCG

GACTGCAGAA

GAAGAAGCAT

AGTCTTTCTT

GAAGCTGAAC

GAAATAAAGG

ATTGGTTTGA

CCAGTGTCTA

GCTGCTGTCA

GAATTTATTT

C CAAAAGGC C

GGACCTCCAC

TATGAAGAAG

TTTGTGGGAC

TGGTGGATAA

TGGCACCGCT

CTTATCGACT

TATAATGTTT

GAGCAATGGA

TTTTCTCAAG

CAGATTGAAC

TAAATGAAAG

TAATCAGCAT

ATATCAAAGA

GGTCAGATGG

ACAATAAGAC

CATGTGAGGA

GTTCTGATAA

AGATTTATGA

TTGAGCAAGA

TCTGGACTGG

GAAGAAGGCG

GCTGCGTGGC

GCTTCAAAGC

CC CCTAAG CC

GTTATAAGGT

GATTCTGCCA

AATTTCTTCA

ATAAA-AGGAG

CTATTATCAT

AGGTATTTCA

ATTTGAGGCC

GTACTCCAAA

TTATAATTGA

CCGTCCTGTA

TAAAAGCCAT

GAATTAGCGA

TTCCTGTGAC

TAGGTAAACC

CTTCGTTAGA

TTCCTTTTCA

CAAGCGATAC

AAGACTTTAT

1200 1260 1320 1380 1440 1500 1560 1620 1680 1740 1800 1860 1920 1980 2040 2100 2160 2220 2280 2340 2400 2460 2520 2580 2640 2700 2760 2820 2880 2940 3000 3060 3120 TACATCCTTG CTTCCGGATA TGGAAGCTAC T-TTATGGATT GGTTTGCGCT GGACTGCCTA WO 96/23882 WO 9623882PCTIUS96/0 1383

TGAAAAGATA

ATTGGTTAGT

CTGTGCCCTA

CTGCAGTGAA

GACGTTGCAG

AAAGACTCTG

GAGCATCACG

TTCCTTATGG

GAAACGTCTT

ATTAGACACT

TTGCTACTAT

TCCATCTCCT

AATAACAAAG

ACTGAATCCA

TGAGCAACTG

AAATAATTCT

AAGACCAACT

TATTCAAACC

TTGTAAAATT

GCCATATGAA

AAACATGTGT

CTTTCTGGAA

TGATGGAAGT

GAAAGGCCAA

TGAAAAATGC

GCTGTCCCGT

GATCCAGTAC

CAAAAAATTG

TGAGAATAAA

GCTTGGATTA

GACATTTGTC

AGCTTCAAAT

CAAAGTGCCT

AACAAATGGA

GGGAGGCTGA

ATACTCAACC

CGCCACTTTG

AATGCTTCAG

ACTTGGCACA

GACCCTTACC

ATCGGACTCT

CATTTTAGTC

GATGGATTCT

CCAGGAAATG

GTTCTAAATA

AATAGGCATA

AAATCACATA

CTGTACTTCA

CTTATGTGGT

ATAAAAA.ATG

TTTAAAGTTA

GAAATGGTTG

GATGGTATTT

TCTCAAAGTG

GATATTGTAA

GAATCAAGTT

ACATCTCCTG

AACTCTGTTA

CTTACATATT

AAGGGTCACT

TGTTCAAAAC

TTTGTGAGCA

TCTCAACATT

AAATGGGAAA

GAAACTTGGA

CTGGGCCCTG

CAGATAACAG

GAATACCAGA

TCCAAAAATC

TGTCTCTCTG

AAACTGTAAA

GTGCTAAAAG

AGCAGGCATT

TCAGTCAAGA

GCTGGGCTGA

GGAAAACAGT

AGACTGAAAA

CTCCGTGGAT

TGGCAACAAC.

TTCTGAGTAT

ATTATATGGC

TTGATAAGAC

AGAGGTTTTT

TTGAAGAAGC

ACTACAAAGA

ACAGTGTTAT

GAGGTCACTT

AACGTGATGG

TTGAATGGTC

GAAATTGTGT

AGGATGGTGC

CATCAAGATG

GTTACAAGTC

ATGATCACTC

GACTGATGAG

CTGTTGACCA

ATAAAAGTAA

AAAAAGTTGA

ATTACACAGC

AGAGCTGACG

AAATTTTTTT

ACCGTTTACT

TCAGAAATAT

GTATCTAAAT

GGAGTGTCTG

CCTCAGTGTG

TGATGAACTC

AACTAATGGG

TGATTGCAAT

AGAGGTCAAA

ACCATTTCAG

ACAGGATGAA

TCGAGATGAA

TTCATGGGTC

CCCACTGTCA

GGCTGGTTTA

AGTTTATTTT

AGAATATAAT

TCAAAAAALAG

GGCAAGCGTT

ATTTCCACTA

TGATGGTAGT

TCTCTTGGAT

TATTTGTTAT

TCCAGCAGCA

TGATCAGGCA

TGCAACTATC

GGAAAATAAT

GTCTTGGAGT

GAGTGGTGTT

ATGTGAACAT

AATAGCTATC

TACAGTAACT

GAGGAAGAGT

GGGACGTGGA

TCAGAAGTTA

AATCTGTACA

AAAAGTAACA

CAGGCGCTCC

AACTTTGGTT

CAACTCGAAG

GACAATCAAC

CCAGTTGACA

AACTGTTGCT

GTTCATACTA

AAGGAGAATA

ATGTTAGGAA

TATACACATT

AGTACTGACG

CACCAGCACA

ACTACACTGC

GTAACATGGT

CACAACCAAA

TGGGTTGGGC

ACATTTGACT

CCAAAAGGAA

AALACCTACAA

AAAGAGAATG

TTGCACAGTT

GTTTCCATAA

AACATTACCA

TGGTTAGATG

GGAAGATGTA

GGTTTTGGAA

ATAGTTGCCA

TTCACCCATT

CTCGCTACCA

ATTTTACATC

AAAGCAGACA

AAATAATCCC

TGCAGCTGGT

TTCACAACTC

GGTCAGATGG

ACTGTGTAGT

CAGGTGCTAT

GTGTTAAATG

ACAATTTCAT

AATGCCAGAA

ACTTTGTTCT

TAACTTATAG

GGAGAGCAGG

GCTTCTGGGA

GCATTCTTGC

CACAGTTTAT

ATGAAGCATT

ATGGCCAGCT

TCTCAAGTCA

ATATCCCATG

CTTGGAAACA

AAGCTAAAAA

GGTCACGGTG

TTTCAGAGGC

AAGATGAAGA

TGAGAGTTTG

GATCAGAAGT

GCATGTTGAT

GAGTTGTCTG

CACTAAGTAT

3180 3240 3300 3360 3420 3480 3540 3600 3660 3720 3780 3840 3900 3960 4020 4080 4140 4200 4260 4320 4380 4440 4500 4560 4620 4680 4740 4800 4860 4920 4980 5040 5100 WO 96/23882 WO 9623882PCr[US96O 1383 CTTAGTTCTC ATGGGCGGAC TGATTTGGTT CCTCTTCCAA GGGTTTCTCA TCAGTTCGAT ATGCACAAGG AGTGAATGAA TTTCCATGAC TAAATTCTTC TAAAAGTTTT CTAATTTGCA AGTCACTTAA AATGTCCAGT GTCAGTATTT ACTCTGCTCC TTTTTCAGTT GTTTAGATCT AGGCATGTGC TGGTATCCAC CCATGTTTAT CACCCTAATT AATAGAATGG AGGGGACTCC ATTGTTTGAC AGTAATA INFORMATION FOR SEQ ID NO:8: SEQUENCE CHARACTERISTICS: LENGTH: 1825 amino acids TYPE: amino acid C) STRANDEDNESS: not relevant TOPOLOGY: not relevant (iMOLECULE TYPE: protein

AGGCACCGTT

GATGAGATTA

CTAATGTGTT

AAAGTAGAAC

AGTTAATTCC

AAAGCTGGAA

TGCACCTGGC

TGCTTCCTTC

ATGAGAAATT

TCTTAAATAC

CTGCTAAATG

CTGAAGTCAA

5160 5220 5280 5340 5400 5460 5477 (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vii) IMMEDIATE SOURCE: CLONE: DEC-205 Asn 1 Leu Ala Ser Gly Gly Arg Gln Leu Glv Leu Leu Gly 5 Arg Met Ser Arg Val Arg Met Arg Thr Gly 25 Leu Leu Phe Trp Pro 10 Trp Arg Thr Arg Pro Glu Gly Ala Thr Pro Phe Phe Asp Ser Gly Arg 40 Pro Leu His Arg Arg Pro Ala Glu Pro Gly Asn Thr Ala Ala Asn Phe Thr Ile Gly Lys Cys Ile Lys Asp Pro 70 Lys Tyr Gly Trp Ile 75 Val Ala Asp Asp Cys Giu Thr Glu Asp Ser Leu Trp Lys Ser Gin His Arg Leu Phe His Leu Val Asn Glu 115 Trp Lys Cys His 100 Leu Gin Lys Cys Leu 105 Cys Leu Asp Ile Arg Met Phe Ser 120 Leu Asp Ser Ser Al a 125 Arg Thr Lys Ser 110 Met Leu Trp Tyr Arg Leu Glu His His 130 Ala Leu Ser 135 Gly Tyr Gly Ala Lys Asp Gly 145 Trp His 150 Ser Thr Ala Ile Ser 155 Cys Ala Ser Asp Val1 160 Lys Lys 'Gly Gly 165 Arg Glu Giu Ser Asp Gin Pro Tyr His 175 Giu Phe Glu Ile Tyr Thr Asp Gly Asn Ser Gly Arg Pro Cys WO 96/23882 WO 962382PCTIUS96/0 1383 Pro Phe Let Asp Arg 225 Trp Thr Ala Asp Tyr 305 Leu Ser Cys Val Gly 385 Asn Leu Leu Ile Leu 465 Pro Ser His 210 Lys Giu Al a Asp Lys 290 Ser Asn Cys Giu Giu 370 Trp Ser Ile His Asn 450 Thr Asn Cys 195 Sex Trp Lys Le2 Leu 275 Giu Ala Trp Ala Ala 355 Leu Leu Trp Ser Asn 435 Ile Tyr Cys Glu Sle Gly Giy Asn Ser 260 Leu Gly Arg Asp Arg 340 Gin Thr Pro Asp Ile 420 Giu Pro Trp Val Glu .500 Asp Gly Thr Trp Pro Ile Giu 245 Trp Ser Ile Gly Pro 325 Met Leu Asp Asn Lys 405 His Asp Thr Asp Ser 485 Lys Trp Cys 230 Gin Lys Ile Ala Trp 310 Asp Asp Pro Vai Asn 390 Ala Ser Ile Leu Giu 470 Tyr Leu Cys 215 Leu Phe Giu Asn Lys 295 Giu Arg Ala Tyr Trp 375 Gly His Leu Lys Phe 455 Asn Leu Lys 200 Ala Lys Gly Ala Ser 280 Ile Trp Pro Giu Val 360 Thr Phe Al a Al a Glu 440 Gin Giu Gly Tyr His Thr Pro Ser Tyr 265 Al a Phe Ser Ser Ser 345 Cys Tyr Cys Lys Asp 425 Giu Trp Pro Glu Val1 505 His Thr Giu Cys 250 Val Ala Trp Asp Ala 330 Gly Arg Ser Tyr Cys 410 Val Val Ser Asn Leu 490 Cys Asp Leu Asn 235 Tyr Ser Giu Ile His 315 Pro Leu Lys Asp Leu 395 Lys Glu Trp Asp Val 475 Gly Lys Cys Asn 220 Gly Gin Cys Leu Gly 300 Lys Thr Trp Pro Thr 380 Leu Al a Val Ile Gly 460 Pro Gin Arg Ile 205 Tyr Cys Phe Gin Thr 285 Leu Pro Ile Gin Leu 365 Arg Val1 Phe Val1 Gly 445 Thr Tyr Trp Lys 190 Leu Git Giu Asn Asn 270 Tyr Asn Leu Gly Ser 350 Asn Cys Asn Ser Val 430 Leu Giu Asn Lys Gly 510 IAsp Tyr Asp *Thr 255 *Gin Leu Gin Asn Gly 335 Phe Asn Asp Giu Ser 415 Thr Lys Val Lys Val 495 Glu Giu Asp Asn 240 Gin Gly Lys Leu Phe 320 Ser Ser Thr Al a Ser 400 Asp Lys Asn Thr Thr 480 Gin Lys Leu Asn Asp Ala Ser Ser Asp Lys 520 Met Cys Pro Pro Asp Giu Gly Trp WO 96/23882 PCT/US96/01383 113 Lys Arg His Gly Glu Thr Cys Tyr Lys Ile Tyr Glu Asp Glu Val Pro 530 535 540 Phe Gly Thr Asn Cys Asn Leu Thr Ile Thr Ser Arg Phe Glu Gin Glu 545 550 555 560 Tyr Leu Asn Asp Leu Met Lys Lys Tyr Asp Lys Ser Leu Arg Lys Tyr 565 570 575 Phe Trp Thr Gly Leu Arg Asp Val Asp Ser Cys Gly Glu Tyr Asn Trp 580 585 590 Ala Thr Val Gly Gly Arg Arg Arg Ala Val Thr Phe Ser Asn Trp Asn 595 600 605 Phe Leu Glu Pro Ala Ser Pro Gly Gly Cys Val Ala Met Ser Thr Gly 610 615 620 Lys Ser Val Gly Lys Trp Glu Val Lys Asp Cys Arg Ser Phe Lys Ala 625 630 635 640 Leu Ser Ile Cys Lys Lys Met Ser Gly Pro Leu Gly Pro Glu Glu Ala 645 650 655 Ser Pro Lys Pro Asp Asp Pro Cys Pro Glu Gly Trp Gin Ser Phe Pro 660 665 670 Ala Ser Leu Ser Cys Tyr Lys Val Phe His Ala Glu Arg Ile Val Arg 675 680 685 Lys Arg Asn Trp Glu Glu Ala Glu Arg Phe Cys Gin Ala Leu Gly Ala 690 695 700 His Leu Ser Ser Phe Ser His Val Asp Glu Ile Lys Glu Phe Leu His 705 710 715 720 Phe Leu Thr Asp Gin Phe Ser Gly Gin His Trp Leu Trp Ile Gly Leu 725 730 735 Asn Lys Arg Ser Pro Asp Leu Gin Gly Ser Trp Gin Trp Ser Asp Arg 740 745 750 Thr Pro Val Ser Thr Ile Ile Met Pro Asn Glu Phe Gin Gin Asp Tyr 755 760 765 Asp Ile Arg Asp Cys Ala Ala Val Lys Val Phe His Arg Pro Trp Arg 770 775 780 Arg Gly Trp His Phe Tyr Asp Asp Arg Glu Phe Ile Tyr Leu Arg Pro 785 790 795 800 Phe Ala Cys Asp Thr Lys Leu Glu Trp Val Cys Gin Ile Pro Lys Gly 805 810 815 Arg Thr Pro Lys Thr Pro Asp Trp Tyr Asn Pro Glu Arg Ala Gly Ile 820 825 830 His Gly Pro Pro Leu Ile Ile Glu Gly Ser Glu Tyr Trp Phe Val Ala 835 840 845 Asp Leu His Leu Asn Tyr Glu Glu Ala Val Leu Tyr Cys Ala Ser Asn 850 855 860 His Ser Phe Leu Ala Thr Ile Thr Ser Phe Val Gly Leu Lys Ala Ile 865 870 875 880 WO 96/23882 PCT/US96/01383 114 Lys Asn Lys Ile Ala Asn Ile Ser Gly Asp Gly Gin Lys Trp Trp Ile 885 890 895 Arg Ile Ser Glu Trp Pro Ile Asp Asp His Phe Thr Tyr Ser Arg Tyr 900 905 910 Pro Trp His Arg Phe Pro Val Thr Phe Gly Glu Glu Cys Leu Tyr Met 915 920 925 Ser Ala Lys Thr Trp Leu Ile Asp Leu Gly Lys Pro Thr Asp Cys Ser 930 935 940 Thr Lys Leu Pro Phe Ile Cys Glu Lys Tyr Asn Val Ser Ser Leu Glu 945 950 955 960 Lys Tyr Ser Pro Asp Ser Ala Ala Lys Val Gin Cys Ser Glu Gin Trp 965 970 975 Ile Pro Phe Gin Asn Lys Cys Phe Leu Lys Ile Lys Pro Val Ser Leu 980 985 990 Thr Phe Ser Gin Ala Ser Asp Thr Cys His Ser Tyr Gly Gly Thr Leu 995 1000 1005 Pro Ser Val Leu Ser Gin Ile Glu Gin Asp Phe Ile Thr Ser Leu Leu 1010 1015 1020 Pro Asp Met Glu Ala Thr Leu Trp Ile Gly Leu Arg Trp Thr Ala Tyr 1025 1030 1035 1040 Glu Lys Ile Asn Lys Trp Thr Asp Asn Arg Glu Leu Thr Tyr Ser Asn 1045 1050 1055 Phe His Pro Leu Leu Val Ser Gly Arg Leu Arg Ile Pro Glu Asn Phe 1060 1065 1070 Phe Glu Glu Glu Ser Arg Tyr His Cys Ala Leu Ile Leu Asn Leu Gin 1075 1080 1085 Lys Ser Pro Phe Thr Gly Thr Trp Asn Phe Thr Ser Cys Ser Glu Arg 1090 1095 1100 His Phe Val Ser Leu Cys Gin Lys Tyr Ser Glu Val Lys Ser Arg Gin 1105 1110 1115 1120 Thr Leu Gin Asn Ala Ser Glu Thr Val Lys Tyr Leu Asn Asn Leu Tyr 1125 1130 1135 Lys Ile Ile Pro Lys Thr Leu Thr Trp His Ser Ala Lys Arg Glu Cys 1140 1145 1150 Leu Lys Ser Asn Met Gin Leu Val Ser Ile Thr Asp Pro Tyr Gin Gin 1155 1160 1165 Ala Phe Leu Ser Val Gin Ala Leu Leu His Asn Ser Ser Leu Trp Ile 1170 1175 1180 Gly Leu Phe Ser Gin Asp Asp Glu Leu Asn Phe Gly Trp Ser Asp Gly 1185 1190 1195 1200 Lys Arg Leu His Phe Ser Arg Trp Ala Glu Thr Asn Gly Gin Leu Glu 1205 1210 1215 Asp Cys Val Val Leu Asp Thr Asp Gly Phe Trp Lys Thr Val Asp Cys 1220 1225 1230 WO 96/23882 PCT/US96/01383 115 Asn Asp Asn Gin Pro Gly Ala Ile Cys Tyr Tyr Pro Gly Asn Glu Thr 1235 1240 1245 Glu Lys Glu Val Lys Pro Val Asp Ser Val Lys Cys Pro Ser Pro Val 1250 1255 1260 Leu Asn Thr Pro Trp Ile Pro Phe Gin Asn Cys Cys Tyr Asn Phe Ile 1265 1270 1275 1280 Ile Thr Lys Asn Arg His Met Ala Thr Thr Gin Asp Glu Val His Thr 1285 1290 1295 Lys Cys Gin Lys Leu Asn Pro Lys Ser His Ile Leu Ser Ile Arg Asp 1300 1305 1310 Glu Lys Glu Asn Asn Phe Val Leu Glu Gin Leu Leu Tyr Phe Asn Tyr 1315 1320 1325 Met Ala Ser Trp Val Met Leu Gly Ile Thr Tyr Arg Asn Asn Ser Leu 1330 1335 1340 Met Trp Phe Asp Lys Thr Pro Leu Ser Tyr Thr His Trp Arg Ala Gly 1345 1350 1355 1360 Arg Pro Thr Ile Lys Asn Glu Arg Phe Leu Ala Gly Leu Ser Thr Asp 1365 1370 1375 Gly Phe Trp Asp Ile Gin Thr Phe Lys Val Ile Glu Glu Ala Val Tyr 1380 1385 1390 Phe His Gin His Ser Ile Leu Ala Cys Lys Ile Glu Met Val Asp Tyr 1395 1400 1405 Lys Glu Glu Tyr Asn Thr Thr Leu Pro Gin Phe Met Pro Tyr Glu Asp 1410 1415 1420 Gly Ile Tyr Ser Val Ile Gin Lys Lys Val Thr Trp Tyr Glu Ala Leu 1425 1430 1435 1440 Asn Met Cys Ser Gin Ser Gly Gly His Leu Ala Ser Val His Asn Gin 1445 1450 1455 Asn Gly Gin Leu Phe Leu Glu Asp Ile Val Lys Arg Asp Gly Phe Pro 1460 1465 1470 Leu Trp Val Gly Leu Ser Ser His Asp Gly Ser Glu Ser Ser Phe Glu 1475 1480 1485 Trp Ser Asp Gly Ser Thr Phe Asp Tyr Ile Pro Trp Lys Gly Gin Thr 1490 1495 1500 Ser Pro Gly Asn Cys Val Leu Leu Asp Pro Lys Gly Thr Trp Lys His 1505 1510 1515 1520 Glu Lys Cys Asn Ser Val Lys Asp Gly Ala Ile Cys Tyr Lys Pro Thr 1525 1530 1535 Lys Ala Lys Lys Leu Ser Arg Leu Thr Tyr Ser Ser Arg Cys Pro Ala 1540 1545 1550 Ala Lys Glu Asn Gly Ser Arg Trp Ile Gin Tyr Lys Gly His Cys Tyr 1555 1560 1565 Lys Ser Asp Gin Ala Leu His Ser Phe Ser Glu Ala Lys Lys Leu Cys 1570 1575 1580 WO 96t23882 PCTIUS96/01383 116 Ser Lys His Asp His Ser Ala Thr Ile Val Ser Ile Lys Asp Giu Asp 1585 1590 1595 1600 Giu Asn Lys Phe Val Ser Arg Leu Met Arg GiU Asn Asn Asn Ile Thr 1605 1610 1615 Met Arg Val Trp Leu Gly Leu Ser Gin His Ser Val Asp Gin Ser Trp 1620 1625 1630 Ser Trp Leu Asp Gly Ser Giu Val Thr Phe Val Lys Trp Giu Asn Lys 1635 1640 1645 Ser Lys Ser Giy Val Giy Arg Cys Ser Met Leu Ile Aia Ser Asn Giu 1650 1655 1660 Thr Trp Lys Lys Val Giu Cys Giu His Giy Phe Gly Arg Val Val Cys 1665 1670 1675 1680 Lys Vai Pro Leu Gly Pro Asp Tyr Thr Ala Ile Ala Ile Ile Vai Ala 1685 1690 1695 Thr Leu Ser Ile Leu Vai Leu Met Giy Gly Leu Ile Trp Phe Leu Phe 1700 1705 1710 Gin Arg His Arg Leu His Leu Ala Gly Phe Ser Ser Val Arg Tyr Ala 1715 1720 1725 Gin Gly Val Asn Glu Asp Glu Ile Met Leu Pro Ser Phe His Asp Xaa 1730 1735 1740 Ile Leu Leu Lys Val Phe Xaa Phe Aia Leu Met Cys Tyr Glu Lys Leu 1745 1750 1755 1760 Val Thr Xaa Asn Val Gin Cys Gin Tyr Leu Leu Cys Ser Lys Val Giu 1765 1770 1775 Leu Leu Asn Thr Phe Ser Val Val Xaa Ile Xaa Ala Cys Ala Gly Ile 1780 1785 1790 His Ser Xaa Phe Pro Ala Lys Cys His Val Tyr His Pro Asn Xaa Xaa 1795 1800 1805 Asn Gly Gly Asp Ser Lys Ala Gly Thr Giu Val Lys Leu Phe Asp Ser 1810 1815 1820 Asn 1825

Claims (51)

1. An isolated DEC, wherein DEC is an integral membrane protein which: is expressed by dendritic cells, thymic epithelial cells, lung epithelial cells, small intestine epithelial cells and brain capillaries; has an apparent molecular weight of 205 kDa by polyacrylamide gel electrophoresis; comprises ten lectin domains, a transmembrane domain and a short cytoplasmic tail containing a coated pit localization consensus sequence; and has an amino acid sequence which has a high degree of homology to the amino acid sequence of a human DEC as depicted in SEQ ID NO: 8 up to amino acid 1743 or as encoded by a nucleic acid sequence corresponding to the sequence depicted in SEQ ID NO: 7.

2. The isolated DEC of claim 1, which is a human DEC.

3. The isolated DEC of claim 2, which has the carboxyl terminal amino acid sequence RHRLHLAGFSSVRYAQGVNEDEIMLPSFHD (SEQ ID NO:1). 000

4. The isolated DEC of claim 2 or claim 3, which binds to a rabbit polyclonal antibody raised against full length murine DEC but does not react with monoclonal antibody NLDC-145. eset 25 5. The isolated DEC of any one of claims 2 to 4, which has the amino acid sequence depicted in SEQ ID NO: 8.

6. The isolated DEC of claim 1, which is a murine DEC.

7. An isolated nucleic acid sequence encoding the isolated DEC of any one of claims 1 to 6. 118

8. The nucleic acid sequence of claim 7 which is: a nucleic acid sequence corresponding to the sequence depicted in SEQ ID NO:7; an allelic variant of the nucleic acid sequence of a nucleic acid sequence encoding a polypeptide having the amino acid sequence depicted in SEQ ID NO:8 up to amino acid 1743; or an allelic variant of the nucleic acid sequence of

9. An expression vector comprising the nucleic acid sequence of claim 7 or claim 8 operatively associated with an expression control sequence. A recombinant host cell comprising the expression vector of claim 9.

11. A recombinant host cell according to claim 10, being a mammalian cell selected from the group consisting of a Chinese hamster ovary cell, an African Green Monkey COS cell, a Madin-Darby canine kidney cell and an NIH-3T3 fibroblast cell. .9.

12. An antibody reactive with the DEC of any one of claims 1 to 6, provided that the antibody is not NLDC-145 or 6D2.

13. A method for identifying a ligand for the DEC of any one of claims 1 to 6, which S method comprises: 9 contacting a protein comprising at least one DEC lectin domain with a 25 candidate ligand; and S* detecting binding of the candidate ligand with the DEC lectin domain; wherein detection of binding of the candidate ligand and the DEC lectin domain indicates that the ligand candidate is a ligand for DEC.

14. The method of claim 13, wherein the ligand is a saccharide. 119 The method of claim 13 or claim 14, wherein the protein comprising at least one DEC lectin domain is expressed by cells as an integral membrane protein or is irreversibly associated with a solid phase support, and the candidate ligand is labelled, such that binding of the candidate ligand with the DEC lectin domain is detected by detecting association of the label with the cells or with the solid phase support respectively.

16. The method of claim 13 or claim 14, wherein the protein comprising at least one DEC lectin domain is solubilized, and the candidate ligand is irreversibly associated with a solid phase support, such that binding of the candidate ligand with the DEC lectin domain is detected by detecting binding of the protein with the solid phase support.

17. The method of any one of claims 13 to 16, wherein the protein comprising at least one DEC lectin domain is a truncated DEC protein or is a full length DEC protein.

18. A pharmaceutical composition comprising a molecule targeted to a tissue from pulmonary circulation, intestinal circulation, pulmonary airways, lumen of the small intestine, dendritic cells in the skin and T cell areas of lymphoid organs, thymus or i ""20 brain, which molecule is conjugated to a DEC-ligand, where DEC is as defined in any one of claims 1 to 6, which DEC-ligand is a carbohydrate that binds to DEC or to an anti-DEC antibody, and a pharmaceutically acceptable carrier. 00

19. The pharmaceutical composition of claim 18, wherein the molecule is an anti- cancer drug, an anti-viral drug, an antibiotic, an anti-parasitic drug or an anti- inflammatory drug. The use of a DEC-ligand, being a carbohydrate identified by its ability to bond to DEC, where DEC is as defined in any one of claims 1 to 6, and which DEC-ligand is also capable of binding to an anti-DEC antibody, in the manufacture of a molecule targeted .to a tissue from pulmonary circulation, intestinal circulation, pulmonary airways, 120 lumen of the small intestine, dendritic cells in the skin and T cell areas of lymphoid organs, thymus or brain.

21. A recombinant vector for introduction of a gene into dendritic cells, thymic epithelial cells, lung epithelial cells, small intestine epithelial cells or brain capillary cells, comprising a DNA vector conjugated to a DEC-ligand, said DEC-ligand being a carbohydrate identified by its ability to bind to DEC, where DEC is as defined in any one of claims 1 to 6, and wherein the DEC-ligand is also capable of binding to an anti- DEC antibody.

22. A recombinant vector according to claim 21, which is a viral vector, a liposome vector or a naked DNA vector.

23. A vaccine comprising an antigen from a pathogen conjugated to a DEC-ligand, said DEC-ligand being a carbohydrate identified by its ability to bind to DEC, where DEC is as defined in any one of claims 1 to 6, and wherein the DEC-ligand is also capable of binding to an anti-DEC antibody, and an immune stimulator. S 24. A vaccine according to claim 23, wherein the pathogen is a virus, a bacterium, a 20 parasite or a tumor.

25. A vaccine according to claim 23 or claim 24, wherein the immune stimulator is a cytokine, a lymphokine or an adjuvant.

26. A composition to induce tolerance or immune suppression comprising an autoantigen or an allergen conjugated to a DEC-ligand, said DEC-ligand being a carbohydrate identified by its ability to bind to DEC, where DEC is as defined in any one of claims 1 to 6, and wherein the DEC ligand is also capable of binding to an anti- DEC antibody, with the proviso that the composition lacks immune stimulatory agents.

27. A composition according to claim 26, wherein the autoantigen is myelin basic protein, collagen or a fragment thereof, DNA, a nuclear protein, a nucleolar protein, a mitochondrial protein or a pancreatic p-cell protein.

28. A product comprising: a cell which expresses DEC, where DEC is as defined in any one of claims 1 to 6; and an antigen against which tolerance is to be induced, said antigen expressing a DEC-binding moiety; for combined or sequential use in a method of inducing tolerance to said antigen in a patient in which tolerance is indicated as a preventative treatment or as a therapy.

29. The product of claim 28, wherein the cell is a dendritic or epithelial cell.

30. The product of claim 28, wherein the cell is one which has been modified by recombinant technology to express DEC.

31. A conjugate of: an antigen, an autoantigen or an allergen, against which tolerance is to be 20 induced, and a carbohydrate identified by its ability to bind to DEC, where DEC is as defined in any one of claims 1 to 6, said carbohydrate also being capable of binding to an anti-DEC antibody, I for use in a method of inducing tolerance to said antigen in a patient in which 25 tolerance is indicated as a preventative treatment or as a therapy. o

32. A conjugate according to claim 31, wherein the autoantigen is myelin basic protein, collagen or a fragment thereof, DNA, a nuclear protein, a nucleolar protein, a mitochondrial protein or a pancreatic p-cell protein. 122

33. A method for identifying targeting mechanisms for DEC, where DEC is as defined in any one of claims 1 to 6, comprising: contacting a protein comprising the cytoplasmic tail, or a fragment thereof, of the DEC protein with a candidate protein that targets the DEC receptor for antigen presentation; and detecting binding of the candidate protein with the DEC lectin domain or binding of the candidate protein with the DEC cytoplasmic tail; wherein detection of binding indicates that the ligand candidate is a ligand for DEC or a binding protein for the cytoplasmic tail.

34. A method of inducing tolerance in a patient in which tolerance is indicated as a preventative treatment or as a therapy, which method comprises introducing a cell into a subject, along with an antigen to which tolerance is desired, wherein said cell expresses DEC, where DEC is as defined in any one of claims 1 to 6, and said antigen expresses a DEC-binding moiety. e

35. A method according to claim 34, wherein the cell is a dendritic cell.

36. A method according to claim 34, wherein the cell is an epithelial cell.

37. A method according to any one of claims 34 to 36, wherein the patient is treated to prevent the onset of a disease.

38. A method according to claim 35or claim 36, wherein the cell is modified by 25 recombinant technology to express DEC.

39. A method of inducing tolerance to an antigen in a patient in which tolerance is indicated as a preventative treatment or as a therapy, which method comprises: conjugating the antigen with a DEC-binding moiety which is a carbohydrate identified by its ability to bind to DEC, where DEC is as defined in any one of claims 1 to 6, said DEC-binding moiety also being capable of binding to an anti-DEC antibody; and administering said conjugate to a patient in need of such preventative treatment or therapy. A method according to claim 39, wherein the patient is treated to prevent the onset of a disease.

41. A method according to claim 39, wherein the antigen conjugated with a DEC- binding moiety is introduced directly into the thymus, either by targeting or physical injection.

42. The use of a quiescent cell which expresses DEC, where DEC is as defined in any one of claims 1 to 6, together with an antigen to which tolerance is desired, for the manufacture of a pharmaceutical composition for inducing tolerance in a patient in which tolerance is indicated as a preventative treatment or as a therapy. g 43. The use according to claim 42, wherein the cell is a dendritic cell. •"20 44. The use according to claim 42, wherein the cell is an epithelial cell. S

45. The use according to any one of claims 42 to 44, wherein the patient is to be Streated to prevent the onset of a disease. oS S •25 46. The use according to claim 43 or claim 44, wherein the cell has been modified by recombinant technology to express DEC.

47. The use of a conjugate of an antigen and a DEC-binding moiety which is a carbohydrate identified by its ability to bind to DEC, where DEC is as defined in any one of claims 1 to 6, said DEC-binding moiety also being capable of binding to an anti- RAEC antibody, for the manufacture of a pharmaceutical composition for inducing tolerance to the antigen in a patient in which tolerance is indicated as a preventative treatment or as a therapy.

48. The use according to claim 47, wherein the patient is to be treated to prevent the onset of a disease.

49. The use according to claim 47 wherein the pharmaceutical composition is suitable for administration directly into the thymus, either by targeting or direct injection. An isolated DEC according to any one of claims 1 to 6, substantially as described herein and with reference to any one of Examples 1 to

51. An isolated nucleic acid sequence according to claim 7 or claim 8, substantially as described herein and with reference to Example

52. An expression vector according to claim 9, substantially as described herein.

53. A recombinant host cell according to claim 10 or claim 11, substantially as described herein. S: 54. An antibody according to claim 12, substantially as described herein and with reference to any one of Examples 1 to 4 *5a55* S 25 55. A method according to any one of claims 13 to 17, substantially as described herein.

56. A pharmaceutical composition according to claim 18 or claim 19, substantially as described herein. 4 7 The use of a DEC-ligand according to claim 20, substantially as described herein. 125

58. A recombinant vector according to claim 21 or claim 22, substantially as described herein.

59. A vaccine according to any one of claims 23 to 25, substantially as described herein. A composition according to claim 26 or claim 27, substantially as described herein. 9* 9 2 25 99 C

61. A product according to any one of claims 28 to 30, substantially as described herein.

62. A conjugate according to claim 31 or claim 32, substantially as described herein.

63. A method according to claim 33, substantially as described herein.

64. A method according to any one of claims 34 to 41, substantially as described herein. The use of a cell according to any one of claims 42 to 46, substantially as described herein.

66. The use of a conjugate according to any one of claims 47 to 49, substantially as described herein. Dated this 14 day of December, 1999. THE ROCKEFELLER UNIVERSITY By its Patent Attorneys MADDERNS w-"t7J